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Antibodies have been engaging with infectious diseases since the evolution of 
cartilaginous fish, though it is only in very recent history that humans have been able to 
harness this expertise. The concept of using antibodies as therapeutics was first put into 
practice in the late 1890’s and was called serum therapy. Although this remedy was 
revolutionary for the treatment of virulent infections, significant side effects as well as 
the introduction of modern antibiotics caused a rapid decline of the practice in the 1930s. 
It is now 80 years later and antibodies for infectious indications are experiencing a 
renaissance. In particular, the evolution of antibiotic-resistant bacteria, the emergence of 
new pathogens, a growing population of immunocompromised individuals, and the 
continual search for the next cure has caused many to take a second look at antibodies. 
The exceptional specificity and biocompatibility of antibodies makes them agreeable 
therapeutics, and the invention and maturation of protein engineering has given us a toy 
box of new strategies for their design. In particular, next-generation formats, such as 
antibody mixtures, bispecific antibodies, and T-cell-receptor driven approaches, are 
proving useful for the treatment of infectious diseases. These new formats are able to 
provide broad coverage against mutable pathogens and open new therapeutic avenues by 
redirecting the immune system. In this dissertation I will lead you through my last 5 years 
of research and show you what I have learned about engineering and applying next-
generation antibody therapeutics for infectious diseases.  
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Table of Contents 
List of Tables ...........................................................................................................x 
List of Figures ........................................................................................................ xi 
Chapter 1: Engineering principles and pipeline for therapeutic antibodies for 
infectious disease ............................................................................................1 
Abstract ...........................................................................................................1 
Introduction .....................................................................................................2 
Engineering antibodies for infectious diseases ...............................................6 
Selection of target and affinity maturation ............................................7 
Improving neutralization with oligoclonal antibody mixtures.............12 
Fc engineering for improved function and half-life .............................15 
Designing novel antibody formats for novel methods of action ..........17 
A survey of anti-infective antibodies in development ..................................20 
Prophylaxis of common diseases in high-risk patients ........................24 
Respiratory Syncytial Virus ........................................................24 
Human Cytomegalovirus ............................................................24 
Hepatitis B and Hepatitis C.........................................................25 
Pertussis ......................................................................................25 
Neutralization of bacterial toxin bioterrorism agents ..........................25 
Anthrax .......................................................................................25 
Botulism ......................................................................................26 
Other bacterial toxins ..................................................................26 
Treatment and prevention of healthcare-associated infections ............27 
Clostridium difficile infection.....................................................27 
Staphylococcus Aureus Pneumonia ............................................27 
Pseudomonas aeruginosa pneumonia .........................................28 
Potent neutralization of deadly viruses ................................................28 
Human immunodeficiency virus - 1 ...........................................28 
Influenza A..................................................................................29 
 vii 
Ebola ...........................................................................................29 
Rabies ..........................................................................................30 
Other emerging viruses ...............................................................30 
Broad spectrum and host-mediated approaches ...................................30 
Unusual cell morphology ............................................................30 
Host immune regulation ..............................................................31 
Conclusion ....................................................................................................32 
Chapter 2: A cocktail of humanized anti-pertussis toxin antibodies limits            
disease in murine and baboon models of whooping cough ..........................33 
Abstract .........................................................................................................33 
Introduction ...................................................................................................34 
Materials and Methods ..................................................................................37 
Study design .........................................................................................37 
Antibody variable region cloning and humanization ...........................38 
Protein expression & purification ........................................................38 
ELISA and binding assays ...................................................................39 
In vitro neutralization ...........................................................................40 
Bacterial strain and growth ..................................................................41 
Ethics Statement...................................................................................41 
Murine pharmacokinetic assay ............................................................41 
In vivo mouse challenge ......................................................................42 
Baboon challenge study .......................................................................42 
Statistical Analysis ...............................................................................43 
Results ...........................................................................................................44 
Cloning and humanization of murine 1B7 and 11E6 antibodies .........44 
Hu1B7 and hu11E6 antibodies are biochemically and              
biophysically similar to their murine predecessors .....................44 
The binary combination of hu1B7 and hu11E6 is synergistic .............46 
Hu1B7 and hu11E6 protect mice prophylactically from                             
B. pertussis infection ...................................................................48 
 viii 
Hu1B7 and hu11E6 protect baboons therapeutically from                
infection by B. pertussis ..............................................................51 
Discussion .....................................................................................................55 
Acknowledgements .......................................................................................60 
Chapter 3: Synergistic neutralization of pertussis toxin by a                            
bispecific antibody in vitro and in vivo .........................................................61 
Abstract .........................................................................................................61 
Introduction ...................................................................................................62 
Materials and Methods ..................................................................................65 
Protein preparation and purification ....................................................65 
Modeling hu1B7 and 11E6 epitopes on PTx .......................................66 
PTx binding assays ..............................................................................67 
Protein biophysical characterization ....................................................68 
In vitro PTx neutralization assay .........................................................69 
Murine PTx leukocytosis study ...........................................................70 
Ethics statement ...................................................................................71 
Results ...........................................................................................................72 
Antibodies hu1B7 and hu11E6 can simultaneously bind                          
the same toxin molecule..............................................................72 
Crosslinking of two epitopes on a single PTx molecule is                     
likely not required for synergistic neutralization ........................73 
Expression and purification of a stable hu1B7/hu11E6                  
bispecific antibody ......................................................................74 
Biophysical characterization of monoclonal, Fab, and                   
bispecific antibodies....................................................................77 
A hu1B7/ hu11E6 bispecific antibody has similar in vitro                      
PTx binding activity to the binary mixture .................................79 
The bispecific antibody neutralizes PTx activities in vitro ..................84 
The antibody mixture and bispecific antibody synergistically             
inhibit PTx-induced leukocytosis in vivo ....................................86 
Discussion .....................................................................................................91 
Acknowledgements .......................................................................................97 
 ix 
Engineering a novel soluble TCR- Immunoglobulin hybrid molecule ..................98 
Abstract .........................................................................................................98 
Introduction ...................................................................................................99 
Methods.......................................................................................................103 
Cloning of surface display, library screening, and soluble             
expression plasmids ..................................................................103 
EpiCHO transfection ..........................................................................103 
Tetramer preparation ..........................................................................104 
Flow cytometry ..................................................................................104 
Library design and cloning ................................................................104 
Library transfection and sorting .........................................................105 
Soluble protein expression and purification ......................................106 
Enzyme-linked immune-sorbent assay (ELISA) ...............................107 
Jurkat cell staining .............................................................................108 
Results .........................................................................................................109 
A CMV-specific TCR, RA14, can be displayed on the                      
surface of CHO cells .................................................................109 
A mammalian display system can be used to screen for                     
affinity improvement ................................................................111 
Bispecific TCR/Ig precursors can be expressed and purified                 
from CHO cells .........................................................................115 
Discussion ...................................................................................................120 
Acknowledgements .....................................................................................123 
Appendix A ..........................................................................................................124 
Supplementary Materials for Chapter 2 ......................................................124 
References ............................................................................................................132 
Vita .......................................................................................................................155 
 x 
List of Tables 
Table 1. Anti-infective monoclonal antibodies approved in the United States. ......3 
Table 2. Antibodies for infectious diseases in US clinical trials  ..........................21 
Table 3. Biochemical characterization of 1B7 and 11E6 antibodies .....................46 
Table 4. Library design and size. .........................................................................114 
Table 5. Humanized antibodies are more similar to the human repertoire                 
than the original murine antibodies.................................................130 
Table 6. Baboon model challenge details ............................................................131 
 xi 
List of Figures 
Figure 1. Therapeutic antibodies approved in the United States. ............................3 
Figure 2. Key tenets of antibody engineering. .........................................................7 
Figure 3. Humanized, chimeric and murine antibodies have similar                    
binding affinities to PTx. ..................................................................45 
Figure 4. The hu1B7 and hu11E6 antibodies have higher anti-PTx titers                 
than P-IVIG and can simultaneously bind PTx. ...............................47 
Figure 5. The binary combination of hu1B7 and hu11E6 is synergistic                     
and more potent than P-IVIG in vitro. ..............................................48 
Figure 6. Prophylactic treatment with humanized antibodies protects                     
mice against pertussis. ......................................................................50 
Figure 7. Therapeutic treatment with antibody cocktail reduces                  
leukocytosis and accelerates bacterial clearance in baboons. ...........52 
Figure 8. Orientation and stoichiometry of the hu1B7 and putative                     
hu11E6 epitopes. ...............................................................................73 
Figure 9. Production of bispecific hu1B7/hu11E6 antibody. ................................75 
Figure 10. Biophysical characterization of bispecific and parent antibodies. .......78 
Figure 11. Biochemical characterization of bispecific and parent antibodies. ......81 
Figure 12. In vitro PTx neutralization measured by inhibition of                            
CHO cell clustering...........................................................................85 
Figure 13. Antibody-mediated suppression of PTx-induced                        
leukocytosis in vivo. ..........................................................................88 
Figure 14. Diagram of the proposed hybrid T-cell receptor/Immunoglobulin 
molecule, or TRIG. .........................................................................102 
 xii 
Figure 15. RA14 TCR is displayed on the surface of CHO cells. .......................110 
Figure 16. Design of CDR mutagenesis library. ..................................................113 
Figure 17. CDR3β library sorting. .......................................................................115 
Figure 18. Design, expression, and characterization of αCD3 and sTCR-Fc. .....117 
Figure 19. Specific activity of humanized antibody variants. .............................124 
Figure 20. Antibody thermal stability. .................................................................125 
Figure 21. Competition ELISA to assess solution binding affinities                            
of purified antibodies. .....................................................................125 
Figure 22. Binding kinetics of antibody-PTx interaction.. ..................................126 
Figure 23. Pilot murine protection data with recent human clinical                      
isolate D420 and murine 1B7. ........................................................127 
Figure 24. Concentrations of anti-PTx antibodies in baboons. ............................128 
Figure 25. Detection of the hu1B7/hu11E6 combination in the              
nasopharyngeal wash of baboons. ...................................................129 
Figure 26. Histopathological analysis of lung tissue. ..........................................130 
  
 
 
1 
 
Chapter 1: Engineering principles and pipeline for therapeutic 
antibodies for infectious disease 
ABSTRACT 
Parasitic and infectious diseases cause over 9.5 million deaths worldwide 
annually(1). Antibodies, a fundamental component of the natural immune response to 
infectious pathogens, are rarely developed for these indications due to cheaper small 
molecule drugs and effective vaccines. However, a growing niche of specialty 
applications and the emergence of antibiotic-resistant pathogens has spurred development 
of antibodies targeting infectious diseases. There are currently 4 such recombinant 
antibodies approved in the US, with 40 in clinical trials. These high-affinity antibodies 
are commonly targeted toward secreted toxins, the pathogen’s surface, or cellular 
receptors, and can make for a potent, fast-acting therapeutic. Fc engineering is often 
employed to provide a longer half-life or enhanced effector function. In particular, next-
generation formats such as antibody mixtures and bispecific antibodies have a bright 
future for infectious applications due to their ability to recognize wider target variability 
and induce novel mechanisms of clearance. The recent growth of the biologics industry, 
along with a demonstrated need for novel anti-infective agents, makes it likely that 
recombinant antibodies will become a more common approach for the treatment and 
prevention of infectious disease.  
  
2 
 
INTRODUCTION 
Global sales of monoclonal antibody products have grown from ~$39 billion USD 
in 2008 to nearly $75 billion in 2013, and are projected to reach ~$94 billion in 2017(2). 
Monoclonal antibodies, already the driver of the biotech industry with 24.6% of US sales 
in 2012(3), are set to capture an even larger share of the market due to a faster growth in 
sales and higher approval rate over other pharmaceuticals(2, 4). Although the first 
recombinant antibody was approved in 1986, 29 of the 56 therapeutic monoclonal 
antibody products currently marketed in the US (as of April 2017) have been approved in 
the last 5 years (Fig. 1A), including the first bispecific antibody approval in 2014(5).  Of 
the currently marketed products, ~43% are for cancer indications and ~39% are for 
inflammatory or autoimmune disorders, while only ~7% are for infectious diseases (Fig. 
1B). These include palivizumab (Synagis), approved in 1998 for the prevention of 
respiratory syncytial virus (RSV) in infants(6); Raxibacumab(7) (Abthrax) in 2012 and 
obiltoxaximab(8) (Anthim) in 2016 for the treatment and prevention of inhalational 
anthrax, respectively; and bezlotoxumab(9) (Zinplava) in 2016 for prevention of 
recurrent C. difficile infection (Table 1). We have identified 40 recombinant antibodies in 
US clinical trials for infectious indications, with 30 currently in phase II or III trials. With 
a historical success rate of ~26% and an average time to approval of 7 years(2), it is 
likely that several more anti-infective antibodies will enter the market in the foreseeable 
future. 
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Figure 1. Therapeutic antibodies approved in the United States(5).  
A, US therapeutic antibody approval by year. Solid- currently on the market, striped- withdrawn or 
discontinued. B, Approved indications of currently marketed therapeutic antibodies. Orange- infectious, 
blue- inflammatory or autoimmune, purple- cancer, grey-other. Inflammatory/autoimmune includes other 
diseases related to immune system hyperactivity such as transplant rejection and asthma, cancer includes 
other neoplastic diseases such as Castleman disease. Other includes bone loss, macular degeneration, blood 
clot prevention and high cholesterol.  
 
Table 1. Anti-infective monoclonal antibodies approved in the United States. 
Name Disease Target Affinity 
(nM) 
Isotype Approval 
(US) 
Developer 
Palivizumab(6) 
(Synagis) 
RSV Viral glycoprotein- 
RSV fusion (F) protein 
2.6(10) Humanized 
IgG1 
1998 Medimmune 
Raxibacumab(7) 
(Abthrax) 
Anthrax Bacterial toxin- 
protective antigen 
2.8(11) Human  
IgG1 
2012 GlaxoSmithKline 
Obiltoxaximab(8
) (Anthim) 
Anthrax Bacterial toxin- 
protective antigen 
0.3(12) Chimeric 
IgG1 
2016 Elusys 
Therapeutics 
Bezlotoxumab(9) 
(Zinplava) 
C. difficile Bacterial toxin- 
enterotoxin B 
0.05-
0.8(13) 
Human  
IgG1 
2017 Merck 
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Although using antibodies for infectious diseases may seem like somewhat of a 
niche field, there are many applications for which antibodies are uniquely suited. As 
compared to small-molecule drugs, antibodies possess two unique traits which can be 
leveraged to create quality therapeutics. First, antibodies are highly specific, allowing 
differential targeting of pathogens, receptors, or even specific glycoforms(14) in a sea of 
similar neighbors. In contrast, commonly-used antibiotics can have significant impacts on 
natural populations of commensal or symbiotic bacteria in addition to the targeted 
species, for example in the gut microbiome(15), opening the door to overgrowth of 
opportunistic pathogenic bacteria in the absence of normally present competitors(16). 
This mechanism is a common cause of recurrent C. difficile infections, and was the 
driving force behind the development of anti-toxin antibodies which can prevent 
symptomatic reinfection(17). Another potential advantage of high specificity is a 
reduction in the spread of resistance, especially in non-target organisms(18). While 
constantly evolving pathogens certainly respond to selective pressure from 
antibodies(19), such mutations will only impact that particular antibody therapeutic, 
rather than a whole class of antibiotics. In light of increasing incidence of antibiotic-
resistant infections(20), there is now significant interest in developing antibody 
therapeutics to treat or prevent bacterial infections like methicillin-resistant S. aureus(21).   
 
A second unique characteristic of antibodies is that they are natural molecules of 
the immune system and can be engineered to interact with or avoid various immune 
pathways. Therapeutic development often involves discovery of antibody binding regions 
capable of neutralizing pathogens, followed by engineering efforts directed toward 
affinity improvement(12). The resulting antibodies can block the interaction of 
pathogenic antigens with host receptors and/or facilitate clearance of antigen or 
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pathogens when immune complexes are formed. Importantly, antibodies which function 
by neutralization can be potent prophylactic agents even in those without a fully-
functioning immune system. This passive immunization approach is useful for short-term 
protection of high-risk individuals, such as infants or transplant patients, from common 
infections such as RSV(6) or Hepatitis C Virus (HCV)(22). In contrast, there is 
increasing evidence of the importance of Fc-mediated effector functions, which can 
contribute to complement-mediated lysis and phagocytosis of pathogens(23), and 
antibodies with improved efficacy can be identified through Fc engineering. Such 
antibodies include high-value therapeutic agents against elusive targets like HIV(24), 
which has so far outlasted small molecule drugs and vaccine discovery efforts. In either 
case, antibodies are typically safe and well-tolerated, have few off-target effects, and do 
not interfere with other drugs.  
 
A growing list of antibiotic-resistant bacteria, emerging pathogens, and 
immunocompromised individuals shows that new anti-infective drugs are urgently 
needed. In the next section we will detail the essential considerations in optimizing 
antibodies for infectious diseases, which include traditional areas such as specificity, 
affinity, and Fc engineering, as well as emerging technologies such as antibody mixtures 
and novel formats. Finally, we will survey indications for which antibodies are in clinical 
trials or preclinical development, and comment on future directions in the field.  
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ENGINEERING ANTIBODIES FOR INFECTIOUS DISEASES 
The efficacy and mechanism of action of an antibody is defined and refined by 
several key parameters, including specificity and affinity, clonality, format, and Fc 
function (Fig. 2). A therapeutic candidate is usually first isolated for its specificity, which 
can be further enhanced to improve potency. Fc engineering can be used to increase half-
life or alter immune system interactions, which in some cases is the major therapeutic 
mechanism. Antibody mixtures and alternative formats are emerging as strategies with 
particular relevance to infectious diseases, and may be crucial for broad coverage of a 
mutable pathogen or for inducing novel clearance mechanisms of elusive targets. In this 
section we will discuss considerations of each of these areas in the context of targeting 
pathogenic diseases. 
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Figure 2. Key tenets of antibody engineering. 
 Designing an antibody therapeutic  requires conscious consideration of several parameters, incuding what 
the antibody targets and how tightly it binds (specificity and affinity), the number of specificities to include 
(clonality), interaction with the immune system (Fc function, e.g. glycoslyation or half-life extending 
mutations), and how the antibody is formatted (format, e.g. bispecifics or ADCs).  
 
Selection of target and affinity maturation 
Antibody engineering begins with specificity; antibodies can be raised against 
nearly any target, but the choice will define the mechanism of action and efficacy. In the 
case where the desired specificity is known, antibodies are relatively easily isolated by 
immunization of wild-type or humanized mice, followed by library screening to identify 
neutralizing antibodies. In a desire to reduce immunogenicity, there is a push toward 
developing fully-human antibodies, which can be isolated from vaccinated or immunized 
human volunteers(25). In many cases an effective target may not be known intuitively, 
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but can be inferred based on what dominates the natural immune response to the 
pathogen in protected hosts. In other cases, for example HIV, broadly-neutralizing 
antibodies are an extremely rare natural event, but therapeutic antibodies can be isolated 
from the few individuals who are naturally resistant to disease progression(26). Most 
anti-infective antibodies fall into one of three major categories; antibodies that neutralize 
soluble antigens, antibodies that target intact pathogens, and antibodies that block host 
receptors. 
 
Bacterial toxins are not infectious themselves, but are the causative agents of 
morbidity in bacterial infections such as B. pertussis(27), S. aureus(28), and C. 
difficile(29). Antibodies binding the toxin are therefore not directly anti-infective, but 
rather can prevent physiological damage, inflammation, and other symptoms while 
antibiotics and the host immune system clear the infection(17). In some cases the toxin is 
also immunosuppressive(30), and anti-toxin antibodies may lead to a reduction in the 
bacterial load(8). Neutralizing antibodies commonly function by blocking receptor-
binding sites on the toxin(27, 31), but can also work by preventing conformational 
changes(32) or enhancing immune complex formation and removal(33).  Anti-toxin 
antibodies are also an ideal prophylactic agent for bioweapons such as anthrax(34) and 
botulism(35), as they can provide “instant immunity” against highly-lethal toxins for 
several months.  
 
Antibodies can also directly target bacteria by binding surface proteins(36) or 
lipopolysaccharides (LPS)(37). In such cases the antibodies can initiate complement- or 
antibody- mediated cytotoxicity or phagocytosis, and are considered bactericidal(37). 
This mechanism is therapeutically relevant for treating infections of antibiotic-resistant 
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bacteria like P. aeruginosa, which is cleared in healthy individuals by complement-
mediated opsonophagocytosis or killing(37). A recombinant IgM antibody directed 
against a common P. aeruginosa surface LPS serotype is able to recruit host immune 
cells(37) and is in clinical trials for the treatment of nosocomial pneumonia(38). Binding 
the extracellular surface is also a convenient way to deliver other drugs to the area, as 
demonstrated with an antibody-antibiotic conjugate that targets intracellular S. 
aureus(14).  
 
Antiviral antibodies are typically directed against surface glycoproteins on the 
capsid (naked viruses) or envelope. For example, most influenza A antibodies in 
development target hemagglutinin (HA), which mediates fusion of the virus to the host 
cell. These antibodies can therefore neutralize the virus through two mechanisms; direct 
blocking of membrane fusion in the endosome and lysis of coated particles via antibody-
dependent cellular cytotoxicity (ADCC)(39). Even within a particular glycoprotein 
antigen, antibodies targeting different epitopes may utilize distinct mechanisms for 
neutralization. The RSV F protein has significantly different pre- and post-fusion 
structures, and while epitopes within the antigenic site II are mostly conserved between 
these two structures, epitopes in the more recently described antigenic site Ø are only 
present in the pre-fusion structure(40, 41). Thus, an antibody targeting site II may be 
neutralizing even after viral attachment, while a neutralizing antibody targeting site Ø 
likely functions by preventing the conformational change required for fusion(40). 
Interestingly, only anti-RSV antibodies targeting antigenic site II were found to have Fcγ-
dependent mechanisms(42), which is yet another example of how the fine epitope 
specificity can drive mechanism.  
 
10 
 
An alternative approach to treating diseases with antibodies is to target host 
receptors that are involved in disease progression. For example, there are several 
therapeutic HIV antibodies in development that bind the host receptors CD4(43) or 
CCR5(44), and prevent required conformational changes to allow viral entry. A benefit of 
targeting the host receptor is that the therapeutic can work on a broad spectrum of viral 
isolates, as long as they have the same entry mechanism. Checkpoint inhibitors such as 
anti-PD1 antibodies, which have recently been approved for several cancers, also have 
potential for treating infectious diseases by reversing T-cell exhaustion associated with 
chronic antigen stimulation(45). Other immune modulating antibodies targeting 
cytokines(46) or complement(47) are also in clinical trials for infectious indications.  
 
A key consideration in all of these approaches is that the targeted epitope needs to 
be highly conserved. Pathogens can escape a therapeutic either at the population level, 
where a diversity of circulating strains with different antigenic properties is available to 
infect a host; or within a single host, where high mutation rates in the pathogen can 
quickly generate escape mutants in response to therapeutic pressure. For example, 
naturally-elicited influenza A antibodies are targeted against the highly-variable 
hemagglutinin (HA) head, necessitating a constantly evolving vaccine formulation to 
keep up-to-date with the year’s dominant strain(48). In contrast, promising recombinant 
antibodies against influenza A typically recognize the less-variable HA stalk, and are 
chosen based on their ability to neutralize both group1 and group 2 strains(49, 50). One 
influenza A antibody in clinical trials was computationally designed to bind a conserved 
epitope by rationally targeting highly networked residues that are less likely to be 
mutated(51).  Similarly, the quest for broadly neutralizing antibodies against HIV has 
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focused on conserved features in the gp120 envelope protein(52), which reduces the 
chance of functionally-active escape variants.  
 
Affinity maturation is the process by which tighter binding antibodies are 
generated and selected for, which happens naturally in vivo over the course of an 
infection. Accordingly, substantial protein engineering effort has traditionally been 
placed on affinity maturation of therapeutic antibody candidates. This is often done by 
generating targeted libraries to the complementary-determining regions (CDRs) that bind 
the epitope, transfecting those libraries into a phage or yeast display library, and using a 
panning or flow cytometry method to select for improved binders. In many cases a clear 
correlation can be seen between antibody affinity and in vitro and in vivo efficacy, as 
nicely demonstrated for antibodies targeting the anthrax PA toxin(12) and staphylococcal 
enterotoxin B(53). The rationale is simple; a higher-affinity antibody will spend more 
time bound to the antigen, thus is more efficient at providing its protective effect.  
 
While the effects of affinity improvements can be easily spotted in vitro or in 
simple animal models, at a certain point there may be minimal additional protection 
provided in human disease. This is illustrated by the painful parable of motavizumab, an 
ultra-high affinity version of pavilizumab. Extensive affinity maturation was performed 
through saturation mutagenesis of the CDR loops and selection using phage display(54).  
The final selected variant, motavizumab, exhibited a 70-fold higher affinity, was 
protective at one-hundredth the dose, and even displayed additional therapeutic 
mechanisms(10). Unfortunately, clinical trials were unable to show the superiority of 
motavizumab and also exposed higher rates of hypersensitivity reactions, and ultimately 
the FDA voted against motavizumab approval(55). Interestingly, during development, it 
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was noticed that affinity improvement due to faster association rates (kon) rather than a 
slower off-rate (koff) resulted in improved neutralization of virus in vitro(54), but also 
increased non-specific tissue binding(10). Although these issues were resolved before 
clinical trials, the increased hypersentivity reactions may be attributable to this cause, and 
serve as a reminder that antibody selectivity for the target over non-target antigens is just 
as important as the overall affinity.  
 
Improving neutralization with oligoclonal antibody mixtures 
The natural immune response is polyclonal, and for good reason; infectious 
pathogens are, by definition, highly variable and highly mutable. A polyclonal mixture 
therefore is powerful in that it can provide broad protection against a variety of strains in 
the environment as well as genetic shift inside the host(56). In addition, a natural 
antibody response includes antibodies specific to many different possible epitopes, and 
such a mixture could theoretically neutralize a pathogen through several complementary 
pathways. Although the specific protective agent was not known at the time, this 
powerful efficacy was appreciated, and “serum therapy” was first deployed in the late 
1800s for a variety of diseases(57). Serum therapy for diphtheria consisted of an infusion 
of purified equine serum from animals immunized with diphtheria toxin, and reduced the 
mortality rate in children from 50% to 5%(58). Use rapidly declined in the 1930s due to 
side effects from poor purity and the invention of the first antibiotics(59), but similar 
approaches are still used today for the treatment and prevention of diseases like tetanus, 
rabies, and congenital cytomegalovirus (CMV)(60).  
 
Modern serum therapy consists of high titer immunoglobulin (IG) purified from 
the pooled sera of human (or in certain cases, animal) donors, and is subject to strict 
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purity and safety standards(61). However, as a human-sourced product, IG suffers from 
other drawbacks including a limited supply, lot-to-lot variability, and a risk of blood-
borne pathogen transmission(56). In addition, even though specialty IG preparations are 
enriched for pathogen-specific antibodies, extremely high doses (100s of mg/kg) are 
required for efficacy(60). Recombinant antibody therapeutics can overcome many of the 
limitations of IG, and there is some precedence for using monoclonals to treat infectious 
diseases. For example, a single high-affinity recombinant antibody targeting the RSV F 
protein was able recapitulate or even exceed the efficacy of the IG preparation(62), and is 
recommended over RSV-IG for high-risk infants(63).  
 
Despite success of several monoclonal anti-infective antibodies, for many 
applications an antibody mixture may improve efficacy. This may be a critical strategy 
for the treatment of highly mutable pathogens such as HIV, which is able to escape even 
from highly potent broadly neutralizing antibodies(64).  A mixture of antibodies targeting 
distinct epitopes would be expected to protect against a broader range of circulating HIV 
strains, while also reducing the chance of escape variants. In a recent paper, mixtures of 
two to four antibodies were able to neutralize 100% of viruses from a panel of 125 strains 
at conditions where the monoclonal only neutralized 25-66%(65). In a macaque treatment 
model, administration of a mixture of two antibodies controlled viremia for two to five 
times longer than monotherapy, with loss of efficacy correlated to the decline of antibody 
in the plasma rather than viral escape(66).  
 
Recombinant antibody mixtures may also benefit from synergy of several 
components, leading to increased efficacy and lower required doses. In such cases, the 
individual antibodies often utilize distinct neutralization pathways for efficient clearance 
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of a pathogen. This is illustrated by a mixture of two antibodies that bind staphylococcal 
enterotoxin B (SEB), a notable superantigen and potential bioweapon. One antibody 
blocked the TCR binding site on the toxin and was independently neutralizing, but 
addition of a second non-neutralizing antibody significantly improved efficacy by 
inducing formation of immune complexes(67). Notably, in some cases antibodies which 
are minimally protective individually may be potent components of a mixture, such as a 
ternary mixture of anti-botulism toxin antibodies which exhibited a 20,000-fold increase 
in potency compared to each individual antibody(35). Synergy is not limited to 
antibodies; potent synergy has been observed between antibodies and small-molecule 
antiviral drugs(68), and such combination therapy is a viable therapeutic strategy.    
 
Oligoclonal antibody mixtures are an exciting maturation of the field of antibody 
technology; we are now able to better understand and appreciate the enormous capability 
and finesse of the natural immune response, and finally have the technology to begin to 
replicate it. High-throughput screening of antibody mixtures remains a challenge, and to 
date most antibody mixtures have been rationally chosen from a small subset of 
monoclonals . In addition, validation of superior in vivo performance of the mixture 
should be emphasized early on, as antibody mixtures are moderately to significantly more 
costly to develop(69). The recent approval of bezlotoxumab (Zinplava) serves as a 
cautionary tale; while preliminary mouse studies supported the idea that a combination of 
two antibodies (actoxumab and bezlotoxumab) against C. difficile toxins A and B 
improved efficacy, it was not until phase III trials and follow up studies that actoxumab 
was dropped from the combination due a lack of added benefit(70). That being said, there 
are currently 9 antibody mixtures for infectious diseases in clinical trials, and many more 
in development. New strategies for efficient production of these mixtures at 
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manufacturing scale are being developed(69), including single-pot strategies that can 
significantly reduce costs(71). FDA approval requirements are evolving to match this 
new therapeutic modality, and it is no longer required to perform separate efficacy trials 
for each component(72) . 
 
Fc engineering for improved function and half-life 
Recombinant antibodies are almost exclusively of the IgG class, which is the most 
common antibody class found in the serum and most commonly associated with long-
term protective effects. The IgG class is further divided into four isotypes (IgG1, IgG2, 
IgG3, IgG4), which have ~90% sequence homology but  differences in some surface 
exposed residues and the hinge region(73). Distinct structures lend each isotype to 
different jobs; for example, IgG2 can form covalent dimers and is important for the 
targeting of repetitive bacterial surface carbohydrates(74), while IgG4 can swap arms to 
become functionally monovalent and so mediate anti-inflammatory effects(75). In 
practice, the vast majority of therapeutic antibodies have been developed as IgG1, partly 
due to historical precedence and prevalence in the natural immune response and partly 
due to function. There are several approved IgG2 and IgG4 antibodies, typically with 
stabilizing mutations in the IgG4 hinge to prevent fab arm exchange(76). IgG3 is not 
commonly pursued as a therapeutic molecule, in part due to hinge instability, more 
complex manufacturing, and a shorter serum half-life(73).  
 
The four IgG isotypes have subtle differences in surface exposed residues in the 
Fc region which causes differential binding of Fcγ receptors (FcRs) expressed on immune 
cells(77). Antibody-mediated effector functions such as antibody-dependent cellular 
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and 
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complement-dependent cytotoxicity (CDC)(76) can be powerful mechanisms against 
infectious pathogens.  The balance of binding to particular activating and inhibitory 
receptors determines the magnitude and type of effector response; IgG1 is highly 
activating and induces potent ADCC and CDC, whereas IgG4 is mostly inert(73).  
Although alternative isotypes are not often characterized, proper isotype selection can be 
a critical factor in antibody efficacy, as demonstrated with an antibody targeting  C. 
neoformans(78). Another approach is to modify the Fc region for altered FcR binding and 
therefore altered immune interaction. For example, antibodies targeting the influenza 
hemagglutinin stalk were found to be potent inducers of ADCC, and Fc variants with 
enhanced binding affinity to activating FcγRs significantly improved survival in a murine 
challenge study(79). In some instances it may be desirable to have a very inert Fc region, 
as present on IgG4. For example, activating antibodies against dengue virus are 
correlated with increased disease severity, due to antibody-dependent enhancement in 
which opsonization increases infectivity(80).  
 
Post-translational modifications such as glycosylation can impact FcR binding, 
and need to be considered during antibody optimization. IgG antibodies contain a 
conserved N-glycosylation site at N297, which is located near the N-terminus of the CH2 
region and helps stabilize an open conformation(81). Mutations at this site which prevent 
glycosylation result in a significant loss in FcR binding, C1q binding, ADCC and CDC.  
A wide diversity of glycoforms are generated during manufacturing, and vary 
significantly between different proteins and different expression platforms(82). Control 
of glycosylation may be a way to fine-tune antibody effector functions further; a recent 
paper generated IgGs with homogenous glycoforms, and found that fucosylation of the 
core glycans significantly reduced ADCC(83). 
17 
 
The neonatal Fc receptor (FcRN) is expressed throughout the body and functions 
to transport and recycle circulating antibodies. This transport process is initiated by 
extracellular binding of the antibody at physiological pH, followed by internalization and 
acidification of the endosome, subsequent dissociation of the antibody from the receptor 
at low pH and return of the antibody to the cell surface(84). FcRn binds an epitope at the 
CH2-CH3 domain interface, and engineering of this site can be used to modify the FcRn 
binding characteristics of the antibody.  The well- characterized M252Y/ 
S254T/T256E (YTE) mutant has improved affinity for FcRn while maintaining 
the pH selectivity(85),  which results in a nearly 4-fold improvement in in vivo half-
life(86). These and other half-life-extending mutations can have a significant impact on 
the efficacy and economy of antibody prophylaxis; a YTE variant of an RSV-targeting 
therapeutic is currently in clinical trials, and is projected to reduce dosing from once per 
month to once per season(87).  
 
TRIM21 is a recently described cytosolic FcR that binds antibody-bound virus 
inside the cell. TRIM21 is expressed in most tissues and most antibody classes, and 
seems to function as a “last line of defense” against virus that has escaped immune 
evasion(88). The antiviral activity of TRIM21 is sensitive to the kinetics of Fc binding, 
and engineering of antibodies with improved TRIM21 binding may be a useful strategy 
for therapeutic anti-viral antibodies(89).  
 
Designing novel antibody formats for novel methods of action 
Huge advances in cloning, expression and purification technologies over the past 
40 years allow protein engineers today to have a veritable toolbox of antibody bits and 
pieces to play with. Novel formats, such as antibody-drug conjugates and bispecific 
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antibodies, have the potential to change the therapeutic paradigm by rewiring the immune 
system. For evolving, diverse targets such as infectious pathogens, such non-native 
approaches may be a critical strategy for curing disease.  
 
Antibody-drug conjugates (ADCs) exploit an antibody’s natural specificity to 
deliver a therapeutic to a desired area. While the conjugated drug is the active molecule 
for therapeutic benefit, the antibody specificity and affinity will define where the payload 
is delivered. A crucial design element is a linker between the antibody and payload, 
which is cleaved under specific conditions to release the active drug(90). Although ADCs 
are mostly being investigated as a way to target toxic chemotherapy agents to cancerous 
cells, a similar strategy can be used to target antibiotics to sites of bacterial infection. An 
antibody-antibiotic conjugate is currently being developed for the treatment of S. aureus, 
which is often a stubborn infection in healthcare settings(14). The antibody moiety 
targets a cell-wall glycopolymer, tethering the antibiotic to the bacterial surface, which is 
then released when the bacteria are phagocytosed. In this case the antibody-antibiotic 
conjugate allows the antibiotic to reach a protected infective reservoir which is not 
accessible to standard antibiotic approaches(14).  
 
Bispecific antibodies bind two distinct targets, the choice of which will define the 
mechanism of action. There are over 60 formats of bispecific molecules in development, 
with applications in cancer, inflammatory, and infectious diseases(91). The simplest 
application is to use a bispecific as a way to target two distinct antigens with the same 
molecule, which in some cases can be an alternative to an antibody mixture(92). A more 
nuanced usage is to leverage bispecificity as a way to increase the selectivity and 
effective affinity for a challenging target. For example, a bispecific antibody for P. 
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aeruginosa can easily find and bind to the ubiquitous exopolysaccharide Psl, and once 
anchored is then able to more effectively target the rarer but therapeutically relevant PcrV 
protein(93).  Finally, the original and arguably most powerful application of bispecific 
antibodies is to simultaneously bind and redirect cytotoxic T cells (CTLs) to infected 
cells(94). This has been demonstrated in the context of HIV infection using a bispecific 
antibody fragment which targets HIV envelope protein on the surface of infected cells 
and CD3 of CTLs(95). The bispecific antibody is capable of inducing an effective 
immune synapse and allows the cytotoxic T-cell to kill the infected target cell. 
 
ImmTAVs function similarly to T-cell redirecting bispecifics, except that the 
surface-antigen-specific arm is replaced with a soluble T-cell receptor (TCR)(96). Unlike 
antibodies, which typically recognize conformational epitopes on extracellular pathogens, 
TCRs recognize linear peptides that are displayed on HLA molecules. The TCR/peptide-
HLA interaction is the natural mechanism by which the immune system recognizes 
intracellular pathogens, and thus is a particularly interesting complex for infectious 
disease. An ImmTAV targeting an immunodominant HIV epitope has been shown to 
mediate killing of infected cells in vitro(96), and may be an interesting approach for other 
elusive viral infections.  
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A SURVEY OF ANTI-INFECTIVE ANTIBODIES IN DEVELOPMENT 
There are currently 40 therapeutic antibodies or combinations in development for 
infectious indications (Table 2), with many more in preclinical and discovery phases. 
Herein we briefly survey particular applications for which antibodies are being 
developed, which can broadly be grouped as common infections, bioterror threats, 
nosocomial diseases, highly virulent infections, and broad spectrum approaches.    
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Table 2. Antibodies for infectious diseases in US clinical trials (April 2017) 
Name Disease Target Source/Isotype Clonality/Format/Fc Status Developer 
Suptavumab(97) 
(REGN2222) 
RSV Viral glycoprotein- 
RSV F protein 
Human 
IgG1 
Monoclonal Phase III Regeneron 
ALX-0171(98) RSV Viral glycoprotein- 
RSV F protein site II 
Camel 
VHH 
Nanobody Phase II Ablynx 
MEDI8897(87) RSV Viral glycoprotein- 
RSV F protein site Ø 
Human 
IgG1 
Monoclonal with 
extended half-life 
Phase II Medimmune 
CSJ148(99) CMV Viral glycoprotein- 
gB, pentameric compex 
Human 
IgG1 
Mixture (2) Phase II Novartis 
GC1102(100) HBV Viral glycoprotein- 
HBV surface antigen 
Human 
IgG1 
Monoclonal Phase II Green Cross 
Bavituximab(101) 
(PGN401) 
HCV Infected cells- 
Phosphatidylserine 
Chimeric 
IgG1 
Monoclonal Phase II Peregrine 
Pharmaceuticals 
XOMA3AB(102) Botulism Bacterial toxin- 
C. botulinum neurotoxin A 
Human/Humanized 
IgG1 
Mixture (3) Phase I Nanotherapeutics 
514G3(103) S. aureus 
bacteremia 
Bacterial surface- 
Staphylococcus protein A 
Human 
IgG3 
Monoclonal Phase II XBiotech 
MEDI4893(21) S. aureus 
pneumonia 
Bacterial toxin- 
S. aureus alpha toxin 
Human 
IgG1 
Monoclonal with 
extended half-life 
Phase II Medimmune 
AR-301(104) S. aureus 
pneumonia 
Bacterial toxin- 
S. aureus alpha toxin 
Human 
IgG1 
Monoclonal Phase II Aridis 
ASN100(105) S. aureus 
pneumonia 
Bacterial toxin- 
S. aureus alpha toxin/ 
leukocidins 
Human 
IgG1 
Mixture (2) Phase II Arsanis 
DSTA4637S(14) S. aureus 
pneumonia 
Bacterial surface- 
Staph wall techtoic acid 
Human 
IgG1 
Monoclonal ADC Phase I Genentech 
Aerumab(38) 
(panobacumab) 
P. aeruginosa 
pneumonia 
Bacterial surface- 
LPS serotype O11 
Human 
IgM 
Monoclonal Phase II Aridis 
Pharmaceuticals 
Aerucin(106) P. aeruginosa 
pneumonia 
Bacterial exopolysaccharide- 
alginate 
Human 
IgG1 
Monoclonal Phase II Aridis 
Pharmaceuticals 
MEDI-3902(93) P. aeruginosa 
pneumonia 
Bacterial exopolysaccharide-PslI; 
secretion system- PcrV 
Human 
IgG1-Fab-ScFv 
Bispecific Phase II Medimmune 
Ibalizumab(107) HIV-1 Host viral receptor- 
CD4 
Humanized 
IgG4 
Monoclonal Phase III TaiMed Biologics 
PRO 140(44) HIV-1 Host viral receptor- 
CCR5 
Human 
IgG4 
Monoclonal Phase III CytoDyn 
22 
 
Table 2. Antibodies for infectious diseases in US clinical trials, continued 
 
UB-421(108) HIV-1 Host viral receptor- 
CD4 
Humanized 
aglycosylated IgG1 
Monoclonal Phase II United Biomedical 
Inc. 
VRC01(109) HIV-1 Viral glycoprotein- 
gp120 CD4bs 
Human 
IgG1 
Monoclonal Phase II NIAID 
VRC01-LS(110) HIV-1 Viral glycoprotein- 
gp120 CD4bs 
Human 
IgG1 
Monoclonal with 
extended half-life 
Phase I NIAID 
 
3BNC117(111) HIV-1 Viral glycoprotein- 
gp120 CD4bs 
Human 
IgG1 
Monoclonal Phase II Rockefeller 
University 
10-1074(112) HIV-1 Viral glycoprotein- 
gp120 V3 
Human 
IgG1 
Monoclonal Phase I Rockefeller 
University 
3BNC117 + 10-1074(66) HIV-1 Viral glycoprotein- 
gp120 CD4bs + V3 
Human 
IgG1 
Mixture (2) Phase I Rockefeller 
University 
PGT121(113) HIV-1 Viral glycoprotein- 
gp120 V3 
Human 
IgG1 
Monoclonal Phase I International AIDS 
Vaccine Initiative 
VRC07-523LS(114) HIV-1 Viral glycoprotein- 
gp120 CD4bs 
Human 
IgG1 
Monoclonal with 
extended half-life 
Phase I NIAID 
MB66(115) HIV-1/HSV-2 Viral glycoproteins- 
HIV-1 gp120, HSV-2 gD 
Unknown Mixture (2) 
vaginal film 
Phase I Mapp 
Biopharmaceutical 
MEDI8852(50) Influenza A Viral glycoprotein- 
G1/G2 Hemagglutinin stalk 
Human 
IgG1 
Monoclonal Phase II Medimmune/Humabs 
Biomed 
CR8020(116) Influenza A Viral glycoprotein- 
G2 Hemagglutinin stalk 
Human 
IgG1 
Monoclonal Phase II Crucell Holland 
CR6261(117) Influenza A Viral glycoprotein- 
G1 Hemagglutinin stalk 
Human 
IgG1 
Monoclonal Phase II Crucell Holland 
MHAA4549A(39) Influenza A Viral glycoprotein- 
G1/G2 Hemagglutinin stalk 
Human 
IgG1 
Monoclonal Phase II Genentech 
VIS410(118) Influenza A Viral glycoprotein- 
G1/G2 Hemagglutinin stalk 
Human 
IgG1 
Monoclonal Phase II Visterra Inc. 
CT-P27(119) Influenza A Viral glycoprotein- 
G1/G2 Hemagglutinin stalk 
Unknown Mixture (2) Phase II Celltrion 
TCN-032(120) Influenza A Viral surface protein- 
M2 ectodomain 
Human 
IgG1 
Monoclonal Phase II Theraclone Sciences 
Zmapp(121) Ebola Viral glycoprotein- 
Ebolavirus glycoprotein 
Human/Chimeric 
IgG1 
Mixture (3) Phase II Mapp 
Biopharmaceutical 
REGN3470 + 
REGN3471 + 
REGN3479 
Ebola Unknown Unknown Mixture (3) Phase I Regeneron 
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Table 2. Antibodies for infectious diseases in US clinical trials, continued 
 
SYN023 Rabies Viral glycoprotein Humanized 
Unknown 
Mixture (2) Phase II Synermore Biologics 
 
 
Shigamabs(122) 
(cαSTX1/cαSTX2) 
STEC-HUS Bacterial toxin- 
Shiga toxin 1/2 
Chimeric 
IgG1 
Mixture (2) 
 
 
Phase II Taro Pharmaceuticals 
Solaris(47) 
(eculizumab) 
STEC-HUS Host complement protein- 
C5 
Humanized 
IgG2/4 
Monoclonal Phase III University Hospital 
Tolouse/Alexion 
Pharmaceuticals 
Pascolizumab(123) Tuberculosis Host cytokine- 
IL-4 
Humanized 
IgG1 
Monoclonal Phase II National University 
Hospital, Singapore 
Nivolumab(124) Sepsis Host checkpoint inhibitor- 
PD-1 
Human 
IgG4 
Monoclonal Phase I Bristol-Myers Squibb 
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Prophylaxis of common diseases in high-risk patients 
Respiratory Syncytial Virus 
RSV is a common cause of lower respiratory tract disease in infants and children, 
and can cause serious morbidity and mortality in infants with heart or lung disease(62). 
Treatment options in the case of severe options are limited, typically including oxygen 
and respiratory assistance. Medimmune’s pavilizumab (Synagis) was first approved in 
1998 for the prevention of RSV(6), and is currently indicated for use in high-risk pre-
term infants (63). There are three other similar RSV antibodies in clinical trials. 
Regeneron has been quietly developing suptavumab, and Medimmune has a follow-up 
antibody, MEDI8897, which contains the half-life-extending YTE mutations, which 
should result in once-per-season dosing(87). Finally, Ablynx is developing the nanobody 
ALX-0171, which can be nebulized and inhaled. 
 
Human Cytomegalovirus 
Human cytomegalovirus is one of the most ubiquitous pathogens worldwide, 
infecting 50-90% of the population by age 50, yet there is still no vaccine available(125) . 
Primary or reactivated CMV during pregnancy can result in congenital infection of the 
fetus, causing birth defects including hearing loss and neurological defects. Reactivation 
or infection in transplant patients can cause serious morbidity due to immunosuppression, 
and current antivirals have significant toxicity profiles. Novartis is in phase II trials with 
a mixture of two antibodies targeting the gB protein and gH/gL/UL128/UL130/UL131a 
pentameric complex(99), with the goal of preventing CMV replication after stem cell 
transplantation. Genentech’s phase II study of a mixture of two monoclonal antibodies to 
prevent CMV in high-risk kidney transplant patients was moderately successful(126), but 
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the project seems to have been terminated. Recently, a new antigenic “hot spot” was 
identified on the gH protein, and may be a target for future antibody therapeutics(127).  
 
Hepatitis B and Hepatitis C 
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is a 
major cause of liver fibrosis, liver cirrhosis, and liver cancer(22). In the case of a liver 
transplant into HBV or HCV seropositive donors, prophylactic measures are necessary to 
prevent reactivation of the virus. Green Cross has recently completed phase II trials with 
GC1102, a human monoclonal antibody directed against an unknown epitope of the 
hepatitis B surface antigen (HBsAg)(128), for prophylaxis of HBV recurrence in liver 
transplant recipients.  
 
Pertussis 
Despite wide-spread vaccination, whooping cough, or pertussis, infects nearly 4 
million people worldwide a year. Systemic symptoms are caused by pertussis toxin 
(PTx), which is secreted by the pathogen B. pertussis(27). Synthetic Biologics and The 
University of Texas are developing a humanized antibody which neutralizes the 
toxin(27). A bispecific format of the two antibodies has also been tested as single-
molecule alternative to an antibody mixture (92). 
 
Neutralization of bacterial toxin bioterrorism agents 
Anthrax 
Spores of B. anthracis have been developed and used as a bioweapon, with 
inhalation of these spores leading to ~50% mortality rates even with treatment. Morbidity 
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and mortality is caused by three anthrax exotoxins lethal factor (LF) and edema factor 
(EF), which associate with the receptor-binding protective antigen (PA) to target the 
cardiovascular system and liver(129).  Two anti-PA antibodies, raxibacumab 
(Abthrax)(7) and obiltoxaxumab (Anthim)(8), have been approved for the prophylaxis 
and treatment of inhalational anthrax. Raxibacumab is a human IgG1 with an affinity of 
~3nM(11), while obiltoxaxumab is a chimeric IgG1 with an ~10-fold higher affinity(12). 
Both antibodies are currently maintained at the US strategic national stockpile in case of 
a bioweapon emergency.  
 
Botulism 
Botulinum neurotoxin A is the most toxic substance known to man, and is 
classified as a high-risk threat agent for bioterrorism(35). The toxin is secreted by the 
bacterium C. botulinum, and consists of a binding, translocation, and active domain. A 
study of several antibodies binding distinct epitopes on the translocation domain 
exhibited enormous synergy in a mouse challenge model, with a mixture of three 
antibodies showing a 20,000-fold increase in potency compared to any individual 
antibody(35).  
 
Other bacterial toxins 
Other potential bioweapon agents include ricin, which is a potent inhibitor of 
protein synthesis(130); and staphylococcal enterotoxin B(53), which is a superantigen 
that can cause massive cytokine release. Neutralizing antibodies have been identified for 
each of these targets, and may be prophylactic candidates in the future.  
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Treatment and prevention of healthcare-associated infections 
Clostridium difficile infection 
C. difficile is a common intestinal bacterium that can cause symptomatic and 
severe infection when the normal gut microbiome is disrupted. This is frequently 
associated with individuals who are on long-term antibiotic regimens. Bezlotoxumab 
(Zinplava) is a recently-approved monoclonal antibody that neutralizes the enterotoxin 
TcdB, and helps prevent infection recurrence in high-risk individuals(9).  
 
Staphylococcus Aureus Pneumonia 
S. aureus is a common infection that is frequently found at hospitals, along with 
methicillin-resistant strains. S. aureus most often presents as a topical skin infection, but 
can also cause bacteremia or severe pneumonia in weakened individuals, particularly 
those on a ventilator. There are several antibodies in clinical trials for the treatment of 
prevention of S. aureus in high-risk individuals. Aridis is developing a monoclonal 
antibody that neutralizes the alpha-toxin which is a critical component of severe 
disease(104). Medimmune is developing a similar antibody with half-life extending 
mutations(21), while Arsanis is developing an antibody mixture that not only neutralizes 
the alpha toxin but several other toxins as well(105). XBiotech is developing an antibody 
that targets the bacterial surface for bacteremia(103).  Of particular interest, Genentech 
has developed an antibody-antibiotic conjugate that is particularly suited for eliminating 
niches of infective bacteria hiding inside other cells(14).  
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Pseudomonas aeruginosa pneumonia 
P. aeruginosa is another common nosocomial pathogen, and is particularly 
implicated for chronic lung infections in cystic fibrosis patients as well as the formation 
of biofilms. Aridis is developing two antibodies for the treatment of severe P. aeruginosa 
pneumonia; Aerumab is an IgM targeting a common LPS serotype(37, 38), while Aerucin 
is an IgG1 targeting alginate(106), a common biofilm component. Medimmune is 
developing an interesting bispecific antibody, which anchors to the bacteria by binding a 
ubiquitous surface protein and then binds and inhibits the secretion of virulence factors 
from a type III secretion system(93).  
 
Potent neutralization of deadly viruses 
Human immunodeficiency virus - 1 
HIV-1 may be the pathogen most people think of when they hear the word 
“evolution”, and rightly so- HIV-1 still remains incurable, and there is a broad pipeline of 
recombinant HIV antibodies in the pipeline. The first of these antibodies are antagonists 
that block the host receptors where HIV binds, and include ibalizumab(43, 107), PRO 
140(44), and UB-421(108). The second wave of anti-HIV antibodies are those which 
neutralize conserved epitopes on the viral glycoprotein gp120. These entities include a 
native and half-life-extended antibody called VRC01(109, 131) and VRC01-LS(110), a 
similar antibody VRC07-523LS(114), and a more recently described, highly potent 
antibody 3BNC117(111). Several other antibodies that recognize a different region of 
gp120 include PGT121(113) and 10-1074(112). A mixture of two of the most promising 
candidates, 3BNC117 and 10-1074, is also under investigation(66). Finally, Mapp 
Biopharmaceuticals is developing a prophylactic vaginal film containing a mixture of two 
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neutralizing antibodies, which may be an interesting product for the developing 
world(115).  
 
Influenza A 
Influenza A is another highly mutable pathogen that is difficult to vaccinate 
against. Severe infections in the elderly, not to mention the possibility of pandemic 
outbreaks, can cause significant healthcare burdens. There are currently 7 antibody 
products in development for influenza A, which are typically directed against various 
conserved epitopes in the hemagglutinin (HA) stalk. These include the antibodies 
CR6261(117) and CR8020(116) which are specific for group 1 and group 2 HA 
respectively, as well as Medimmune’s MEDI8852(50) and Genentech’s 
MHAA4549A(39) which are active against a wide variety of strains. The broadly-
neutralizing antibody VIS410 is also in development(51, 118), which is notable because 
it was computationally designed. Celltrion is testing an antibody mixture, CT-P27(48), 
while Theraclone is developing TCN-032 which targets a different surface 
glycoprotein(120).  
 
Ebola 
The recent Ebola outbreak in west Africa highlighted the potential of prophylactic 
antibody therapy, and Mapp Biopharmaceutical was able to some testing of its tripartite 
antibody mixture, ZMapp(121, 132). This mixture is under further development, as is 
another antibody mixture from Regeneron.  
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Rabies 
Rabies has a nearly 100% fatality rate in humans, and suspected bites are still 
treated today with prophylactic anti-toxin. A mixture of anti-rabies antibodies from 
Crucell Holland(133) is no longer in development, but Synermore is currently in phase II 
trials with a different, unpublished cocktail.  
 
Other emerging viruses 
Recombinant antibodies may be useful therapeutic agents for emerging infectious 
diseases. Neutralizing antibodies have been described for Zika(134), MERS(135), and 
very recently the Marburg and Ravn filoviruses(136).  
 
Broad spectrum and host-mediated approaches 
Unusual cell morphology 
While the antibodies described above have been exquisitely tailored for a specific 
pathogen, there are several broad-spectrum approaches for anti-infective antibodies. For 
example, phosphatidylserine is a common component of the host cell membrane that 
typically resides on the inside surface. Interestingly, the plasma membrane of virally 
infected cells is unusual, and phosphatidylserine can be found on the extracellular 
surface. Thus, an antibody that recognizes the extracellular phosphatidylserine is 
potentially a broad-spectrum antiviral antibody, and is currently in clinical trials for 
HCV(101).  
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Host immune regulation 
Another approach is to use antibodies to mediate the host immune response. For 
example, the damaging outcomes of shiga toxin-producing E. coli-associated hemolytic-
uremic syndrome (STEC-HUS) is due to severe inflammation of the GI tract mediated by 
complement, and the already-approved C5 binding antibody, eculizumab (Soliris)(47), is 
in clinical trials for this indication. Similarly, an anti-IL-4 antibody, pascolizumab(123), 
may be able to prevent the severe pathology of tuberculosis by neutralizing inflammatory 
cytokines(46). Finally, checkpoint-inhibitors like nivolumab, which bind PD-1 and 
reverse T-cell exhaustion, may be useful for stimulating the immune system(45, 124).  
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CONCLUSION 
There are several niches for which antibodies are particularly suited, such as the 
passive immunization of immunocompromised individuals, neutralization of bioterror 
agents, potent killing of antibiotic-resistant bacteria, and broad neutralization of emerging 
and evasive viruses. The key hurdle- and perhaps rightly so- against developing 
antibodies for infectious disease is the huge costs associated. In the face of much cheaper 
to manufacture small molecules, and one-shot vaccines, there must be a real unmet 
clinical or market need for an antibody therapeutic to be an economically viable option. 
The ultimate success of these therapeutics hinges on efficacy, and careful consideration 
of antibody specificity and affinity, Fc functionality, clonality and format is crucial for 
the development of the next generation of antibody drugs.  
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Chapter 2: A cocktail of humanized anti-pertussis toxin antibodies 
limits disease in murine and baboon models of whooping cough1 
 
ABSTRACT 
In spite of wide-spread vaccination, pertussis rates are rising in industrialized 
countries and remain high world-wide. With no specific therapeutics to treat disease, 
pertussis continues to cause considerable infant morbidity and mortality. The pertussis 
toxin is a major contributor to disease, responsible for local and systemic effects 
including leukocytosis and immunosuppression. Here, we humanized two murine 
monoclonal antibodies that neutralize pertussis toxin and expressed them as human IgG1 
molecules with no loss of affinity or in vitro neutralization activity. When administered 
prophylactically to mice as a binary cocktail, antibody treatment completely mitigated the 
B. pertussis-induced rise in white blood cell count and decreased bacterial colonization. 
When administered therapeutically to baboons, antibody-treated but not control animals 
experienced a blunted rise in white blood cell count and accelerated bacterial clearance 
rates. These preliminary findings support further investigation into the use of these 
antibodies to treat human neonatal pertussis in conjunction with antibiotics and 
supportive care. 
 
                                                 
1 This chapter has been published in final edited form as: 
Nguyen AW*, Wagner EK*, Laber JR, Goodfield LL, Smallridge WE, Harvill ET, Papin 
JF, Wolf RF, Padlan EA, Bristol A, Kaleko M, Maynard JA.  A cocktail of humanized 
anti – pertussis toxin antibodies limits disease in murine and baboon models of whooping 
cough. Sci. Transl. Med. 7, 1–9 (2015). 
 
E. K. W. planned, performed, and analyzed antibody humanization, antibody 
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INTRODUCTION 
Despite wide-spread vaccination, pertussis remains a considerable public health 
concern. In recent decades, infection rates have risen dramatically in industrialized 
countries reaching a 60-year US high in 2012. This rise appears to be due to a variety of 
factors including increased surveillance, strain drift, waning immunity after acellular 
vaccination, and a vaccine-induced Th1/Th2 response instead of the more effective Th1 
response induced by whole cell vaccines and infection(137).  Worldwide, pertussis 
remains a major cause of infant death, claiming ~195,000 lives annually(138). Pertussis 
is of greatest concern for unimmunized infants, as they experience the most severe 
symptoms, including pneumonia and pulmonary hypertension due to severe 
leukocytosis(139). In the absence of alternatives, aggressive interventions including 
leukodepletion and exchange transfusion have been proposed to remove white blood 
cells(140).  
 
It is generally accepted that, in the long-term, an improved vaccine formulation 
better able to prevent disease transmission will be required(137, 141, 142). In the 
meantime, there remains a need for pertussis-specific therapeutics to treat infants with 
severe disease as antibiotics are only effective in the early stages, typically before 
diagnosis. Even after bacteria can no longer be cultured, symptoms persist for many 
weeks, presumably due to residual toxins. 
 
While B. pertussis produces a wide array of toxins and adhesins, several lines of 
evidence point to the pertussis toxin (PTx) as a critical virulence factor.  This AB5 toxin 
is essential for full bacterial pathogenicity(143), exhibiting local and systemic effects 
through its enzymatically active A subunit and its receptor binding B subunit. The overall 
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effects of PTx are inhibition of the innate immune response and induction of 
leukocytosis. Specifically, in mouse models of pertussis infection, the presence of PTx 
decreases pro-inflammatory chemokine and cytokine production(144), reduces neutrophil 
recruitment to the lungs, and increases bacterial burden(145). While these effects have 
not all been demonstrated in human disease, PTx does appear important in primates as 
well. In vitro, PTx has been shown to have an inhibitory effect on human dendritic cell 
migration that is predicted to slow their recruitment to secondary lymph nodes and 
subsequent activation of T-cells(146). In human infants, PTx production positively 
correlates with the extreme lymphocytosis that can lead to pulmonary hypertension(147).  
Finally, whereas most acellular vaccines are comprised of PTx in combination with other 
antigens, Denmark relies on a monocomponent PTx vaccine and reports no increase in 
symptomatic infection(148).  
 
Accordingly, high anti-PTx antibody levels are considered to correlate with 
protection(142, 149), and passive immunization with anti-PTx serum has been recognized 
as a potential therapeutic modality for neonatal pertussis. In the past two decades, two 
human polyclonal anti-PTx immunoglobulin preparations were tested and showed 
promise for treating pertussis in newborns(150–152). However, treatment with polyclonal 
antisera can be problematic due to low and variable neutralizing capacities as well as an 
unreliable supply.  For passive immunization, monoclonal antibodies provide a 
considerable advantage as they can be selected for high affinity and potent neutralizing 
abilities. For these reasons, the high titer intravenous immunoglobulin product to treat 
RSV was replaced with a single neutralizing antibody in 1996.  
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To treat pertussis, we propose a combination of two anti-PTx monoclonal 
antibodies selected to achieve high potency and to limit the possibility of allelic variants 
that could escape neutralization. Among the numerous anti-PTx monoclonal antibodies 
that have been evaluated over the past three decades, the murine antibodies 1B7 and 
11E6 stand out as uniquely protective in mouse models of pertussis infection(153, 154). 
However, murine antibodies are no longer considered suitable for use in humans due to 
their immunogenicity. Here we cloned and humanized the murine 1B7 and 11E6 
antibodies, produced them as human IgG1 antibodies in CHO cells, and extensively 
characterized them in vitro. The humanized antibodies were assessed in a murine 
challenge model using a recent human B. pertussis isolate and compared to the high-titer 
intravenous immunoglobulin preparation (P-IVIG) used in recent human clinical 
trials(151). Finally, the antibodies were tested in a newly described baboon model 
considered highly relevant for the development of pertussis therapeutics(155). 
Collectively, the data support further animal modeling to assess the potential for passive 
immunotherapies to mitigate human neonatal pertussis. 
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MATERIALS AND METHODS 
Study design 
The objective of this study was to assess the protection conferred by two 
humanized anti-pertussis toxin antibodies in animal models of pertussis. In both the 
mouse and baboon model, strain D420, a recent clinical isolate of B. pertussis, was used 
to infect the animals.  
 
An established murine model used to develop the current vaccine was employed 
to evaluate the prophylactic protection conferred by these antibodies(153). BALB/c and 
C57BL/6 mice were used for the pharmacokinetic analysis and pertussis challenge, 
respectively. Based on pilot studies, groups of 6 mice were expected to detect antibodies 
with 75% of expected activity with 80% confidence in a one-tailed test with p=0.05 
(Appendix A Fig. 23). Mouse studies were terminated at day 10, based on pilot studies 
showing large differences in outcome at this time.  
 
A weanling baboon model was recently developed that may be more 
representative of human disease progression as evidenced by colonization of the trachea, 
WBC rise and paroxysmal coughing(155). This model was used to assess protection 
conferred by these antibodies when administered therapeutically on day 3 after infection, 
with four control animals and four treated animals. One control baboon became 
moribund, and data was not available after day 10 for that animal. Baboons were 
randomly assigned to groups and animal caretakers and laboratory technicians were 
blinded. The baboon study was terminated after ~21 days, or when WBC and bacterial 
colonization levels began to approach pre-infection levels. 
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Antibody variable region cloning and humanization   
The murine 1B7 and 11E6 variable region genes(153) were amplified from 
hybridoma cells by RT-PCR using degenerate primers and cloned into pAK100 as 
described(156). Positive clones were identified by monoclonal phage ELISA using a PTx 
coated plate (1 µg/ml in PBS; List Labs), followed by sequencing. Humanized variants 
were designed in silico via five different methods: (a) ‘veneering’ (ven); (b) ‘grafting of 
abbreviated complementarity determining regions (CDRs)’ (abb); (c) ‘specificity 
determining residue-transfer’ (sdr); and (d) grafting of intact CDRs onto the hu4D5 
framework or (e) a composite framework (fra)(157, 158). The resulting designed variable 
region genes were synthesized with human IgG1/ kappa constant domains by DNA 2.0 in 
pJ602 or pJ607 vectors. For chimeric constructs, murine variable regions were similarly 
cloned with human constant regions(156). 
 
Protein expression & purification   
For small-scale expression, plasmid DNA was transiently transfected into CHO-
K1 cells (ATCC) and purified using protein A affinity chromatography as 
described(156). Large scale preps were prepared by Catalent (Somerset, NJ) from 
polyclonal CHO cell lines, followed by protein A and anion chromatographic steps and 
buffer exchange into PBS. P-IVIG was obtained from the Massachusetts Public Health 
Biologic Laboratory (Lot IVPIG-2). P-IVIG was prepared as a 4% IgG solution from the 
pooled plasma from donors immunized with tetra-nitromethane inactivated pertussis 
toxoid vaccine(152).  
 
39 
 
ELISA and binding assays 
For indirect PTx ELISAs, a high-binding 96-well ELISA plate (Costar) was 
coated with 1 μg/ml PTx.  The plate was blocked with milk for 1 hr, followed by 
incubation with duplicate anti-PTx antibody dilutions from 50 μg/ml for 1 hr at 25 C. 
After washing and detection with 50 μl of 1 μg/ml goat anti-mouse-Fc-HRP (murine 
antibodies, Thermo Fisher), goat-anti-human Fc-HRP (chimeric and human antibodies, 
Thermo Fisher) or goat-anti-monkey IgG (H/L)-HRP (baboon serum; Bio-Rad), signal 
was developed with TMB Substrate (Thermo Fisher Scientific), quenched with 1M HCl 
and the absorbance at 450 nM recorded. To monitor antibody concentrations in cell 
culture supernatant, an Fc capture ELISA was employed, using the protocol above with 
the following modifications: a 5 μg/ml goat-anti-human Fc (Thermo Scientific) coat and 
2 μg/ml goat-anti-human kappa-HRP (SouthernBiotech) secondary antibody. For Fha 
ELISAs with baboon sera, a 1 μg/ml Fha (List) coat and 1:10,000 dilution of goat-anti-
monkey IgG (H/L)-HRP (Bio-Rad) secondary antibody was used. Data were scaled to the 
maximum response observed for positive control serum collected from an animal 3 weeks 
post-infection. 
 
PTx binding affinity was determined by both competition ELISA and surface 
plasmon resonance (SPR). For competition ELISA, an ELISA plate was coated with PTx 
and blocked as described above. While the plate was blocking, 3.25 nM of each antibody 
in PBS-T-milk was incubated with different concentrations of PTx (200 nM to 0.1 nM). 
The ELISA plate was washed and 50 μl of the antibody/PTx mixtures added. The plate 
was incubated for 15 min at 25 C. The plate was then washed, secondary antibody added 
and ELISA developed as above. The resulting curves were fit to equilibrium binding 
equations(159) corrected for bivalent binding.  
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Surface plasmon resonance analysis was performed using a BIAcore 3000 (GE 
Healthcare, Uppsala, Sweden; 1B7 variants) or Reichert SR7500DC (AMETEK, Berwyn, 
PA, USA; 11E6 variants) instrument with dextran chips. Antibodies were immobilized 
using standard EDC/ NHS chemistry to a level of 500-1000 response units as 
described(157). PTx was injected in duplicate at 30 µL/min or 100 µL/min (m1B7, 
ch1B7), with concentrations between 5-200nM diluted in running buffer (PBS or HBS, 
pH 7.4, 0.05% Tween). The surface was regenerated with a combination of 4M 
magnesium chloride and 10mM glycine, optimized independently for each antibody. 
Baseline correction was performed by subtracting simultaneous runs over an in-line 
control flow cell. The on- and off-rates were calculated using BIAevaluation software 
(Pharmacia Biosensor) or TraceDrawer (Reichert). Reported values are the average and 
standard deviation of all on- and off- rates calculated for each protein. 
 
In vitro neutralization  
Inhibition of CHO cell clustering was used to determine in vitro neutralization of 
antibody preparations as described(157). Briefly, antibody was serially diluted across a 
96-well tissue plate from 50 nM to 1.5 pM in the presence of 5 pM PTx. Antibody and 
PTx were incubated for 30 minutes at 37 C after which 2x104 freshly trypsinized CHO 
cells were added per well. After incubation at 37 C for 20 hours, the degree of clustering 
was scored as 0 (no clustering), 1 (equivocal), 2 (positive clustering), or 3 (maximal 
clustering). Experiments were performed in triplicate and scored independently by two 
researchers. Neutralizing dose is expressed as the molar ratio of antibody:PTx resulting in 
a score of 2. 
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Bacterial strain and growth  
B. pertussis strain D420 was isolated from a critically ill infant in Texas in 
2002(160). Bacteria were maintained on Regan-Lowe Agar (Becton Dickinson) 
supplemented with 10% sheep’s blood (Hemostat) with 20 µg/mL cephalexin. Liquid 
cultures were grown overnight in Stainer-Schölte broth with heptakis at 37 °C to mid-log 
phase.  
 
Ethics Statement  
All animal procedures were performed in a facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care International in accordance 
with protocols approved by UT Austin (#2012-00084, #13080701), PSU (#40029) and 
the University of Oklahoma Health Sciences Center (#14‐072‐I) Animal Care and Use 
Committee and the principles outlined in the Guide for the Care and Use of Laboratory 
Animals. 
 
Murine pharmacokinetic assay  
An in vivo pharmacokinetic study was completed using groups of six ~12 weeks 
old female BALB/c mice as described previously(161). Chimeric 11E6, humanized 11E6, 
humanized 1B7, or a 1:1 mixture of the humanized 1B7 and 11E6 antibodies at the same 
total antibody concentration were diluted to 250 μg/ml in PBS and 200 μl injected 
subcutaneously. Blood samples were collected via the tail vein at seven time points 
between 0 to 336 hours. Antibody concentration in sera was measured by PTx ELISA. 
After the final time point, mice were euthanized via CO2 inhalation and cervical 
dislocation. To estimate the beta half-life, the data was fit to a single exponential decay 
model: 𝐶(𝑡) = 𝑏𝑒𝑥𝑝(−𝛽𝑡).  
42 
 
In vivo mouse challenge  
Groups of six randomly assigned weanling C57BL/6 mice were each injected 
intraperitoneally with a single antibody (20 µg), P-IVIG (20 µg), or the antibody 
combination (10 µg hu1B7+10 µg hu11E6), or PBS two hours before sedation with 5% 
isofluorane in oxygen and inoculation with 5x10
6
 CFU B. pertussis strain D420 in PBS 
by pipetting 50 µL on the external nares.  Investigators were not blinded. The % weight 
change was calculated by the following formula:  ((day 10 weight – day 0 weight/day 0 
weight)*100) for each individual mouse. On day 10 mice were euthanized by CO2 
inhalation and the respiratory tract was excised for enumeration by serial plating on 
Regan Lowe agar supplemented with 10% sheep’s blood (Hemostat Resources) 
containing 40 ug/mL cephalexin. Colonies were counted after 5 days at 37oC. 
 
To assess the number of CD45+ white blood cells, blood was collected by orbital 
bleed (day 10) in a microtainer containing EDTA (Becton, Dickinson, and Company), 
and 50 µL blood were lysed in 4 mL red blood cell lysis solution (Alfa Aesar) for 6 
minutes.  Cells were incubated with anti-CD45 APC, washed, and resuspended in 2% 
paraformaldehyde before acquisition on the LSR Fortessa flow Cytometer (Becton, 
Dickinson, and Company). List mode data was then analyzed on FlowJo 7.6.1 (Treestar), 
with data reported as total WBC per 40 ul blood.  
 
Baboon challenge study   
Baboon studies were performed at the Oklahoma Baboon Research Resource at 
the University of Oklahoma Health Sciences Center as described previously(155). 
Weanling baboons were selected to be 6-9 months old at the time of challenge. Groups 
consisted of four animals based on published vaccination studies(155). The inoculum for 
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each direct challenge was between 109–1010 cfu as determined by optical density and 
confirmed by serial dilution and plating. The bacterial inoculum (1 ml) was delivered on 
day 0 via intranasal and intratracheal infusion. On day 3 after infection, animals were 
sedated and humanized anti-pertussis toxin antibodies administered intravenously (20 
mg/kg each). Post challenge, baboons were anesthetized and evaluated twice weekly for 
enumeration of circulating WBC, serum antibody levels, and nasopharyngeal bacterial 
load. Nasopharyngeal washes were diluted and plated on Regan–Lowe plates to quantify 
bacterial cell counts. Video recordings of each cage allowed quantification of cough 
rates. Sera were assessed for antibody titers to Bordetella antigens Fha and PTx by 
ELISA. At the end of the study, baboons were euthanized with an intravenous injection 
of euthanasia solution and necropsy was performed. Tissues were embedded and stained 
with H&E and evaluated by a veterinary pathologist. 
 
Statistical Analysis  
Mean ± error values were determined for all appropriate data. For the murine 
challenge experiment, one-way ANOVA with Tukey’s simultaneous test with 
significance (p <0.05) was used to determine statistical significance between groups.  
Error bars reported in mouse, baboon, and CHO cell assay experiments represent the 
standard error. All other error reported is the standard deviation. 
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RESULTS  
Cloning and humanization of murine 1B7 and 11E6 antibodies  
As the first step in humanization, the murine 1B7 (m1B7) and 11E6 (m11E6) 
antibody heavy and light chain variable region genes were cloned via RT-PCR from 
hybridoma cells using a degenerate primer set and PTx-reactive genes were identified. 
Next, 3-5 humanized variants of each variable region were generated in silico and the 
murine and humanized genes cloned into eukaryotic expression vectors encoding human 
IgG1 heavy or  light chain constant domains. All pairwise heavy-light chain 
combinations were expressed by transiently transfected CHO cells and the supernatant 
used to monitor specific PTx binding activity (Appendix A Fig. 19). Combinations 
yielding the highest specific activity were further analyzed after medium-scale expression 
and protein A purification. From these data, a single lead candidate was selected for each 
antibody which exhibited similar ELISA profiles as the murine parents and high 
expression (~5-10 pg/ cell/ day). Sequences of these variants are notably more human, as 
monitored by z-score (Appendix A Table 5)(162). 
 
Hu1B7 and hu11E6 antibodies are biochemically and biophysically similar to their 
murine predecessors   
After transient CHO cell expression and purification, the murine (m), chimeric 
(ch) and humanized (hu) antibodies were pure (~95%) and migrated at the expected sizes 
in SDS-PAGE gels (Fig. 3A). Increased thermal stability was observed, indicating that 
both the human constant and humanized variable regions are stabilized relative to the 
murine versions (Table 1, Appendix A Fig. 20).  
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Figure 3. Humanized, chimeric and murine antibodies have similar binding affinities to 
PTx.   
A, SDS-PAGE comparing purified murine, chimeric and humanized variants of 1B7 and 11E6 in reduced 
and non-reduced forms as indicated. Molecular weights standards (kDa) are shown in lane 1. B, Indirect 
ELISA comparing the binding of all three versions of each antibody to PTx: murine (), chimeric () and 
humanized () and isotype control () antibodies shown. The absorbance data was normalized such that 
the maximum signal is 1.0; each sample was run in duplicate and each assay performed at least three times 
with different protein preparations.  
 
Binding to PTx was initially assessed by ELISA (Fig. 3B) and competition 
ELISA (Appendix A, Fig. 21). The murine and chimeric versions of each antibody, 
presenting identical variable region amino acid sequences but appended with murine and 
human constant domains respectively, exhibited very similar binding affinities as 
measured by competition ELISA (Table 1). We next collected kinetic binding data using 
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surface plasmon resonance with immobilized antibody. The SPR-measured association 
and dissociation rates were similar for the murine, chimeric and humanized variants, 
yielding affinities within error for all three 1B7 variants (Kd ~0.70.5 nM) and all three 
11E6 variants (Kd ~2.3  0.7 nM; Table 1, Appendix A Fig. 22).  
 
Table 3. Biochemical characterization of 1B7 and 11E6 antibodies 
 Melting temp 
(°C), second 
transition 
Kd, 
competition 
ELISA (nM); 
(# exp) 
Kd, SPR; nM 
(2) 
on-rate × 
105, SPR 
(sec-1 M-1) 
off-rate × 10-
4, SPR (sec-
1) 
m1B7  74.8 ± 0.7 0.4 ± 0.2 (5) 0.7 ± 0.2 
(0.32) 
1.7 ± 0.3    1.2 ± 0.3   
ch1B7 78.1 ± 0.5 0.5 ± 0.3 (3) 0.5 ± 0.4 
(0.74) 
1.5 ± 0.1   0.8 ± 0.5   
hu1B7 79.0 ± 0.3 
 
1.2 ±  0.7 (6) 0.7 ± 0.5 
(0.75) 
0.9 ± 0.2  0.7 ± 0.5   
m11E6 67.3 ± 0.4 5 ± 1 (3) 2.4 ± 0.9 
(2.20) 
1.3 ± 0.7 3 ± 3 
ch11E6 69.4 ± 0.4 5 ± 2 (4) nd* nd* nd* 
hu11E6 74.4 ± 0.4 7 ± 3 (5) 2.3 ± 0.7  
(1.25) 
0.8 ± 0.4  1.7 ± 0.7  
* nd, not determined 
 
The binary combination of hu1B7 and hu11E6 is synergistic  
Not only do hu1B7 and hu11E6 bind PTx tightly, but as monoclonal antibodies, 
they exhibit ~100-fold and 10-fold higher PTx-specific binding titers, respectively, than 
the P-IVIG used previously to treat human infants(151) (Fig. 4A). Furthermore, PTx is 
able to simultaneously bind hu1B7 and m11E6, suggesting their effects may be 
synergistic (Fig. 4B). Indeed, while either antibody alone protects CHO cells against 
PTx-mediated morphological changes at ~70:1 (hu1B7) and ~40:1 (hu11E6) molar ratios, 
an equimolar binary combination exhibits enhanced protection (~20:1; Fig. 5A) which is 
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more neutralizing than an equivalent P-IVIG dose (~120:1; Fig. 5B)(153). Accordingly, a 
1:1 molar ratio of hu1B7 and hu11E6 was selected for subsequent animal protection 
studies.  
 
 
Figure 4. The hu1B7 and hu11E6 antibodies have higher anti-PTx titers than P-IVIG and 
can simultaneously bind PTx.  
A, Humanized 1B7 and 11E6 antibodies and high-titer P-IVIG were assessed for PTx binding by ELISA. 
An ELISA plate was coated with PTx, blocked, incubated with the indicated concentrations of P-IVIG (), 
hu1B7 (), or hu11E6 (). B, Sandwich ELISA to assess simultaneous binding of 1B7 and 11E6. Each 
sample was run in duplicate and each assay repeated at least three times.  
 
 
48 
 
 
Figure 5. The binary combination of hu1B7 and hu11E6 is synergistic and more potent 
than P-IVIG in vitro.  
The CHO cell clustering assay was used to determine the molar ratio of antibodies to PTx required for 
complete neutralization of CHO morphology changes. A, Different ratios of hu1B7 and hu11E6 were 
compared to determine the most potent ratio. B, An equimolar ratio of humanized 1B7 and 11E6 was 
compared to the same ratio of murine antibodies and P-IVIG. Results depict average of three replicate 
experiments; statistical significance determined by single-factor ANOVA and Tukey’s test with α=0.05.  
 
Hu1B7 and hu11E6 protect mice prophylactically from B. pertussis infection  
While not a natural host for B. pertussis, mouse models share some characteristics 
of human disease and were used to develop all vaccines to date. In particular, the rate of 
bacterial clearance in immunized mice after aerosol challenge correlates with vaccine 
efficacy in children(163). Previously, the Sato group performed murine protection studies 
with m1B7 and m11E6 using intracerebral and inhalation models with B. pertussis strain 
18-323(153, 154).  Since this study was preparatory for non-human primate studies, we 
replaced strain 18-323, which infects mice efficiently but is a hyper-virulent strain of 
atypical B. pertussis lineage, with strain D420, a recent human clinical isolate used to 
develop the baboon model and which expresses the dominant alleles of major virulence 
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factors(160). Pilot studies determined that prophylaxis with 5 g m1B7 antibody 
followed by infection with 5x10
6
 cfu D420 resulted in statistically significant differences 
in WBC, bacterial colonization and weight gain over a 10-day period with groups of six 
animals (Appendix A Fig. 23).   
 
Recognizing that antibodies with human constant domains will be cleared from 
the blood more rapidly than murine antibodies, we assessed the murine in vivo clearance 
rates of the humanized antibodies for comparison to previously measured m1B7 rates. 
Mice were administered chimeric or humanized antibodies or a binary cocktail of 
humanized antibodies (2 mg/kg subcutaneously), and sera were collected over 14 days 
with anti-PTx concentrations measured by ELISA. The beta elimination half-lives of 
~100 hrs for humanized and chimeric antibodies with human constant domains were 
similar, and, as expected, shorter than that for m1B7 (~210 hrs)(161). We used these data 
to estimate that a 20 g dose of humanized antibodies would result in similar serum 
concentrations on day 10 as the 5 g m1B7 dose used in pilot studies.  
 
Accordingly, weanling mice were administered 20 g each of a single humanized 
or chimeric antibody, P-IVIG, the binary humanized antibody mixture or a PBS control 
(n=6 per group) before inoculation with 5x10
6
 cfu B. pertussis strain D420. At ten days 
post-inoculation, untreated mice exhibited ~five-fold increase in WBC relative to naïve 
mice (Fig. 6A; Appendix A Table S3), lost weight (Fig. 6B) and were heavily colonized 
by B. pertussis (Fig. 6C). In contrast, all mice receiving monoclonal antibodies exhibited 
significantly decreased WBC levels as compared to PBS-treated mice (p<0.001; Fig. 6A). 
Animals receiving the 1B7 antibody resembled uninfected mice more closely than those 
receiving only 11E6 or P-IVIG for all outcomes. This was most pronounced in terms of 
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weight gain, as mice receiving ch1B7, hu1B7 or the antibody mixture gained 
significantly more weight than PBS-treated animals (p<0.05; Fig. 6B). Mice treated with 
the antibody cocktail were indistinguishable from naïve animals in terms of WBC and 
weight gain and had significantly lower WBC than P-IVIG-treated mice (p<0.05, Fig. 
6A). Finally, mice treated with the binary antibody cocktail had a ~10-fold reduced 
bacterial colonization levels as compared to untreated mice (p<0.01, Fig. 6C), similar to 
the reduced colonization observed for PTx-deletion strains(164).  P-IVIG was previously 
tested in human clinical trials(151, 152) with promising initial outcomes; if the 
correlation between performance in the mouse model holds for human outcomes, this 
humanized antibody combination could be more protective than P-IVIG. 
 
 
Figure 6. Prophylactic treatment with humanized antibodies protects mice against 
pertussis.  
Mice (n=6) were each administered 20 g antibody intraperitoneally two hours before infection with 5x106 
cfu B. pertussis D420 bacteria. The infection severity was assessed on day 10 by A, CD45+ leukocyte 
count (WBC), B, weight gain and C, bacterial colonization of the lungs. No bacteria were recovered from 
uninfected animals. Means  standard error are shown; significance * p<0.05, ** p<0.01 and *** p< 0.001 
versus PBS-treatment is indicated, using Tukey’s simultaneous test. Additionally, only P-IVIG-treated 
mice had WBC distinguishable from uninfected naïve mice (p<0.01) and mice treated with hu1B7, ch1B7 
or the antibody cocktail had lower WBC than P-IVIG-treatment for equivalent doses (p<0.05). Only mice 
treated with P-IVIG and ch11E6 exhibited reduced weight gain relative to uninfected mice (p<0.05). 
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Hu1B7 and hu11E6 protect baboons therapeutically from infection by B. pertussis  
Finally, we used a recently developed nonhuman primate model to assess the 
feasibility of our antibody cocktail to treat established disease.  In this model, bacteria are 
administered intranasally and intratracheally to weanling baboons, who then exhibit 
symptoms of classical pertussis including colonization of the trachea, increased WBC 
counts, and a characteristic cough. No other clinical changes have been associated with 
disease(155).  B. pertussis strain D420 was administered to eight weanling animals on 
Day 0. Three days later, when the WBC had begun to rise (>14,000/l; Appendix A 
Table 6), the humanized antibody cocktail (20 mg/kg each antibody) was administered 
intravenously to four of the animals. All eight animals were then monitored for WBC, 
cough and bacterial colonization (Appendix A Table S4).  
 
Disease in the untreated animals (n=4) was typical of the model(155): the WBC 
rose into the 40,000/l range by day 5 before beginning to decline, approaching baseline 
after 23 days (Fig. 7A). These animals were heavily colonized by B. pertussis (107-108 
cfu recovered by nasopharyngeal wash on days 3-17) and remained elevated for the 
duration of the study (Fig. 7B). One control animal (C1) became moribund after 
exhibiting an extremely high WBC. In contrast to the controls, all four animals receiving 
antibody treatment exhibited a blunted rise in WBC and accelerated removal of bacteria 
from the nasopharynx (Fig. 7C). At the time of treatment, two of the treated animals had 
achieved high levels of nasopharyngeal colonization (10
7
-5x10
8
 cfu; denoted H1 and H2), 
while the other two treated animals experienced moderate levels of nasal carriage  (~104 
cfu; denoted M1 and M2). These animals exhibited a sharp decrease in WBC coincident 
with antibody treatment. The measured antibody beta-phase elimination half-life in the 
treated baboons was 104 days, thus the hu1B7 and hu11E6 levels remained high for the 
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duration of the study (Appendix A Fig. 24). ELISA detection of PTx-reactive antibodies 
in nasopharyngeal washes indicated that the administered antibodies were present in the 
mucosa of treated but not control animals (Appendix A Fig. 25). 
 
 
Figure 7. Therapeutic treatment with antibody cocktail reduces leukocytosis and 
accelerates bacterial clearance in baboons.  
Weanling baboons were inoculated with 109-1010 B. pertussis D420 bacteria on Day 0. On day 3 after 
infection (indicated by arrow), animals in the treatment group (n=4) were administered hu1B7 and hu11E6 
antibodies intravenously, while control animals (n=4) were given nothing. All animals were subsequently 
monitored for A, WBC count, B, bacteria recovered by nasopharyngeal wash and C, coughing on the days 
indicated.  Groups shown include controls (solid black icons, dashed line, C1-C4), treated animals who 
were mildly colonized (grey icons, dotted black line, M1 and M2), and treated animals which were heavily 
colonized (hollow icons, solid grey line, H1 and H2). D, Serum anti-Fha titers for individual animals are 
shown to assess endogenous immune responses. Titers were normalized to the maximum response 
observed for serum from a historical control baboon, collected three weeks after experimental infection. 
Serum was not available for animal C3.  
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In this study, the baboon model exhibited variability in cough severity and clinical 
progression, as is seen in human pertussis(165). All the animals coughed, but this did not 
strongly correlate with WBC or bacterial colonization levels. Three of the four controls 
exhibited substantial coughing (>10 per hour) through day 9, while the two heavily 
colonized, treated animals experienced heavy bouts of coughing (60+ per hour on day 3) 
which diminished rapidly after antibody treatment (Fig. 7C; Appendix A Table 6).  All 
treated animals exhibited reduced cough rates by day 5, which were reduced to <5 per 
hour by day 9. No other clinical observations (body temperature, weight, activity level; 
Appendix A Table S4) were found to correlate with disease and potential variables such 
as insulin, histamine sensitization and blood chemistry have not been evaluated in this 
model. Notably, PTx does not appear to be responsible for coughing as B. parapertussis 
does not express PTx, yet causes a similar cough in humans(165).  Thus, we would not 
expect PTx neutralization to affect the cough except indirectly by protecting the innate 
immune system and the resulting enhanced bacterial clearance.  
 
Histological examination of moribund control animal C1 noted a normal trachea 
with dense bronchopneumonia and large abcesses, similar to that seen in post-mortem 
analyses of infants that died of pertussis(139). B. pertussis was recovered from the 
trachea and right lung of this animal. Histopathology from recovering control and treated 
animals showed evidence of abcesses and small consolidations. Thus, the damage that 
occurred to the lung tissue during the first 72 hours of infection may not have had time to 
repair, consistent with the long-term sequelae following severe pertussis. 
Histopathological analyses of treated, mildly colonized animals had some abnormalities 
(fibroses and consolidations) but were overall much healthier (Appendix A Fig. 26). 
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We were interested in why two treated animals were less efficiently colonized. To 
explore this, we evaluated baseline serum antibody levels recognizing another major 
Bordetella antigen, filamentous hemagglutinin (Fha) by ELISA (Fig. 7D). Animals with 
clear pertussis symptoms had no baseline serum Fha titer but exhibited detectable levels 
by day 20, consistent with a primary immune response(155). Interestingly, the two co-
housed animals with low levels of nasal carriage also had relatively high initial anti-Fha 
titers, which exhibited rapid increases starting on day 6, as expected for a secondary 
immune response(155). From one of these animals, B. bronchiseptica was recovered in 
the nasal wash (<100 cfu) in addition to B. pertussis. Therefore, we hypothesize that 
baboons are subject to B. bronchiseptica infection and that concurrent exposure partially 
protected these two animals, as does prior B. pertussis infection(141).  
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DISCUSSION    
Before widespread vaccination, a number of blood products and polyclonal 
immunoglobulins were used to treat human pertussis, some with positive, albeit poorly 
controlled, results(166). More recent preparations were developed on the presumption 
that PTx is responsible for the severe symptoms of disease and therefore preparations 
enriched in anti-PTx antibodies would mitigate the symptoms. However, this clinical 
strategy is limited by the expectation that only a fraction of PTx-specific antibodies in a 
polyclonal preparation would be neutralizing. In contrast, the monoclonal antibodies 
utilized in this study were selected specifically for their capacity to neutralize PTx, 
individually and synergistically. The initial feasibility data using murine and baboon 
models reported here support the concept of passive immunotherapy to neutralize PTx’s 
pathological effects.  
 
Previously, two polyclonal anti-PTx preparations elicited by immunization with 
inactivated PTx were assessed in controlled trials. One showed a significant, ~3-fold 
decrease in the number and duration of whoops versus placebo-treated children, an effect 
which was most pronounced when treatment was initiated within the first seven 
days(150). A subsequent P-IVIG preparation used for Phase 1/2 trials in infants showed 
declines in lymphocytosis and paroxysmal coughing by the third day after 
treatment(151). Unfortunately, Phase 3 trials did not support this initial promise, as the 
product expired before study enrollment was completed(152). Given the dosage and 
blood volume of infants enrolled in these studies, both achieved the goal of high and 
sustained anti-PTx titers but observed variable effects on clinical outcomes.  
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The murine antibodies 1B7 and 11E6 are each highly protective alone, and the 
combination was previously shown to function synergistically in aerosol and intracerebral 
murine models(154). Notably, they were more efficacious than a polyclonal anti-PTx 
preparation and provided significant protection when administered up to seven days after 
infection as measured by survival, leukocytosis and bacterial colonization(153). Since 
11E6 is thought to competitively inhibit PTx binding to cellular receptors(154), this 
antibody appears to prevent the initial PTx-cell interaction, but may require a 2:1 
stoichiometry for complete neutralization of the two binding sites on each PTx molecule. 
Unlike 11E6, 1B7 appears to alter PTx intracellular trafficking such that the toxin never 
reaches its G-coupled protein target(157). Hu1B7 and m11E6 can simultaneously bind 
PTx (Fig. 4), indicating that the epitopes do not overlap and supporting the hypothesis 
that hu1B7 and hu11E6 are synergistic by virtue of complementary mechanisms. This 
notion is further supported by the in vitro CHO cell neutralization data shown here, in 
which the humanized antibodies displayed synergy when combined in an equimolar ratio 
(Fig. 5). Based on these data, we think synergy is highly likely, although the murine 
studies presented here were designed to demonstrate protection conferred by humanized 
antibodies against a clinically relevant strain as opposed to synergy. 
 
The promising clinical results with P-IVIG and the availability of murine 
antibodies conferring in vivo protection with complementary mechanisms led us to 
hypothesize that humanized versions of these antibodies would efficiently block PTx 
activities and treat pertussis symptoms in humans. The humanized 1B7 and 11E6 
antibodies are biochemically similar to the original murine versions, leading to the 
expectation that they will exhibit similar efficacy. This was initially evaluated in a 
prophylactic murine aerosol model using a recent human clinical isolate. Not only did the 
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humanized antibodies protect as well as the chimeric antibodies, but the individual 
antibodies and the binary combination significantly mitigated disease in terms of weight 
gain, lung colonization and WBC (Fig. 6).  
 
The murine aerosol mouse model was used to develop current acellular vaccines 
and support their progression to human clinical trials. However, in 2012 a non-human 
primate model, which may have better predictive value for human disease, was first 
reported.  Using this model, we observed leukocytosis and bacterial colonization in 
control animals which resolved after three weeks, typical of the model(155). Antibody-
treated animals exhibited a blunted WBC rise and accelerated bacterial clearance (Fig. 7), 
supporting a role for these antibodies to treat pertussis in critically ill infants.  
 
Notably, the baboon model introduces a large number of bacteria (109-1010 CFU) 
into the respiratory tract, resulting in rapid onset of disease, with WBC elevation apparent 
in 2-3 days and heavy coughing in 3-4 days. In contrast, humans are likely infected with a 
smaller inoculum via contact or aerosols, exhibiting comparable clinical symptoms 2-3 
weeks after infection(167). This is similar to baboons experimentally infected by contact 
or aerosol transmission, who showed peak WBC several weeks after infection(168). 
Together, these data suggest that the baboon clinical symptoms observed on day three 
correspond to human symptoms several weeks after infection.  As there is no prior data 
evaluating pertussis therapeutics in baboons, treatment on day three post-infection was 
selected due to the rapid onset of disease in baboons, the expected antibody serum half-
life, and the appearance of endogenous baboon antibody responses as early as 12-days 
post-infection. Additional animal modeling and human clinical trials would determine the 
windows during which antibody treatment could affect disease outcomes. 
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Interestingly, the two baboons that were only mildly colonized with B. pertussis 
were likely partially protected through concurrent exposure to B. bronchiseptica. This 
organism is endemic in many animal populations but has not been described in 
baboons(165). Here, two co-housed animals were mildly colonized by B. pertussis (103 -
104 cfus recovered), with similar day 3 WBC and coughing as all other animals; 
symptoms which resolved rapidly upon antibody administration (Appendix A Table 6). 
Protection against B. pertussis infection has been observed for mice previously infected 
with B. bronchiseptica(169); concurrent exposure in baboons may also provide some 
cross-protection. An important implication is that baboons must be protected from and 
monitored for B. bronchiseptica exposure prior to use in B. pertussis studies. 
 
By immediately arresting PTx activities, the hu1B7/hu11E6 antibody cocktail 
appears to have two effects on disease progression, as observed in both the murine and 
baboon models. First, since PTx is directly responsible for the elevated WBC, blocking 
this activity prevents further leukocytosis, protecting against pulmonary hypertension and 
organ failure, the specific causes of infant death from pertussis. Second, by modifying 
Gi/o proteins, PTx interferes with innate immune responses; in particular, chemotaxis to 
the lungs and subsequent oxidative burst(144, 145). Antibody-mediated blockade of these 
activities is expected to allow neutrophils and macrophages to more efficiently 
phagocytose B. pertussis, thereby resolving the pertussis infection and preventing 
secondary infections. As there is no evidence to support direct antibacterial effects 
mediated by these antibodies, protection of the innate immune system would explain the 
~10-fold reduction in bacterial colonization levels observed in mice (Fig. 6) and baboons 
(Fig. 7) after antibody treatment. These results are consistent with studies showing 
similar reductions in murine colonization by PTx-deficient B. pertussis and B. 
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parapertussis strains(143, 164, 170) and the inability of acellular vaccination to prevent 
subsequent bacterial colonization of mice or baboons(141, 171). While the bacteria 
localize in the lungs, the various murine responses to PTx, including hyper-insulinemia 
and histamine sensitization, suggest the toxin is widely distributed and thus antibodies are 
likely required systemically to neutralize PTx activities.   
 
Two potential challenges for an antibody therapeutic to treat pertussis are 
maternal vaccination and early identification of exposed or high-risk infants. Currently, 
maternal vaccination is the leading strategy in development to protect newborns from 
pertussis prior to initiation of standard vaccination schedules at two months of age. The 
goal is to induce high levels of maternal anti-pertussis antibodies for transfer to the fetus 
in utero that then confer protection after birth.  While maternal vaccination is attractive 
for many reasons, recent uptake data in the US indicate that with optimal healthcare 
access, 40% of newborns remain unprotected(172), while 86% of pregnancies covered by 
Medicare did not receive the vaccine(173). Moreover, the resulting infant anti-pertussis 
titers can be modest at birth and decay rapidly(174). This will leave many infants 
unprotected and the need for a therapeutic in urgent situations will remain. The 
neutralizing antibodies described here could provide a complementary therapeutic 
strategy when maternal immunization fails.  Similarly, therapeutic use of anti-pertussis 
antibodies will require accurate and timely identification of high-risk cases such that the 
therapy can be administered when it is most effective. We expect minimal interference 
with subsequent vaccination since only two of the many epitopes included in the vaccine 
would be masked by hu1B7 and hu11E6.  
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We believe these data in aggregate support continued development of the 
humanized 1B7 and 11E6 antibodies toward clinical application. To this end, we are 
currently planning experiments in neonatal baboons as these appear to better mimic 
severe pertussis observed in human neonates(175). While these antibodies have affinities 
typical of those generated by in vivo somatic hypermutation and similar to approved 
antibody therapeutics, enhanced efficacy may be attained through additional protein 
engineering efforts to increase the binding affinity(12) or the circulating half-life(176).  
The evidence presented here and in prior literature suggest that neutralizing PTx will 
improve recovery when added to the current standard of care, however this notion would 
need to be clearly demonstrated in controlled human trials with quantitative endpoints 
prior to broad antibody use. In addition, given the decreasing cost of goods for antibodies 
and support from non-governmental organizations, the antibodies may be able to prevent 
disease in the developing world where infants are most likely to die from pertussis. 
Finally, these results support the notion that PTx is a major protective antigen and should 
continue to be a focus of future pertussis vaccines. 
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Chapter 3: Synergistic neutralization of pertussis toxin by a bispecific 
antibody in vitro and in vivo2 
 
ABSTRACT  
Bispecific antibodies are a rapidly growing class of therapeutic molecules, 
originally developed for the treatment of cancer but recently explored for the treatment of 
autoimmune and infectious diseases. B. pertussis is a re-emerging pathogen, with several 
key symptoms caused by the pertussis toxin (PTx). Two humanized antibodies, hu1B7 
and hu11E6, bind distinct epitopes on PTx and mitigate disease severity in murine and 
baboon models of infection when co-administered. Herein, we describe generation of a 
bispecific human IgG1 molecule combining the hu1B7 and hu11E6 binding sites via a 
knobs-in-holes design. The bispecific antibody showed binding activity equivalent to the 
antibody mixture in a competition ELISA. A CHO neutralization assay provided 
preliminary evidence for synergy between the two antibodies, while a murine model of 
PTx-induced leukocytosis definitively showed synergistic neutralization. Notably, the 
bispecific antibody retained the synergy observed in the antibody mixture, supporting the 
conclusion that synergy is due to simultaneous blockade of both the catalytic and receptor 
binding activities of pertussis toxin. These data suggest that a hu1B7/hu11E6 bispecific 
antibody is a viable alternative to an antibody mixture for pertussis treatment.  
  
                                                 
2 This chapter has been published in final edited form as: 
E. K. Wagner, X. Wang, A. Bui, J. A. Maynard. Synergystic neutralization of pertussis 
toxin by a bispecific antibody in vitro and in vivo. Clin Vaccine Immunol 23, 851-862 
(2016) 
 
E. K. W. planned, performed, and analyzed all experiments.  
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INTRODUCTION 
Despite vaccination, pertussis infection continues to cause ~195,000 deaths 
worldwide, primarily of infants (1). Of the estimated 16 million cases of pertussis each 
year, ~95% occur in the developing world. Even in developed countries, disease 
incidence has increased dramatically over the last decade, reaching pre-vaccination levels 
in some countries (177, 178). This rise has been attributed to shortcomings of the current 
acellular vaccine (179) as well as pathogen adaptation (180). In both cases, high levels of 
circulating disease place young infants at risk, as this population is the most susceptible 
to severe disease. An antibody therapeutic could be used to treat seriously ill infants in 
the developing world and prevent disease in high-risk areas.  
 
Pertussis toxin (PTx) is one of several virulence factors secreted by the gram-
negative bacterium B. pertussis. PTx is directly responsible for suppression of the innate 
immune system (144) and systemic leukocytosis, which is the key clinical indicator of 
severe disease and appears directly responsible for pulmonary hypertension and organ 
failure (181). In addition, low titers of PTx-neutralizing antibodies correlate with 
susceptibility towards clinical infection (149). We previously developed a binary mixture 
of two humanized anti-pertussis toxin antibodies which was able to mitigate whooping 
cough in mouse and baboon models of infection (27).  The antibody hu11E6 blocks 
binding of the toxin to host cells, while the antibody hu1B7 interferes with the catalytic 
pathway. At a dose selected to demonstrate efficacy but not synergy, the individual 
antibodies and mixture were able to completely suppress leukocytosis in a murine 
infection model. The mixture also reduced bacterial colonization ~20-fold.   
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A concern when developing therapeutics for a mutable pathogen is the risk of 
escape variants that are no longer affected by the therapeutic. One approach is to target 
multiple epitopes to reduce this risk and enhance therapeutic efficacy (70). Antibody 
mixtures are able to provide better protection against pathogen adaptation, and can also 
provide broader coverage against a target, such as HIV-1, which exhibits high antigenic 
diversity (65). In addition, combinations of antibodies exhibiting complementary 
mechanisms can be highly synergistic, as was demonstrated with antibodies targeting 
botulinum neurotoxin that were only able to significantly neutralize the toxin when 
formulated as a tertiary antibody mixture (35). Recently, a combination of three 
investigational antibodies was used to treat patients in the 2014 Ebola outbreak after it 
demonstrated efficacy in non-human primates (132). A number of other antibody 
mixtures to treat infectious diseases are in pre-clinical development (70).  While antibody 
mixtures have shown promise as therapeutic agents, additional manufacturing steps for 
formulation and quality control of the mixture can add significant complexity and cost. 
Antibody mixtures are typically classified as combination drugs, and documentation of 
the safety of each individual component as well as the mixture is required (72).  
 
In contrast, bispecific antibodies are a new class of therapeutic in which two 
binding specificities are combined in the same molecule. The original application of 
bispecific antibodies was to direct non-specific CD8+ T cells to cancerous cells by 
simultaneously binding the T cell surface protein CD3 and a tumor cell antigen. This 
approach is demonstrated by the first approved bispecific antibody in the US, 
Blinatumomab (94), and modifications of this strategy are currently being pursued for a 
number of other cancer applications.  Bispecific architecture has more recently been 
explored as a way to crosslink two surface antigens, and shows promise as a mechanism 
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to enhance neutralization potency against infectious targets such as antibiotic-resistant P. 
aeruginosa (182) as well as HIV-1 (183). The applications of bispecific antibodies are 
rapidly expanding, and the development of better methods to make bispecific antibodies 
is an active area of research.  
 
We previously observed that an equimolar mixture of the hu1B7 and hu11E6 anti-
PTx antibodies was more effective in vitro than either antibody alone (27).  This led us to 
hypothesize that a bispecific antibody containing these two binding sites would capture 
the therapeutic potential of the mixture in a single molecule. Importantly, this construct 
would also provide insight into the structural basis of synergy exhibited by these two 
antibodies. Herein, we describe the development of a bispecific anti-PTx antibody with 
human IgG1 architecture. The bispecific antibody was able to bind the two cognate PTx 
epitopes simultaneously and exhibited an effective affinity similar to that of the antibody 
mixture. A murine neutralization assay demonstrated clear synergy between the hu1B7 
and hu11E6 antibody combination as well as within the bispecific antibody. This 
evidence supports the conclusion that synergy between hu1B7 and hu11E6 is due to more 
complete neutralization of toxin activity from simultaneous blockade of the receptor 
binding and catalytic pathways, and also suggests that a bispecific antibody may be a 
viable alternative to an antibody mixture for the treatment of pertussis.  
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MATERIALS AND METHODS 
Protein preparation and purification 
Large-scale preparations of hu1B7 and hu1E6 were prepared by Catalent 
(Somerset, NJ) using polyclonal CHO cell lines followed by protein A chromatography, 
anion chromatography and buffer exchange into PBS pH 7.0 (27). Fab fragments were 
prepared by digestion of the parent monoclonal antibodies using immobilized papain 
(Thermo Scientific Pierce), followed by protein A chromatography and buffer exchange 
into PBS pH 7.4.  
 
Bispecific antibody expression plasmids were generated by introducing the 
previously described T366Y (knob, hu1B7H+) or Y407T (hole, hu11E6H-) point 
mutations (184) into an antibody expression vector containing human IgG1 constant 
heavy domains (185). The modified heavy chain and native light chain plasmids were 
transfected in a 1:1 ratio into confluent T-150 flasks containing adherent CHO-K1 cells 
using Lipofectamine 2000 (Life Technologies). Supernatant was collected over one week, 
purified using protein A chromatography and stored in PBS pH 7.4. Bispecific antibody 
was prepared by incubating a 1:1 molar ratio of the hu1B7H+ and hu11E6- parental 
antibodies at ~2 mg/mL in PBS pH 7.4 with 10mM EDTA and 50mM 2-MEA (Thermo 
Scientific Pierce) for 90 minutes at 37 °C. The partially reduced sample was then buffer 
exchanged into PBS pH 7.4 and stored overnight at 4 °C to allow re-oxidation and 
heterodimerization (186). 
 
The PTx holotoxin (PTx) and its B subunit (PTx-B) were obtained from List 
Biological Laboratories. The A subunit (PTx-220K), a version of the pertussis toxin A 
subunit truncated at residue 220 and appended with a terminal lysine residue and hexa-
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histidine tag, was expressed from plasmid pAK400 as described (157). Briefly, 
BL21(DE3) cells containing the expression vector were grown in TB at 25C to an 
OD600 of 1.5, then induced with 1mM IPTG for 5 hours. Cell pellets were collected and 
the periplasmic contents recovered by osmotic shock. PTx-220K was purified by 
immobilized metal affinity chromatography followed by size exclusion chromatography 
(Superdex S75 column on an ÅKTA FPLC). Purified PT-220K was biotinylated via its 
sole lysine by incubation with a 50-fold molar excess of EZ-Link Sulfo-NHS-Biotin 
(Thermo Scientific) at 4C overnight, followed by buffer exchange into PBS pH 7.4. 
Biotinylation was confirmed with ELISA, in which a hu1B7 coat was used to capture 
PTx-220K which was then detected with streptavidin-HRP (BD Pharmingen). 
 
Modeling hu1B7 and 11E6 epitopes on PTx 
The hu11E6 antibody sequence was submitted to a public Rosetta antibody server 
(187, 188) for modeling. Four models with diverse structures were selected and submitted 
to PatchDock (189, 190) for an initial docking estimate, using the residues within 10 
angstroms of the sugar residues on PTx structure 1PTO (191) as a constraint for binding 
area. The best docking run for each antibody structure was submitted to Rosetta 
Docking2 for refinement. The epitope for the top docking runs was defined as all residues 
on the PTx structure within 4 Å of the CDRs. The final consensus epitope was defined as 
residues consistently contacted in both the S2 and S3 subunits.  An average plane was 
calculated from the coordinates of all surface exposed residues in each epitope, and a line 
normal to this plane was added using a custom PyMol script. 
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PTx binding assays 
All ELISAs followed the same general procedure, with specific modifications 
detailed below. First, a high-binding 96-well ELISA plate (Costar) was incubated 
overnight at 4 C with the coat protein in PBS, pH 7.4. Second, the plate was blocked. 
Third, protein dilutions were prepared in the plate in duplicate. After any additional 
protein incubation steps, the secondary antibody was added to the plate. After the final 
incubation and washes, the plate was developed with TMB substrate (Thermo Fisher 
Scientific), quenched with 1N HCl and the absorbance measured at 450 nm using a 
SpectraMax M5. All incubation steps proceeded for one hour at room temperature. Wash 
steps in between incubation steps used PBS with 0.05% tween-20 (PBST), while the 
blocking buffer and assay diluent used was PBS with 5% powdered milk (PBSTM).   
 
For the PTx sandwich ELISA, the plate was coated with 1 µg/mL of murine 1B7 
or 11E6, blocked, then incubated with dilutions starting from 70-100 nM of PTx-220K, 
PTx-B, or full PTx. The sandwich was completed with 1 µg/mL human 1B7 or 11E6, 
labeled with a 1:2500 dilution of goat-anti-human Fc-HRP (Thermo Scientific Pierce), 
and developed as above.  
 
For the bispecific sandwich ELISA, the plate was coated with 1 µg/mL PTx-B, 
blocked, then incubated with antibody dilutions starting from 20 µg/mL. Following 
incubation with 1 µg/mL PTx-220K-biotin, binding was detected with streptavidin-HRP 
(BD Pharmingen) at a 1:5000 dilution. 
 
For the PTx binding ELISA, the plate was coated with 0.2 µg/mL PTx, blocked, 
then incubated with antibody dilutions starting from 5 µg/mL (hu1B7 variants) or 10 
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µg/mL (hu11E6 variants). Binding was detected using goat-anti-human constant kappa-
HRP antibody (Thermo Scientific Pierce) at a 1:1250 dilution. Data shown is 
representative of three independent experiments.  
 
PTx binding affinity was determined by competition ELISA. A high-binding plate 
was coated with 0.2 µg/mL PTx and blocked as described above. While the plate was 
blocking, a 3 nM (mAbs and bispecific) or 6 nM (Fabs) solution of each protein was 
incubated with dilutions of PTx starting from 200 nM. After equilibration for an hour at 
room temperature, the PTx/antibody mixtures were transferred to the washed ELISA 
plate in duplicate and allowed to incubate for 15 minutes at room temperature to capture 
unbound antibody. Binding was detected with goat-anti-human Fc-HRP (monoclonal and 
bispecific antibodies) or goat-anti-human constant kappa-HRP (Fab fragments) and 
signal developed as above. The resulting curves were fit to equilibrium binding equations 
(192) corrected for bivalent binding (193) where appropriate. Three independent 
experiments were performed. Statistical significance was determined by 1-way ANOVA 
and Tukey’s Test.  
 
Protein biophysical characterization 
For mass spectrometry analysis, 100 g each of the hu1B7H+, hu11E6H- and 
hu1B7/hu11E6 bsAb antibodies were digested with the IdeS enzyme (Promega) for 1 
hour at 37 C. The digested products were run on a Superdex S200 size exclusion column 
using an FPLC instrument (Äkta, GE Healthcare) with PBS pH 7.4 as a running buffer, 
and the peak corresponding to ~100kD was collected based on MW standards and buffer 
exchanged into 50mM ammonium acetate using a centrifugal filter (Amicon). The 
antibodies were analyzed by LC-MS on an Orbitrap Fusion mass spectrometer 
69 
 
(ThermoFisher). A linear gradient of 0.1% formic acid and water and 0.1% formic acid 
and acetonitrile over 15 minutes was used to elute the antibodies from a ProSwiftTM RP-
4H (1 x 50 mm) monolithic column (ThermoFisher). The Orbitrap Fusion was operated 
in Standard Pressure Mode at 15000 resolution from 1800-4500 m/z, with 20 microscans 
and a source fragmentation energy of 35V. Following acquisition, data was deconvoluted 
using MagTran and Protein Deconvolution 4.0. 
 
To assess protein size and purity, 3 g of each purified protein was analyzed by 
SDS-PAGE. Proteins were incubated with reducing or non-reducing loading buffer and 
incubated for 5 minutes at 80°C or 30s at 42°C respectively. The protein was loaded onto 
a 10% acrylamide gel or 4-20% gradient gel (Bio-Rad) and run at 120V prior to staining 
with GelCode Blue (ThermoFisher). 
 
To assess protein stability, the antibody thermal melting temperature was 
measured by differential scanning fluorimetry.  Purified antibodies were prepared at 400, 
200, and 100 µg/mL in PBS pH7.4 and mixed with protein thermal shift dye (Life 
Technologies) as described in the product literature. Quantification of fluorescence was 
measured using a ViiA-7 instrument at a ramp rate of 1°C/minute, with derivative 
melting temperature (Tm) values calculated from Protein Thermal Shift software 
(Applied Biosystems, V1.2). Samples were run in triplicate.  
 
In vitro PTx neutralization assay  
Inhibition of CHO cell clustering was used to determine in vitro neutralization 
ability of antibody preparations as described (194). Briefly, antibody was serially diluted 
across a 96-well tissue plate from 800 to ~0.4 nM in the presence of 4 pM PTx. Antibody 
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and PTx were incubated for 30 minutes at 37 C, after which 1x104 freshly trypsinized 
CHO-K1 cells were added per well. After incubation at 37 C for an additional 48 hours, 
the degree of clustering was scored as 0 (no clustering), 1 (equivocal), 2 (positive 
clustering), or 3 (maximal clustering). Neutralizing dose is expressed as the lowest 
antibody-to-PTx molar ratio resulting in a score of 1. Samples were run in duplicate and 
three independent experiments were performed. Statistical analysis was performed with 
the Kruskal-Wallace test (for data not coming from a Gaussian distribution) and Dunn’s 
post-hoc test.  
 
Murine PTx leukocytosis study  
An in vivo leukocytosis assay was performed as previously described (195, 196) 
with the following modifications: First, 2 g PTx or 2 g PTx plus 20 g of total 
antibody were pre-incubated for two hours at room temperature to allow for binding 
equilibration. These preparations were then injected into a lateral tail vein of 5-6 week 
old female BALB/c mice. Four days later, blood was collected by terminal cardiac 
puncture and combined with Na2EDTA to a final concentration of 10 mM to prevent 
clotting. Blood (10 l) was lysed in 150 l mouse red blood cell lysis buffer (Alfa Aesar) 
for 15 minutes, washed with PBS+2%FBS, and stained for one hour on ice with 2.5 
µg/mL anti-mouse CD45 antibody or isotype control antibody, each labeled with Alexa 
Fluor 488 (BioLegend). Samples were run on a flow cytometer (BD LSR-Fortessa) with 
CountBright absolute counting beads (Life Technologies) to calculate the total number of 
white blood cells (WBC) per l blood. Group sizes were based on power calculations 
from pilot experiment data, with groups of 6 (PBS) or 10-11 (PTx and antibody treated) 
mice per group. In a pilot experiment, mice were administered PBS or 200 g of hu1B7 
by intra-peritoneal injection (n=3 per group), with blood taken on day 4 from a lateral tail 
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and processed as above. In addition, blood was also taken on day 0 from the lateral tail 
vein of these and other mice to assess the variability in baseline WBC counts. Statistical 
analysis was performed using a 1-way ANOVA and Tukey’s test.  
 
Ethics statement   
All animal procedures were performed in a facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care International in accordance 
with protocols approved by The University of Texas at Austin (AUP-2014-00414) 
Animal Care and Use Committee and the principles outlined in the Guide for the Care 
and Use of Laboratory Animals. 
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RESULTS 
Antibodies hu1B7 and hu11E6 can simultaneously bind the same toxin molecule 
PTx is an AB5 toxin, with the S1 subunit comprising the “active” A subunit and 
subunits S2 through S5 comprising the receptor “binding” B subunit. The antibody 
hu11E6 binds two homologous sites on the B subunit and thus prevents the initial 
interaction between the toxin and glycosylated receptors on host cells (154), while the 
antibody hu1B7 binds the A subunit, preventing ADP-glycosylation of cytoplasmic Gi/o 
receptors (157). We thus hypothesized that the synergy previously observed between 
hu1B7 and hu11E6 was due to a more complete neutralization of the toxin function when 
both the binding and catalytic activities of the toxin are blocked (27). This effect would 
be maximal if the hu1B7 and hu11E6 epitopes on a single PTx molecule could be 
simultaneously bound by their corresponding antibodies, creating a hu1B7-PTx-hu11E6 
complex. To evaluate this as a possible mechanism, we wanted to confirm that binding of 
one hu1B7 or hu11E6 antibody did not preclude binding of a second antibody to the same 
toxin molecule. 
 
We addressed this question via a series of ELISA assays in which one antibody 
(murine 1B7 or 11E6) was used to capture PTx, which was then detected by a second 
antibody (hu1B7 or hu11E6; Fig. 8A). As suggested by the known binding stoichiometry, 
the full-length toxin can be sandwiched between two 11E6 antibodies or any combination 
of 1B7 and 11E6 antibodies: both the m1B7/ hu11E6 and m11E6/ hu11E6 combinations 
gave strong signals while the m1B7/ hu1B7 combination did not. Similarly, the B subunit 
alone only had a positive signal by the m11E6/ hu11E6 combination, albeit with lower 
signals reflecting the lower affinity of 11E6. Similarly, the S1 subunit could not be 
sandwiched by any combination of 1B7 and 11E6. These data confirm that hu1B7 and 
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hu11E6 can bind the same PTx molecule simultaneously, and suggest that multiple 
bispecific antibodies could simultaneously bind a single toxin molecule. 
 
 
Figure 8. Orientation and stoichiometry of the hu1B7 and putative hu11E6 epitopes.   
Antibody hu1B7 binds a single well-defined epitope on the S1 subunit while hu11E6 binds two highly 
homologous epitopes present on both the S2 and S3 subunits. (A) PTx can simultaneously engage 
antibodies binding the hu1B7 and hu11E6 epitopes. Shown is a sandwich ELISA in which one antibody is 
used to capture PTx (solid icons), the A subunit (S1-220K, grey icons) or B subunit (hollow icons), which 
is then detected by a second antibody. Tested antibody pairs include an m1B7 capture antibody with hu1B7 
detection (m1B7/hu1B7; circles), m1B7 capture with hu11E6 detection (m1B7/ hu11E6; squares), or 
m11E6 capture with hu11E6 detection (m11E6/hu11E6; triangles).  Error shown is the range of two 
duplicate samples in a single experiment. (B) PTx showing the relative locations of the hu1B7 and hu11E6 
epitopes. The experimentally defined hu1B7 epitope is shown in dark blue and the two predicted hu11E6 
epitopes in light green. The lines extending from the epitopes are normal to the average plane, 
approximating the angle at which a bound Fab would project. A full length huIgG1 structure (PDB 1HZH, 
(197)) with the antigen binding sites highlighted in red is shown at the same scale. Graphics generated with 
PyMol. 
 
Crosslinking of two epitopes on a single PTx molecule is likely not required for 
synergistic neutralization 
To further understand the constraints on antibody-PTx binding, we highlighted 
the amino acid residues recognized by hu1B7 and hu11E6 on the crystal structure of PTx 
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(191) (Fig. 8B). The hu1B7 epitope has been experimentally defined: it localizes 
primarily to the S1 subunit (157), and was finely resolved using a combined yeast 
display/ high-throughput sequencing approach (198). Although experimental epitope 
mapping of hu11E6 has not been performed, the murine antibody has been reported to 
bind epitopes present in the homologous S2 and S3 subunits, thereby inhibiting PTx from 
binding glycosylated and sialylated cellular receptors (154). We further refined the 
putative hu11E6 epitopes by docking Rosetta models (187, 188) of the antibody onto the 
toxin, guided by the location of oligosaccharides in a relevant crystal structure (PDB ID 
1PTO) (191).  The resulting structure shows that the two predicted hu11E6 epitopes and 
single known hu1B7 epitope are located on different faces of PTx and are oriented in 
opposing directions. The midpoints of any two epitopes are approximately 50Å apart, 
which is much narrower than the typical ~130Å wingspan of a crosslinking antibody 
(199). A line normal to the best-fit plane calculated from the solvent-exposed residues 
was used to approximate the orientation of an antibody bound to the PTx surface. Even 
considering a large elbow angle of 125° between the variable and constant regions (200), 
the geometry suggests that a single antibody molecule, whether monoclonal or bispecific, 
would only be able to interact with a single epitope at a time. Thus, complete blockade of 
all three epitopes would require a stoichiometry of three antibodies for every PTx 
molecule. 
 
Expression and purification of a stable hu1B7/hu11E6 bispecific antibody 
Since hu1B7 and hu11E6 previously exhibited synergy in vitro as native IgG1 
antibodies, we chose to develop a bispecific antibody with natural architecture using the 
knobs and holes platform (184) followed by in vitro assembly to form the desired 
heterodimer (186) (Fig. 9A). The resulting human IgG1 bispecific is structurally similar 
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to the hu1B7 and hu11E6 monoclonal antibodies, facilitating comparisons among the 
variants, with the added benefits of low immunogenicity and enhanced circulating half-
life due to FcRn binding (91).  
 
 
 
Figure 9. Production of bispecific hu1B7/hu11E6 antibody.   
(A) Schematic overview of the process used to create the bispecific antibody. Single amino acid residue 
changes were introduced into the parent antibody Fc domains to create “knob” (T366Y; hu1B7H+) and 
“hole” (Y407T; hu11E6H-) variants, which were expressed and purified separately. An equimolar mixture 
of the two proteins was then subjected to a controlled reduction and re-oxidation reaction, resulting in 
efficient formation of the heterodimeric, bi-specific antibody. (B) Purity of the knob and hole variants and 
2-MEA-catalyzed recombination was monitored by non-reducing SDS-PAGE. Samples shown are with (+) 
or without (-) the three reaction components: hu1B7H+, hu11E6H-, or the 2-MEA red/ox step. (C) Purified 
hu1B7H+, hu11E6H-, and the bispecific antibody were digested with IdeS enzyme to yield F(ab’)2 
fragments. LC/MS was used to determine the purity of the bispecific preparation.  
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To make the bispecific, the T366Y “knob” mutation was introduced into the CH3 
domain of hu1B7 to generate hu1B7H+, while the Y407T “hole” mutation was 
introduced into the CH3 domain of hu11E6 to generate hu11E6H-. These two parent 
antibodies were transiently expressed in separate CHO cell cultures and purified via 
protein A chromatography. Non-reducing SDS-PAGE of the purified proteins revealed 
mixtures of homodimer and half-antibodies at ~75 kDa after storage in PBS pH7.4 (Fig. 
9B). Notably, the hu11E6H- ran primarily as a covalent homodimer at this pH (201), 
while the hu1B7+ showed bands for homodimer and half-antibody, consistent with 
previous reports of an Fc anti-parallel knob-knob dimer (202).  The hu1B7H+ and 
hu11E6H- proteins were combined in an equimolar ratio and subjected to a controlled 
reducing step using 2-mercaptoethanolamine (2-MEA) to generate the heterodimeric 
bispecific antibody (186). Non-reducing SDS-PAGE analysis of the protein product after 
this step shows a significantly reduced presence of the half antibody and high molecular 
weight species, suggesting successful formation of the bispecific antibody (Fig. 9B). 
 
The hu1B7/hu11E6 bispecific antibody was digested with IdeS to generate 
F(ab’)2 fragments, which were purified and  analyzed by LC/MS to assess the purity of 
the bispecific (Fig. 9C). The precursor antibodies hu1B7H+ and hu11E6H- were prepared 
in the same way as controls. The bispecific fragment had a major peak at 97.878 kDa, 
which is a unique molecular weight intermediate to the hu1B7H+ and hu11E6H- 
homodimer weights of 96.669 and 99.087 kDa respectively. The measured masses were 
nearly identical to the expected values calculated from the primary amino acid sequence. 
The bispecific also showed a small peak corresponding to hu11E6H- homodimer, 
representing ~5% of the maximum intensity. As the original reaction was performed at a 
1:1 hu1B7H+:hu11E6H- ratio, we expect a similar proportion of unreacted hu1B7H+. 
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The unreacted fraction hu1B7H+ likely contained a significant amount of half-antibody 
based on SDS-PAGE of the hu1B7H+ precursor, which would not show up in our IdeS 
analysis. Thus, assuming there is a similar amount of unreacted hu1B7H+ also present, 
the final purity of the assembled bispecific antibody is ~90%, consistent with other 
bispecific antibodies generated using the T366Y/Y407T mutations (184).  
 
Biophysical characterization of monoclonal, Fab, and bispecific antibodies 
To provide a point of reference in our functional assays and to assess valency 
effects, we also produced monoclonal hu1B7 and hu11E6 and their Fab fragments. The 
monoclonal antibodies were expressed in transient CHO cell cultures and purified by 
protein A and anion exchange as previously described (27). The Fab fragments were 
generated by subsequent digestion of purified antibody with immobilized papain, 
followed by protein A chromatography to remove undigested antibody and free Fc 
domains. Reducing and non-reducing SDS-PAGE analysis determined that the proteins 
were highly pure (~90% or higher) and of the expected size (Fig. 10A). Reducing lanes 
show characteristic bands at ~50 kDa (intact immunoglobulin heavy chain) and ~25 kDa 
(light chain and Fab heavy chain), while non-reducing lanes show single bands at ~150 
kDa (intact immunoglobulin and bispecific antibody) and ~50 kDa (Fabs).    
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Figure 10. Biophysical characterization of bispecific and parent antibodies.  
(A) Reducing and non-reducing SDS-PAGE was used to assess the size and purity of the hu1B7 and 
hu11E6 full-length and Fab antibody fragments as well as the hu1B7/ hu11E6 bispecific antibody. 3 µg of 
protein were loaded per lane. (B) Differential scanning fluorimetry was performed to determine the melting 
profile of full-length hu1B7 and hu11E6 (solid lines, blue or green respectively), the hu1B7 and hu11E6 
Fabs (dashed lines, blue or green respectively) and the hu1B7/hu11E6 bispecific antibody (grey line). 
Samples were prepared in PBS, pH7.4. Derivative data (d(Fluorescence)/ dTemperature) is aligned below 
the raw melting curves to facilitate identification of transition temperatures. Curves are averages of three 
replicates at 400 µg/ml. 
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Antibody thermal stability was assessed using a differential scanning fluorimetry 
assay to monitor protein unfolding in PBS, pH 7.4 (Fig. 10B). The full-length hu1B7 
profile shows two melting regimes, with the first peak (~71°C) likely representing CH2 
unfolding and the second peak (~79°C) representing CH3 and Fab unfolding (203). In 
this buffer, the hu11E6 domains unfold in a more continuous manner, with the most rapid 
unfolding occurring around 74°C. The Fab formats show similar or slightly higher 
melting temperatures than their full-length counterparts, with derivative melting points of 
~78°C for hu1B7 Fab and ~76°C for hu1E6 Fab.  The bispecific antibody exhibited a 
more complex profile, making it difficult to identify specific melting regimes, but major 
transitions were observed at ~67°C and ~77°C. The introduction of the knob and hole 
mutations is expected to have a slight destabilizing effect on the CH3 domain of the 
bispecific. Derivative traces are also shown to aid in identification of melting transitions 
(Fig. 10B).  
 
A hu1B7/ hu11E6 bispecific antibody has similar in vitro PTx binding activity to the 
binary mixture 
To assess the PTx binding activity of the bispecific antibody and to compare this 
with the activity of the binary antibody, we performed a series of ELISA assays.  To 
verify that the protein was functionally bispecific, we compared the hu1B7/hu11E6 
bispecific and hu1B7H+ and hu11E6H- parent antibodies using a sandwich ELISA (Fig. 
11A). The PTx-B subunit was coated on the plate and used to capture any antibodies with 
the hu11E6 paratope. This was followed by incubation with S1-220K-biotin and 
streptavidin-HRP to detect molecules also containing the hu1B7 binding site. As 
hu1B7H+ only binds S1-220K-biotin, this did not bind to coated PTx-B, while hu11E6H- 
binds PTx-B but cannot be detected with S1-220K-biotin. In contrast, the bispecific 
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antibody was able to simultaneously bind both PTx-B and S1-220K-biotin, exhibiting a 
characteristic logarithmic binding curve with an EC50 of ~4nM.  
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Figure 11. Biochemical characterization of bispecific and parent antibodies.  
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Figure 11. Biochemical characterization of bispecific and parent antibodies.  
 
(A) The hu1B7/hu11E6 bispecific antibody (grey squares) was assessed for presence of each unique 
binding site and the ability to simultaneously engage two different epitopes using a sandwich ELISA. 
Purified PTx-B subunit was used to capture the hu11E6 paratope, followed by biotinylated S1-220K and 
streptavidin-HRP to detect the hu1B7 paratope. The monospecific parent antibodies hu1B7H+ (solid 
circles) and hu11E6H- (hollow circles) were used as controls. (B) An ELISA was used to confirm the PTx 
binding activity of all antibody variants and controls.  A PTx-coated plate was incubated with dilutions of 
full-length hu1B7 or hu11E6 (circles, solid with blue line or hollow with green line respectively), the 
hu1B7 or hu11E6 Fabs (triangles, solid with dashed blue line or hollow with dashed green line 
respectively) or hu1B7/hu11E6 bispecific (squares, solid grey line), followed by anti-human-kappa-HRP to 
detect bound chains. (C) A competition ELISA was used to determine the solution-based equilibrium 
dissociation constant (KD) of all variants. Data is shown for full length (solid bars) and Fab antibody 
formats (striped bars). For all panels, the error shown is the standard deviation. The competition ELISA 
data is averaged from six replicates over three experiments. Statistical significance was determined using 1-
way ANOVA and Tukey’s test. Statistical significance indicated as: *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. In addition to the comparisons shown, hu11E6 Fab was significantly different than all other 
groups (****), and the hu1B7 Fab + hu11E6 Fab mix was significantly different than hu1B7 mAb (*).  
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We next assessed the binding characteristics of all individual antibodies and 
fragments using a direct PTx-binding ELISA (Fig. 11B). All variants displayed strong 
binding to PTx, with the bispecific antibody showing a binding profile nearly identical to 
those of full-length hu1B7 and hu11E6. While the hu1B7 Fab had a curve similar to full-
length hu1B7, the hu11E6 Fab showed a ~2-fold increase in EC50 compared to the full-
length version, suggesting there are significant avidity effects for hu11E6.   
 
For a more thorough investigation into the effective binding affinities of different 
antibody formats, we performed a quantitative competition ELISA wherein antibody 
dilutions were incubated with a constant amount of PTx, after which unbound antibody 
was detected by a direct PTx-binding ELISA (Fig. 11C). We fit curves to this data to 
calculate the equilibrium dissociation constants (KD), with bivalency corrections used for 
the full-length proteins (193). Due to a simple 1:1 interaction with toxin and a binary 
“bound” or “not bound” structure, Fabs provide more accurate affinity measurements. 
The hu1B7 Fab KD was calculated to be 3.1±0.9 nM while the hu11E6 Fab had a 
significantly weaker affinity with a KD of 20±8 nM. The full-length formats showed an 
approximately 3-fold improvement in effective affinity compared to the Fabs, likely due 
to avidity effects. The KD values calculated here for the full-length hu1B7 and hu11E6 
were 0.8±0.1 nM and 6±2 nM respectively, and are comparable to our previous 
competition ELISA and SPR measurements (27).  
 
Both Fab and full-length mixtures as well as the bispecific antibody were tested in 
this assay, although in these cases KD represents an effective affinity.  The mixture of 
full-length antibodies and bispecific antibody exhibited effective affinities intermediate to 
those of the two parents at 2.1±0.8 nM and 1.1±0.4 nM respectively, while the Fab 
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mixture had an effective affinity of 8±4 nM. These affinities are skewed more toward the 
higher affinity of hu1B7, which in this solution-based assay may capture a larger fraction 
of available PTx molecules than the hu11E6 binding site. Notably, the bispecific antibody 
also showed a significant improvement in effective affinity as compared to the Fab 
mixture, supporting the importance of avidity effects.   The data from these three ELISA 
assays in aggregate demonstrate that the hu1B7/hu11E6 bispecific is functionally 
bispecific and binds PTx similarly to the antibody mixture in a solution-based assay.  
 
The bispecific antibody neutralizes PTx activities in vitro  
We next wanted to assess the neutralization capacity of the hu1B7/hu11E6 
bispecific antibody in a simple in vitro model. The CHO cell assay is a commonly used 
method to quantify PTx activity and neutralization by observing morphological changes 
in CHO-K1 cells after incubation with toxin or toxin and antibody (194). This method 
was previously used to observe synergy between hu1B7 and hu11E6, which was maximal 
in an equimolar mixture (27). 
 
A constant amount of PTx (4 pM) was equilibrated with a series of antibody 
concentrations (up to 800 nM) in a 96-well plate. CHO-K1 cells were seeded into the 
wells and incubated for 48 hours, prior to scoring for the degree of cell clustering. Here 
we report the neutralizing ratio as the lowest antibody-to-toxin ratio which was able to 
completely prevent the clustered morphology, corresponding to a score of 1 (equivocal) 
on the established 0 to 3 scale (154), which is a more rigorous analysis than previously 
applied (27) (Fig. 12). Under these conditions, full-length hu11E6 and hu1B7 completely 
neutralized toxin at a ~1,100:1 and ~34,000:1 ratios, respectively. This large discrepancy 
is consistent with previous studies, despite superior performance of hu1B7 in a mouse 
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aerosol challenge (27). In addition, a similar study using a panel of murine anti-PTx 
antibodies, including 1B7 and 11E6, also observed enhanced neutralization in the CHO 
cell clustering assay by anti-B subunit antibodies which did not necessarily correlate with 
protection in vivo (195). The hu1B7+hu11E6 mixture and hu1B7/hu11E6 bispecific were 
also able to fully neutralize the toxin, with antibody-to-PTx ratios of ~700:1 and ~900:1 
respectively. These values are more similar to those observed for hu11E6 than for hu1B7 
alone, despite the presence of fewer hu11E6 binding arms in the mixture or bispecific 
formulation. This is preliminary evidence of synergy and also demonstrates that the 
bispecific format does not compromise B subunit neutralization.   
 
 
Figure 12. In vitro PTx neutralization measured by inhibition of CHO cell clustering.   
Adherent CHO-K1 cells were grown in the presence of 4 pM PTx pre-equilibrated with antibody dilutions. 
The lowest molar antibody-to-toxin ratio able to fully prevent clustering was recorded as the neutralizing 
ratio. Data is shown for neutralization with the full-length and bispecific antibodies (solid bars) and their 
Fab fragments (striped bars). The hu1B7 Fab was not able to fully neutralize the toxin at any concentration 
tested. Data is presented as the geometric mean of six replicates over three experiments, with error bars 
indicating the 95% confidence interval. Statistical analysis was performed using Kruskal-Wallace and 
Dunn’s post-hoc tests. Statistical significance indicated as: *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
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We included the hu1B7 and hu11E6 Fabs as well as a mixture of the two to assess 
the role of valency in PTx neutralization.  In particular, we did not know a priori whether 
the bispecific antibody would better mimic a mixture of monoclonal antibodies or a 
mixture of Fabs. In this assay the antibody was present at a significant molar excess over 
PTx, favoring binding of multiple antibodies to a single PTx. For this reason, we did not 
correct for valency in our ratio calculations. In general, the Fabs required approximately 
three-fold more protein to achieve the same neutralization level as the full-length 
antibodies (3,600:1 for hu11E6 Fab, 2,900:1 for Fab mix; Fig. 12), and we were unable to 
detect neutralization by the hu1B7 Fab under these stringent assay conditions. These 
results correlate well with the increase in effective affinity seen with the full-length 
immunoglobulins in the competition ELISA.  
 
In this plate-based cellular assay there is no mechanism for clearance of antibody-
toxin complexes; thus, in order to prevent cellular intoxication, antibody molecules must 
sequester every PTx molecule for the 48 hour duration of the experiment.  As transiently 
unbound PTx molecules are able to bind cellular receptors and enter the cell via receptor-
mediated endocytosis, even high-affinity antibodies such as hu1B7 and hu11E6 require 
very high ratios to fully neutralize PTx. Thus, the neutralizing ratios reported here are 
much higher than would be expected for an in vivo experiment.  
 
The antibody mixture and bispecific antibody synergistically inhibit PTx-induced 
leukocytosis in vivo 
Systemic leukocytosis is a primary outcome of B. pertussis infection and is 
predictive of severe disease in infants (181). As a proof-of-concept study to assess the 
therapeutic potential of the hu1B7/hu11E6 bispecific antibody, we turned to an in vivo 
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leukocytosis assay which measures the ability of an antibody to neutralize the increase in 
white blood cell (WBC) count induced by the injection of purified pertussis toxin (195, 
196). This assay has previously been shown to be more predictive of protection during 
bacterial infection than the CHO cell assay (195).  
 
In a pilot experiment, juvenile BALB/c mice were injected with 200 µg hu1B7 
antibody or PBS. Whole blood was collected from a lateral tail vein and assayed for 
white blood cells by staining for CD45 and measuring fluorescent cells via flow 
cytometry. In addition, WBC counts were taken from these and other mice on day 0 to 
assess the baseline variability. Treatment with a high dose of hu1B7 did not elevate the 
WBC count as compared to the baseline level or PBS treatment (Fig. 13A). 
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Figure 13. Antibody-mediated suppression of PTx-induced leukocytosis in vivo.  
(A) Antibody treatment alone did not raise WBC. Five-week old female BALB/c mice were administered 
200 µg hu1B7 or an equal volume of PBS via intraperitoneal injection, with the CD45+ WBC measured 
four days after treatment by flow cytometry. WBC counts of these and other mice were taken on day 0 to 
assess the baseline variability. (B) Antibody treatment suppresses PTx-induced leukocytosis. Mice were 
administered equal volumes of PBS, 2 µg PTx in PBS, or 2 µg PTx plus 20 µg total antibody (hu1B7, 
hu11E6, hu1B7+hu11E6 or the bispecific antibody) in PBS via a lateral tail vein injection, with CD45+ 
WBC counts measured four days later by flow cytometry. Hollow symbols indicate the WBC recorded for 
baseline, PBS and PTx-only treated control groups, solid symbols indicate antibody treated groups and 
triangles represent groups that received PTx. Groups were compared using one-way ANOVA and Tukey’s 
test with statistically significant comparisons indicated. Statistical significance indicated as: *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. Comparison of the hu1B7+hu11E6 binary mixture with the 
hu1B7/hu11E6 bispecific antibody was not significant.  
 
In the neutralization experiment, mice were injected with PBS, pre-equilibrated 
mixtures of 2 µg PTx plus 20 µg antibody, or 2 µg of the toxin alone. Four days later, 
whole blood was collected via cardiac puncture and assayed for white blood cells as 
described for the pilot experiment. The toxin alone induced a ~14-fold increase in WBC 
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as compared to PBS-treated mice, while the full-length hu1B7 and hu11E6 antibodies 
were each able to significantly suppress this WBC rise (p<0.0001 and p<0.01, 
respectively; Fig. 13B). Of these, hu1B7 was significantly more effective than hu11E6 
(p<0.001), consistent with previous data showing enhanced in vivo protection against 
bacterial challenge by hu1B7 over hu11E6 (27).  
A relatively low antibody dose (7:1 molar ratio of antibody to PTx) was selected 
to provide only partial suppression of leukocytosis by hu1B7 or hu11E6 to allow for the 
detection of synergy based on pilot experiments (data not shown). Under these 
conditions, an equimolar antibody mixture (10 µg of each antibody) significantly reduced 
WBC versus treatment with the same dose of either hu1B7 or hu11E6 alone (20 µg 
antibody; p<0.0001).  The resulting WBC count was not significantly different than that 
for PBS-treated naïve mice. Since the antibody mixture contains equimolar amounts of 
both the hu1B7 and hu11E6 specificity, simple additivity predicts that the mixture would 
provide a result intermediate to that of either antibody used alone. Instead, the efficacy of 
the mixture was significantly enhanced over either monoclonal preparation, indicating 
synergy between the antibodies.  
 
Synergy of the bispecific antibody can be assessed in a similar way, although 
avidity effects complicate the analysis. As there is only a single hu1B7 epitope on a PTx 
molecule, the bispecific antibody can be expected to retain all of the hu1B7 functionality. 
In contrast, while hu11E6 can also only bind a single epitope at a time, bivalency was 
beneficial in ELISA and CHO assays, thus the bispecific construct may not be able to 
capture the full neutralization potential of hu11E6 with only a single paratope. However, 
treatment with 20 µg of the bispecific antibody still significantly reduced the WBC count 
as compared to either of the monoclonal preparations (p<0.01 vs hu1B7, p<0.0001 vs 
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hu11E6). Notably, there was no difference between WBC count for mice treated with the 
antibody mixture as compared to those treated with the bispecific antibody at this power 
level. These data show that the bispecific antibody was able to capture the synergy 
observed in the mixture.  
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DISCUSSION 
Three of the 52 currently approved antibodies are indicated for the treatment or 
prevention of infectious diseases (204), with dozens more in clinical and pre-clinical 
development (70, 205, 206). Palivizumab was approved in 1998 to prevent respiratory 
syncytial virus (RSV) infection in high-risk patients (6), while raxibacumab and 
obiltoxaximab were approved in 2011 and 2016, respectively, for the treatment of anthrax 
(207, 208). Antibodies may be appropriate therapeutics for a variety of other infectious 
diseases that cause serious disease in high-risk populations, including pertussis. An 
antibody therapeutic could be used to treat seriously ill infants in the developing world 
and prevent disease in high-risk areas, a strategy that is being pursued for pediatric HIV-1 
(209)   In this work, we have further explored the mechanism of synergy between the 
anti-PTx antibodies hu1B7 and hu11E6, and showed that a bispecific antibody captures 
this synergy in a single molecule.  
 
We have previously demonstrated that an equimolar mixture of hu1B7 and 
hu11E6 exhibited synergistic PTx neutralization in vitro, requiring a lower antibody-to-
toxin ratio to achieve the same effect as either hu1B7 or hu11E6 alone (27). Here, we 
showed that while multiple antibodies can simultaneously bind the same toxin molecule 
(Fig. 8A), a single antibody is unlikely to crosslink two of those epitopes (Fig. 8B). Thus, 
if synergy depends upon simultaneous blockade of the hu1B7 and hu11E6 epitopes on 
PT, a bispecific antibody with native architecture would be expected to exhibit similar 
PTx-neutralizing abilities as the mixture. This was confirmed in several in vitro assays to 
assess PTx-binding and in vitro neutralization (Fig. 10, Fig. 11).  Finally, in vivo PTx-
neutralization data with a 7:1 molar excess of antibody not only demonstrated significant 
synergy between hu1B7 and hu11E6, but also confirmed that the bispecific format fully 
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recapitulated this effect (Fig. 13). These results confirm the hypothesis that synergy is 
due to more complete neutralization of the toxin when both the binding and catalytic 
activities are simultaneously blocked, which can be achieved by simultaneous binding of 
hu1B7 and hu11E6 or several bispecific antibodies.  
 
A similar approach was recently reported for ricin toxin, another A-B toxin with 
an analogous intoxication pathway as PTx (210). In that work, camelid variable heavy 
domains blocking the active and binding activities were only partially neutralizing on 
their own, and a mixture of the two top performers did not exhibit synergy (211). In 
contrast, a flexible bispecific construct was developed that was able to crosslink the two 
epitopes, and in doing so significantly changed the dynamics of toxin binding and 
trafficking (212). Thus even in the context of bacterial toxin neutralization, bispecific 
antibodies can be applied in several ways.  
 
Avidity effects were difficult to deconvolute in this system, with the 
paratope:epitope stoichiometry, spatial presentation of the antigen, and relative amounts 
of toxin and antibody all impacting results differently in each assay. While structural 
modeling suggests that simultaneous engagement of two epitopes on the same toxin 
molecule by a single antibody is unlikely, it is possible that the presence of a second 
epitope nearby makes it easier for a bivalent construct to rebind the same toxin, 
essentially “wobbling” between the two epitopes. Avidity effects of multivalent and 
bispecific formats have been modeled (213), and have been proposed as a way to drive 
higher-affinity and higher-specificity binding of targets with multiple epitopes. 
Alternatively, bridging of two toxin molecules by one monoclonal antibody can allow 
bivalent binding of a second antibody to a different epitope, which has been proposed as 
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a mechanism for synergy in the neutralization of anthrax toxin (214). Regardless of the 
exact mechanism, bivalency enhanced the effective binding affinity (Fig. 11C) and in 
vitro neutralization (Fig. 12). In a therapeutic setting, Fabs would not typically be used 
due to their significantly shorter circulating half-life.  
 
While the synergy between hu1B7 and hu11E6 is beneficial for potency and 
reducing the cost of goods, the inclusion of multiple specificities is also important for 
long-term safety and efficacy of a therapeutic. Suppression of escape variants is a 
particular concern for pertussis, as circulating B. pertussis strains appear to have changed 
in response to vaccine-induced immunity. Wide-spread use of acellular vaccines 
containing the adhesion pertactin appears to have provided a considerable fitness 
advantage for naturally occurring pertactin-deficient strains, with the result that 100% of 
clinical isolates in the United States now lack this protein (215). Thus, there is basis for 
concern that widespread use of anti-PTx antibodies could lead to evolution or selection of 
escape variants. Fortunately, PTx appears to be more essential for pathogenesis than 
pertactin, as B. pertussis PTx knock-out strains are minimally infective and severely 
reduced in virulence (143, 164). Moreover, PTx is a key component of all acellular 
vaccines, including a PTx-only vaccine in Denmark, yet only two PTx-deficient strains 
have been isolated in the past eight years worldwide. Both of these strains were recovered 
from unvaccinated individuals co-infected with other Bordetella strains (216), suggesting 
that PT-deficient strains are unlikely to be successful pathogens. The majority of 
sequence variation occurs in the A subunit, which is immunodominant and has five 
distinct circulating alleles (180). It is possible that antigenic drift could lead to PTx 
variants with reduced affinity for neutralizing antibodies, although changes in the A 
subunit are unlikely to affect hu11E6 binding and have previously been shown to have 
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minimal effect on hu1B7 binding (157). However, an antibody therapeutic with multiple 
specificities further mitigates this concern.  
 
The main drawbacks to antibody mixtures are the increased complexity and costs 
of manufacturing and regulatory approval processes. The binary mixture described here 
would likely be produced by separately manufacturing hu1B7 and hu11E6 and adding a 
final co-formulation step. Although this method is simple to implement, it is susceptible 
to batch failure from either individual antibody and requires development of two separate 
manufacturing chains (69).  In addition, antibody mixtures are subject to the same strict 
FDA approval processes as monoclonal preparations, and documentation for the safety of 
each individual component as well as the mixture is needed (72). While bispecific 
antibodies have their own manufacturing challenges, detailed below, the regulatory 
pathway is expected to be simpler. We explored the use of a bispecific antibody as an 
alternative way to package the therapeutic potential of the antibody mixture.  
 
Over 60 distinct bispecific architectures have been reported, ranging from 
constructs with near-native immunoglobulin structure to various scFv-fusions (91). As 
our eventual goal is to use this antibody for passive immunization in high-risk infants, 
stability and a long-circulating half-life are essential characteristics, which suggested the 
use of a format including an Fc region for FcRn-mediated recycling. We chose to use the 
knobs-in-holes mutations (184) on a stabilized 4D5 framework, which is a validated 
approach with a simple protocol. The resulting huIgG1 antibody has a structure nearly 
identical to the parental hu1B7 and hu11E6 antibodies, facilitating direct comparisons 
with the antibody mixture. In several other applications of bispecific antibodies for 
infectious disease, it was found that the chosen bispecific format had a significant impact 
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on potency, with full neutralization only occurring when the molecule was engineered to 
be flexible enough to crosslink two epitopes (182, 183). As hu1B7 and hu11E6 are able 
to neutralize PTx and exhibit synergy without crosslinking epitopes on a single PTx 
molecule, we did not pursue alternative formats.  
 
Bispecific antibodies with native architectures are appealing for their high 
stability, long half-life, and low immunogenicity but are among the most difficult to 
manufacture. These designs require correct assembly of two unique heavy chains and two 
unique light chains into a single heterodimeric protein.  In this case, the modular antibody 
domains that allow for diverse immune responses due to unbiased pairing of many heavy 
and light chain gene products is a detriment: there is minimal thermodynamic driving 
force to favor correct pairing, for instance between a hu1B7 heavy chain and a hu1B7 
light chain versus a hu11E6 light chain. The simple knobs-in-holes design utilized here 
results in over 90% correct assembly of the knob-and-hole heavy chains (184), but 
requires separate expression and purification of the half-antibodies to maintain proper 
pairing between the heavy and light chains. Several processing strategies using the 
knobs-in-holes designs have been developed (186, 217), while engineering of orthogonal 
CH/CL Fab interfaces to drive proper heavy and light chain pairing (218) has paved the 
way for production of a bispecific antibody from a single cell line. Bispecific antibody 
manufacturing is currently a very active area of research, and it is likely that future 
improvements could be included in a second generation of the bispecific antibody 
described here.  
 
The treatment of infectious diseases presents unique challenges, but antibody 
mixtures and bispecific formats have the potential to address currently unmet clinical 
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needs in this area. We have quantitatively demonstrated synergy in vivo between the two 
anti-pertussis toxin antibodies hu1B7 and hu11E6, and shown that this synergy is 
retained when these specificities are expressed as a knobs-and-holes bispecific antibody. 
As the antibody mixture was previously shown to be effective in both murine 
prophylactic and weanling baboon therapeutic models (27), we expect a bispecific 
antibody to recapitulate the efficacy of the mixture in an infection setting.  This bispecific 
antibody is particularly appealing, as the format simplifies the regulatory path while 
retaining the synergy and broader neutralization potential of the binary combination. We 
expect that bispecific and other multivalent antibody formats will see increased 
development for infectious disease applications.   
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Engineering a novel soluble TCR- Immunoglobulin hybrid molecule 
 
ABSTRACT 
T-cell receptors (TCRs) are structurally similar to antibodies and can be 
engineered in similar ways, however they are functionally distinct. While antibodies are 
well-suited for binding conformational epitopes found on extracellular pathogens or 
toxins, TCRs are highly specific for linear peptides displayed on the surface of cells in 
the context of major histocompatibility complexes (MHCs). Thus, soluble TCRs offer a 
complementary approach to antibody therapeutics, and are particularly relevant for viral 
diseases. We have proposed a new bispecific format called a T-cell Receptor- 
ImmunoGlobulin (TRIG) molecule, which is theoretically able to simultaneously bind a 
virally—infected cell via pMHC and a circulating T-cell via CD3. This “immune-
redirecting” approach is becoming a more common strategy for targeting cancer, but is 
also in development for several infectious indications. The TRIG is also unique in that it 
can be expressed in mammalian cells, and contains an Fc region for long half-life and 
effector cell interaction. Herein we describe our efforts to engineer this new format. We 
have developed a CHO surface display method, and optimized it to display a TCR. We 
have generated focused libraries around CDR3α and CDR3β, and are currently screening 
them for higher affinity TCR variants. We have also expressed and purified the sTCR-Fc 
fusion, which is the parent molecule of the bispecific, and are currently optimizing 
expression variables. We believe the TRIG may be a useful format for the treatment and 
prevention of viral diseases, and in the future we hope to test the molecule in a human 
cytomegalovirus model.  
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INTRODUCTION 
As we look towards finding cures for the next round of diseases- antibiotic-
resistant infections, pandemic viruses, rare genetic disorders- we must also look for the 
next generation of therapeutic molecules. Biologic drugs, including recombinant 
antibodies, will likely continue to be key players due to favorable safety profiles and 
developmental timelines(2). Further, there is now considerable interest in innovative new 
protein architectures which can open new pathways for treating disease.  
 
In particular, bispecific antibodies have the powerful ability to harness both 
cellular and humoral immunity. Amgen’s blinatumomab consists of an antibody single-
chain variable fragment (scFv) which can bind CD19, a B cell surface antigen, linked to 
another scFv that binds CD3, part of the T-cell receptor (TCR) complex(219). 
Simultaneous binding of CD3 on circulating cytotoxic T cells (CTLs) and CD19 on a 
tumor cell results in activation of the CTL and lysis of the lymphoma cell(219). Thus, the 
bispecific molecule basically acts as an adaptor; it specifically decorates targeted host 
cells, but can then bind and activate any passing CTL. Blinatumomab was the first 
bispecific antibody approved in the US, and has since been shown to nearly double the 
overall survival rate in acute lymphoblastic leukemia patients over traditional 
chemotherapy(220). Although initial development of bispecific antibodies has been for 
cancer indications, there is no reason this approach cannot be used for infectious, 
particularly viral, diseases. A nearly identical construct targeting the ectodomain of the 
influenza A matrix protein 2 (M2e), which is expressed on the surface of infected cells, 
has shown promise in a murine challenge study(221). Several groups have reported on 
bispecific antibodies targeting CD3 and the HIV envelope protein, which can induce 
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significant cell lysis and reduction of HIV expression in in vitro and ex vivo models(95, 
222).  
 
The ability to make such formats hinged on the maturation of the field of protein 
engineering and antibody production. The first bispecific antibodies were described in 
1961, but these early bispecifics were difficult to produce and purify. In particular, as 
there is minimal driving force for correct assembly, co-expression of two different light 
chains and two different heavy chains results in a mixture of 10 possible proteins(184). 
This problem was partly solved by the introduction of “knobs-into-holes” mutations in 
the CH3 region, which disrupt packing of mispaired products and thermodynamically 
favor correct pairing, resulting in up to 92% efficiency of desired heterodimeric pairing in 
the heavy chains(184). However, heavy and light chain pairing remains an issue, and 
necessitates special production methods or non-native antibody formats. Over 60 such 
bispecific formats have been described, with several in clinical testing(91).  These 
approaches include using linked ScFvs(223) (as used in blinatumomab), adding variable 
region fusions(224), and producing bispecifics in vitro from knob and hole or similar 
parent monoclonals(186). Mutations in the heavy/light interface that allow production 
within a single cell have been identified, though are quite extensive and somewhat 
dependent on the variable region(218, 225).  
 
One unique bispecific format is called an immune-mobilizing monoclonal T-cell 
receptors against Cancer/Viruses (ImmTAC/ImmTAV), and has a high-affinity soluble 
TCR in place of the antigen-targeting ScFv(226). While structurally related, TCRs are a 
different breed than antibodies; antibodies are adept at recognizing conformational 
epitopes on soluble proteins or cell surfaces, and TCRs recognize linear epitopes on 
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peptides derived from intracellular proteins. These peptides are displayed on the cell 
surface in complex with MHC molecules (peptide-MHC, pMHC), and cells displaying 
foreign or anomalous peptides will be recognized by CTLs and attacked. This ability to 
react to intracellular antigen fragments is a key way a healthy immune system eliminates 
endogenous virally infected and cancerous cells. As therapeutic antibodies binding viral 
glycoproteins are only functional in the extracellular space, using soluble TCR-like 
molecules to target infected cells themselves may be a complementary strategy for 
treating viral infections. For example, an ImmTAV specific for an immunodominant HIV 
peptide was able to kill resting and active HIV-positive cells in vitro, and may be an 
approach for eliminating reservoirs of latently infected cells(96). Although this is an 
exciting new strategy there are several protein engineering challenges associated with this 
format. Firstly, wild-type TCRs typically have affinities in the micromolar range, and 
must be affinity matured to the picomolar range to have functional effects as soluble 
monomers(227, 228). Secondly, soluble TCRs (sTCRs) are difficult to express, and are 
commonly expressed and refolded in E. coli(229). Finally, the small size of this construct 
and lack of Fc region results in a half-life of hours rather than the weeks typical for 
IgG(96). To put this into perspective, blinotumomab, which is antibody-based but 
similarly sized and formatted, must be continuously infused at high concentrations over 
several weeks to have therapeutic effects(230).  
 
In this chapter we describe our progress towards generating a novel TCR/Ig 
fusion molecule, called a TRIG (Fig. 14). This format is compelling as it can be 
expressed in mammalian cells without the need of a refolding step, and contains an 
antibody Fc region for long half-life in vivo. To do this, we first optimized a system to 
display RA14, a human TCR associated with human cytomegalovirus (CMV), on the 
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surface of CHO cells. We have designed and generated directed libraries of mutant 
RA14, and are in the process of using CHO cell display to discover high affinity variants. 
We have expressed and purified the wild-type RA14-Fc fusion and a human anti-CD3 
antibody from CHO cells, and are in the process of cloning knob and hole mutations into 
the Fc regions to drive proper assembly. In the near future we hope to use an in vitro 
assembly method to generate bispecific molecules, and test the resulting TRIGs in vitro 
for activity against CMV-infected cells.  
 
 
Figure 14. Diagram of the proposed hybrid T-cell receptor/Immunoglobulin molecule, or 
TRIG.  
The molecule consists of a soluble TCR targeting a viral pMHC fused to an antibody Fc region. The 
antibody arm binds CD3. The CH3 domains include knob and hole mutations(231) to ensure proper 
assembly. Purple, TCR domains. Red, antibody domains.  
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MATERIALS AND METHODS  
Cloning of surface display, library screening, and soluble expression plasmids 
The RA14 sequence was obtained from the protein data bank and synthesized as a 
gblock (IDT). The sequence was cloned into a pcDNA (general expression) or pPyEBV 
(Acyte Biotech) (library screening) backbone along with a murine Igk leader sequence, 
T2A peptide with furin cleavage site (RRKR) and GSG linker(232), and PDGFR 
transmembrane region (Fig. 15A, Fig. 16A). Constructs were cloned in both α-2A-β-TM 
and  β-2A-α-TM orientations. The constant region sequences were either the wild-type 
human germline sequence (UniProt), or included mutations to remove a free cysteine and 
move the terminal disulfide bond(233). The soluble construct was generated by replacing 
the transmembrane region with a human IgG1 hinge, CH2 and CH3. Cloning was 
performed using Q5 hot-start polymerase (NEB) and either traditional cut and ligate 
methods or assembly methods (NEBuilder).  
 
The sequence of 28F11, a human anti-CD3 antibody, was obtained from a 
patent(234), synthesized, and cloned into expression vectors as above.  
 
EpiCHO transfection 
EpiCHO cells (CHO-T) (Acyte Biotech) were grown in CHO-S-SFM II media 
(Gibco) supplemented with 2x GlutaMax and penicillin/streptomycin. For transfection, 
cells were spun and resuspended at a concentration of 1.5x10
6 
cells/mL, with 2 mL plated 
per well in a 6-well plate. For each well, 250 μl of OptiMEM (ThermoFisher) was mixed 
with 10 μl of Lipofectamine 2000 (ThermoFisher), and added to another tube with 250 μl 
of OptiMEM and 4 μg of DNA. The solution was mixed and allowed to equilibrate for 30 
minutes at room temperature, before adding the solution to the appropriate well. The next 
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day, cells were fed an additional 1 mL of media. Cells were scanned for transfection on 
day 2.  
 
Tetramer preparation 
Biotinylated HLA-A*0201 monomer loaded with the CMV-specific pp65495-503 
peptide (NLVPMVTAV) or an irrelevant HCV peptide (KLVALGINAV) were 
purchased from Biolegend and aliquoted. Streptavidin-APC, streptavidin-AF488 and 
streptavidin-AF647 were purchased from ThermoFisher and prepared at 200 μg/mL. To 
make the tetramer, one-tenth the required amount of streptavidin-fluor needed to make a 
4:1 monomer:streptavidin molar ratio was added every 5 minutes on ice over 50 minutes. 
30 μM biotin was then added to block any remaining unconjugated sites.  
 
Flow cytometry 
~1x10
6 
transfected cells were centrifuged gently and resuspended in 50 μl of PBS 
plus 2% FBS (Sigma) with 9-30 μg/mL tetramer and a 1:50 dilution of antiVβ6-5-PE 
(Beckman Coulter). Cells were stained at room temperature for 1 hour, then rinsed and 
resuspended in 1 mL PBS plus FBS. Samples were run on a Fortessa (BD Biosciences). 
All analysis was done using FlowJo software with pre-gating on live cells.  
 
Library design and cloning 
Complementarity-determining regions (CDRs) 3α and 3β were targeted for 
saturation mutagenesis (Fig. 15A). The targeted region included all amino acids directly 
contacting the pMHC(235), as well as an additional residue on either side to impart more 
backbone flexibility (Table 4.1). To limit library size and retain binding affinity, one (3α) 
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or two (3β) residues involved in hydrogen bonding were retained as the wild type 
sequence. To generate the insert, degenerate primers overlapping and extending past the 
CDR were used with upstream primers to synthesize the first fragment. This PCR was 
done 10 times to reduce bias using Q5 hot-start master mix (NEB). A second PCR, 
overlapping the first but outside of the mutagenized region, was performed to make the 
second fragment. The two fragments were run on an agarose gel and gel extracted, mixed 
in an equimolar ratio, put through 10 cycles of annealing and extension, and then 
amplified using primers at the distal ends. The insert and pPyEBV backbone were 
digested with the appropriate restriction enzymes (CDR3α, AgeI and NheI; CDR3β, 
BamHI and NheI, NEB), gel extracted and desalted. For each library ~1μg of vector was 
ligated with insert at a 3:1 (3α) or 6:1 (3β) ratio overnight using T4 ligase (NEB). The 
following day, ligations were desalted and transformed into ~1.5 mL of fresh NEB10β 
electrocompetent cells. After one hour of recovery, dilutions were plated and incubated, 
and colony counts used to estimate the library size. The library was grown to an OD600 of 
2 in liquid culture, which was then used to make frozen stocks and inoculate a new flask 
for overnight growth. Library DNA was prepared the next morning using a Maxiprep kit 
(Qiagen).  
 
Library transfection and sorting 
1 or 2 T-150 flasks (24-48 mL total) of confluent EpiCHO cells were transfected 
as described above, with quantities scaled accordingly. To allow for only a single plasmid 
per cell, transfected DNA was diluted 1:4 with an irrelevant plasmid of similar size and 
no antibiotic resistance gene encoded. T-25 flasks of wild-type positive control as well as 
an irrelevant antibody display control were also transfected. On day 2, cells were scanned 
for surface display to verify transfection, and spun down and resuspended in half-strength 
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selective media (CHO-S-SFM II plus 2x GlutaMax plus 150 μg/mL Hygromycin). On 
day 4 or 5, cells were expanded as needed and transferred into full-strength selective 
media (300 μg/mL Hygromycin). Cells were split regularly in selective media until good 
viability was present in a confluent T-150 (~2 weeks).  
 
For sorting, ~1x10
7 
live cells were spun and resuspended in OptiMEM plus 1% 
BSA and stained as described above. Cells were sorted using a FACSAria, with the sort 
gate biased towards cells showing higher tetramer binding at the same display level. The 
gate was drawn to collect ~1% of the total population, thus resulting in a final sort count 
of ~1x10
5
 cells. The sorted cells were grown up to a T-150 again (~1 week), and the 
process was repeated 1-2 more times.  
 
Soluble protein expression and purification 
For medium-scale expression of the TCR-Fc fusion and αCD3 antibody, two T-
150 flasks of CHO-K1 cells were transfected using the same cell/media/reagent ratio as 
described above. Cells were grown in high-glucose DMEM (Sigma) with 10% low-IgG 
FBS (ThermoFisher) and no antibiotic. Media was collected and replaced over 1-2 weeks. 
Collected media was centrifuged to remove cells, neutralized with 1M Tris pH 8, and 
stored at 4C. 
 
As an initial crude purification, soluble protein was precipitated out with 50% 
saturated ammonium sulfate. The precipitate was collected by centrifugation and 
resuspended in binding buffer (100 mM phosphate, 150 mM NaCl, pH 7.2). Protein in 
binding buffer was loaded onto a protein A column using an FPLC (ÅKTApure, GE 
healthcare), washed several times, and eluted with 100 mM glycine, pH 2.5. Elutate was 
107 
 
immediately neutralized with 1M Tris, pH 8, and buffer-exchanged into PBS pH 7.4 
using a centrifugal filter.  
 
3 μg of purified protein was prepared in reducing or non-reducing buffer and 
incubated for 5 minutes at 80C or 42C respectively. Samples were run on a 4-20% 
gradient gel (BioRad) at 200V for 30 minutes, and stained with GelCode Blue 
(ThermoFisher Scientific).  
 
Enzyme-linked immune-sorbent assay (ELISA) 
An Fc-capture ELISA was used to quantify protein in unpurified media. A high-
binding plate (Costar) was coated with a 1:500 dilution of goat-anti-human-Fc 
(ThermoFisher) in PBS and incubated overnight at 4C, then blocked with a 5% 
milk/PBST solution. Neutralized media was diluted down the plate in duplicate and 
incubated at room temperature for 1 hour. After a 1 hour incubation with a 1:2500 
dilution of goat-anti-human Fc- HRP (SouthernBiotech), the plate was developed with 
TMB and stopped with HCl. Absorbance was read at 450 nm. An irrelevant, high-
expressing antibody with identical Fc region was used as a control.  
 
To more stringently detect correctly assembled sTCR-Fc, binding of the soluble 
protein was assayed using an Fc/Vβ sandwich. The ELISA coat was identical to the Fc-
capture, but the secondary was a 1:2500 dilution of the antiVβ-6-5-PE antibody used for 
flow cytometry. This mouse antibody was detected by a 1:2500 dilution of anti-mouse 
Fc-HRP (Sigma) and developed as above.  
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Jurkat cell staining 
To test binding of the αCD3 antibody 28F11, ~1x106 Jurkat cells were collected, 
centrifuged, and resuspended in PBS plus 2% FBS with 1 μg/mL 28F11. Cells were 
stained on ice for 30 minutes, washed, then stained again with the same concentration of 
anti-human Fc-AF647 (Jackson Immunoresearch). Cells were washed again and then 
analysed on the Fortessa.  
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RESULTS 
A CMV-specific TCR, RA14, can be displayed on the surface of CHO cells 
As our long term goals were to make a soluble TCR from mammalian cells, we 
first wished to optimize an expression system for RA14. Initial testing using the wild-
type sequence with leucine zippers for added stability(236) was not successful, so we 
instead moved to a surface display system for easier troubleshooting of parameters. The 
plasmid for this system (Fig. 16A) includes a murine Igκ leader sequence, which has been 
successful in our lab for antibody expression, and a PDGFR transmembrane which we 
have used for antibody display. The RA14 variable regions (Vα, Vβ) are paired with the 
human germline constant regions (Cα, Cβ), separated by a 2A sequence including a furin 
cleavage site (RRKR) and GSG linker. We used the 2A sequence from the Thosea asigna 
virus, which was shown to have the best cleavage efficiency in CHO cells expressing 
humanized antibodies(232). Notably,  readthrough of the 2A region obviates the need for 
a second secretion signal(237). As only the second chain is fused to the transmembrane 
region, and the order may have some impact on expression, we cloned the construct with 
both the α (α/β-TM) and β (β/α–TM) chains in the first position. Finally, we assessed the 
wild-type constant regions (wtα/β) as well as modified constant regions (dsα/β), which 
have a moved interchain disulfide bond and eliminate a free cysteine, and have proved 
useful for phage and yeast display constructs(238, 239).  
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Figure 15. RA14 TCR is displayed on the surface of CHO cells.  
A, Key elements of the surface display plasmid design. SS, secretion signal from murine Igκ. T2A includes 
a furin cleavage site (RRKR) and GSG linker. TM, transmembrane region from PDGFR. B, Display levels 
of the constructs, as measured by antiVβ6-5 antibody. EpiCHO cells were transfected with plasmid and 
stained 2 days later with pp65 tetramer-APC and antiVβ6-5-PE. Display is percent of live cells staining 
positive for PE. wt, wild-type constant regions. ds, disulfide-modified constant regions. C, Display and 
antigen binding of RA14 as measured by flow cytometry. Purple, pp65 tetramer staining. Grey, irrelevant 
tetramer staining.  
 
The constructs were transiently transfected into EpiCHO cells, and scanned via 
flow cytometry two days later.  As a measure of surface-bound TCR, cells were stained 
with antiVβ6-5-PE. We also made tetramers from biotinylated pMHC and streptavidin-
APC, which increases the avidity and functional affinity of the reagent, and used these to 
check for pMHC binding.  The cells had good viability, and the fraction of live cells 
displaying TCR was quantified by PE signal over background (Fig. 15B). The 2D plots 
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(Fig. 15C) show a population of cells that is binding tetramer proportionally to surface 
display, which is interpreted as properly-folded, surface-expressed TCR. Staining the 
same samples with an irrelevant tetramer did not show this same population. Although 
the tetramers seemed to have a small amount of non-specific binding, use of the antiVβ6-
5 antibody helped confirm the population of interest. From this data it is clear that the 
disulfide-modified constant regions have a substantial positive effect on TCR display in 
both configurations. For either constant region, the α/β-TM configuration was better than 
the β/α-TM configuration, and even showed marginally better tetramer binding at the 
same display level. Transfection of a β-TM only construct confirmed that while the beta 
chain can be secreted alone and detected on the surface, it does not bind tetramer (data 
not shown). From these results, we chose to move forward with the dsα/β-TM construct.  
 
A mammalian display system can be used to screen for affinity improvement 
Although the wild-type affinity of RA14 is relatively high for a TCR, reported as 
27.7μM(235) or 6.3 μM(240) depending on the experimental setup, a higher affinity will 
likely be required for therapeutic success(227). Phage display and yeast display have both 
been used for affinity maturation of TCRs. Using a yeast display system, 100-fold(239) 
to 750-fold(241) affinity improvements were found by saturation mutagenesis of a single 
CDR. A phage display method with larger library sizes achieved a similar 720-fold 
improvement for a single CDR, but remarkably was able to reach a 10
6
-fold affinity 
improvement by targeting multiple CDRs and repeating the process several times(228). 
We have previously developed a CHO-cell surface display method for affinity maturation 
of antibodies (A. Nguyen, unpublished data). Although this method is limited to modest 
library sizes (10
6
), a key benefit is that by screening in the final expression host, the 
soluble molecule is more likely to retain the characteristics selected for in the library. In 
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particular, as soluble TCR expression in mammalian cells is challenging, we decided that 
screening our TCR in this format was relevant and a good proof-of-concept for our CHO 
display system.  
 
The layout of the original expression plasmid was maintained and cloned into the 
pPyEBV vector as shown (Fig. 16A). This large plasmid contains additional features, 
namely an OriP, EBNA-1 gene, and PyOri, which allow semi-stable transfection into 
modified CHO-T cells(242). The PyOri and large T antigen (expressed in the EpiCHO 
cell line, CHO-T) allow plasmid amplification while OriP and EBNA-1 tether the 
plasmid to the chromosome during division. A hygromycin resistance gene allows for 
selection and maintenance of positive transfectants in mammalian culture.  
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Figure 16. Design of CDR mutagenesis library. 
 A, Key elements of the surface display plasmid design for semi-stable transfection. SS, secretion signal 
from murine Igκ. T2A includes a furin cleavage site (RRKR) and GSG linker. TM, transmembrane region 
from PDGFR. Addition of an OriP and EBNA-1 gene allows episomal replication and chromosomal 
tethering. A hygromycin resistance gene allows selection in mammalian culture. Red starred regions 
indicate the approximate location of CDR3α and CDR3β. B, Structural rationale for CDR residues selected 
for mutagenesis. Grey, HLA-A*0201. Magenta spheres, NLV peptide. Purple, RA14 TCR. Based on PDB 
file 3GSN(235). 
 
Due to library size limitations with this system and the known role of TCR CDR3 
loops in recognizing peptide antigens, we chose to make small, targeted libraries in the 
regions most important for binding. In particular, CDR3α and CDR3β make extensive 
contacts with both the peptide and HLA(235) (Fig. 16B), and are important for 
specificity. The final library designs consist of saturation or near-saturation mutagenesis 
of the contacting residues in one of these CDRs, plus one additional flanking residue on 
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either side to allow more flexibility in the backbone (Table 4.1). In each CDR there were 
1 (3α) or 2 (3β) key residues that made hydrogen bonds with both peptide and HLA 
which were retained as wild type. Library inserts were generated using overlap PCR with 
degenerate primers, followed by an overlap extension step to make full-length inserts. 
The inserts and backbone were digested with the appropriate restriction enzymes, ligated 
overnight, and transformed into fresh electrocompetent cells. The final library size is 
estimated from the number of transformants after recovery (Table 1).  
 
Table 4. Library design and size. 
Library 
AA 
sequence 
Codons Library size 
   
AA, 
theo. 
DNA, 
theo. 
DNA, 
actual 
CDR3α NTGNQ NNSNNSNNSAACNNS 2E5 1E6 4E5 
CDR3β PVTGGIYG NBSVBCACCVBCVBCVBCTACNBS 1E6 4E6 1E6 
 
Wild-type residues shown with retained residues in bold purple font. Library residues were randomized 
using primers with the degenerate nucleotides shown.  
 
The libraries were transfected into EpiCHO cells, and transitioned into selective 
media during days 2-5. After two weeks. 1x10
7
 live cells were stained with the antiVβ6-
5-PE antibody and pp65 tetramer-AF647. The cells were sorted based on higher tetramer 
staining for the same antiVβ6-5 staining, indicating improved affinity. Several rounds of 
sorting were performed, with an approximate growing time of 1 week per round (Fig. 
17). The first round of sorting was able to pick out a population of clearly tetramer-
binding cells, and R2 not only enriched that population but eliminated the majority of 
non-binding TCRs. By round 3, several distinct improved populations were observed. 
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Further analysis of clones pulled from the CDR3β library is ongoing, as is sorting of the 
CDR3α library. 
 
 
Figure 17. CDR3β  library sorting.  
Cells were stained with pp65 tetramer-AF647 and antiVβ6-5-PE. Live, single cells were sorted based on 
higher tetramer staining at the same antiVβ staining (display level). Sorting was performed three times. The 
percentage of cells falling within the boxed population is indicated in the upper right hand corner.  
 
Bispecific TCR/Ig precursors can be expressed and purified from CHO cells 
Our overall goal is to generate a novel bispecific TCR/Ig structure (Fig. 14), 
which replaces one arm of a full length antibody with a soluble TCR (T-cell Receptor 
Immunoglobulin Graft, or TRIG). We propose to make the TRIG by separate expression 
of a TCR-Fc and antibody (Fig. 18A), followed by a controlled reducing and re-oxidation 
step to make the bispecific molecule(186). Knob and hole mutations in the Fc CH3 
domain (not shown)(231) will catalyze the formation of stable heterodimers. We have 
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considerable experience with this procedure, and have used it to make bispecific 
pertussis-toxin-binding antibodies with ~90% purity(92).  
 
We chose to work with a fully human CD3 binding antibody, 28F11, which is 
reported to have similar binding affinity and characteristics to OKT3, a commonly-used 
αCD3 reagent(234). The variable regions were synthesized and cloned into separate κ and 
heavy chain expression plasmids, which were transfected into CHO-K1 cells. The media 
was collected over ~1 week, and purified by ammonium sulfate precipitation and protein 
A chromatography. SDS-PAGE of the purified protein (Fig. 18B) indicates high purity, 
with the expected ~50kD (heavy chain) and ~25kD (light chain) bands seen in the 
reduced sample, and a strong ~150kD band (full-length protein) seen in the non-reducing 
lane. The fainter, larger band in the non-reducing lane likely indicated a small amount of 
aggregates, which could be easily cleaned up using size exclusion chromatography. To 
confirm the binding specificity of our purified 28F11, we stained Jurkat cells, a human T-
cell line with endogenous TCR expression, and analyzed them by flow cytometry (Fig. 
18C). Staining of the Jurkat cells was ~91% efficient and resulted in a good 
differentiation from unstained cells, and looks very similar to staining with OKT3 (data 
not shown). Knob and hole mutations have been cloned into these constructs, and a 
small-scale transfection test indicated similar expression to the wild-type construct.  
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Figure 18. Design, expression, and characterization of αCD3 and sTCR-Fc.  
A, Structure of TRIG parent molecules, an IgG1 antiCD3 antibody and sTCR-Fc. Red, antibody domains. 
Purple, TCR domains.  B, SDS-PAGE of purified αCD3 antibody. 3μg of purified antibody was run under 
reducing and non-reducing conditions. C, Staining of Jurkat cells using the αCD3 antibody. Anti-hFc-
AF647 was used to detect the αCD3 antibody, and samples were analyzed by flow cytometry. Grey, no 
primary antibody. Red, αCD3 primary antibody. D, Expression of sTCR-Fc constructs in EpiCHO cells. 
Expression level quantified using an Fc-capture ELISA.  Grey, irrelevant high-expressing antibody control. 
Purple, sTCR-Ig constructs. Solid bars, single-plasmid design. Striped bars, split-plasmid design. E, 
Sandwich ELISA of purified sTCR-Ig. sTCR-Ig detected by anti-hFc and anti-Vβ6-5. Solid icons, dsα/β-Fc 
format. Hollow icons, dsβ/α-Fc format. 
 
A soluble TCR-Fc expression construct was cloned by replacing the 
transmembrane region from the display plasmid with a human IgG1 Fc region. Due to the 
possibility of 2A readthrough, and to allow for further tuning of α and β chain expression 
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ratios, we also cloned the sequences into separate expression plasmids. Plasmids were 
transfected into EpiCHO cells, and the media was harvested 2 days later. An Fc capture 
ELISA of the media was used to detect expression levels as compared to a well-
expressing irrelevant antibody (Fig. 18D). Although the sTCR expression level is much 
lower than the antibody expression, the yields achieved here are significantly higher than 
seen for similar TCR-Ig fusions(243). Switching to a 2-plasmid system, which obviates 
the need for a 2A peptide, resulted in expression nearly as high as the antibody for the 
dsβ/α-Fc construct, but had minimal impact on the dsα/β-Fc construct. The cleavage 
efficiency of both the furin site and 2A peptide are impacted by the surrounding amino 
acids(232), thus it is possible that good expression from the dsβ/α-Fc construct was 
limited by 2A cleavage efficiency.  This suggests that 2A cleavage may not be complete 
in the surface displayed construct either, and further investigation of 2A peptides could 
be beneficial for library screening. Another possibility is that α chain expression is the 
limiting factor, and having the Fc fusion on the α chain helped increase expression, which 
is commonly observed(244). A logical next experiment would be to try several ratios of α 
to β chain transfection and see if this impacts results. Finally, as the ELISA setup 
described here only detects Fc, further testing of the purified protein is needed to validate 
correct assembly.  
 
A preliminary medium scale transfection (2x T-150s) of both the 2A-linked 
constructs, dsα/β-TM and dsβ/α-TM, was performed similarly with media collected over 
~1 week. The media was purified using an ammonium sulfate precipitation followed by 
protein A chromatography. Full-length fusion protein was detected using an Fc/antiVβ6-5 
sandwich ELISA (Fig. 18E), which is more stringent that the Fc-capture ELISA because 
it also detects the Vβ region. Both the dsα/β-Fc and dsβ/α-Fc constructs look similar on 
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the ELISA, suggesting that either order is amenable for soluble protein expression. We 
are currently doing further characterization of the soluble proteins, including affinity 
measurements and stability testing.  
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DISCUSSION 
Herein we have proposed a novel T-cell receptor immunoglobulin fusion 
molecule, and demonstrated the progress we have made towards making this molecule. 
We have been able to express and purify the αCD3 antibody, and are currently optimizing 
high-yield expression of the sTCR-Fc. Although not required for generation of the TRIG, 
we have generated and are screening affinity libraries based on CDR3α and CDR3β, as it 
is likely that higher TCR affinity will be essential for therapeutic efficacy. We have 
extensive previous experience using knob and hole mutations to make bispecific 
antibodies in vitro(92), and we are excited to try this method with the sTCR and antibody 
here. After validation of this new format, a long-term goal is to test its ability to redirect 
T-cells to kill CMV-infected cells.  
 
We took a unique approach by first starting with a display system, which allowed 
for easy quantification and hence troubleshooting of expression. We were quickly able to 
identify key parameters, such as the disulfide-modified constant regions(238), which 
resulted in robust surface expression of the RA14 TCR. For many other TCRs in other 
display systems it was necessary to first generate a random library and screen for 
increased expression to see anything(245), so it is surprising that we were able to see 
such good display with RA14. Interestingly, the TCRs A6 and 1G4, which share the same 
Vβ germline with RA14, did not initially display on the surface of yeast at all, and 
expression mutations that worked for A6 did not work at all in 1G4(246). RA14 does not 
have any of the stabilizing mutations found for A6, so it may just be that RA14 is a 
particularly stable TCR. A potential future application of this display system would be to 
screen for enhanced stability, which has been shown to correlate with expression 
level(245). This would be particularly relevant for our system, since as our displaying 
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platform and expression platform use the same cell line, any improved clones found from 
the screening would likely demonstrate improved expression as soluble molecules. 
Although some engineering has been done using a T-cell display system(247), to our 
knowledge this is the first report of recombinant TCR display on a production cell line.  
 
Moving forward, the TCR affinity will likely be critical for efficacy of the TRIG 
in vitro and beyond. Experiments using various affinities of the ImmTAC format against 
a tumor antigen found that potency correlated with affinity, and TCRs with KD values of 
300-30pM were the most effective(227). In an antiviral format, a very high affinity TCR 
(KD of 3.6 pM) was less effective, and optimal efficacy occurred at a KD of ~200 pM(96). 
Another pertinent measure is the affinity ratio of the antigen and CD3 binding arms, as 
this will significantly influence the distribution and mechanism in vivo. In theory, affinity 
for the cellular antigen should be significantly higher to drive high concentrations of the 
therapeutic at the relevant site, rather than diluting the therapeutic throughout the entire 
circulating CTL population. While blinatumomab has a ~100-fold difference between its 
CD3 and CD19 binding arms(219), ImmTAC formats are reported as having a ~1000-
fold difference(229). Interestingly, a flu-targeting bispecific with the same format as 
blinatumomab has the opposite affinity ratio, yet still showed some success in a murine 
challenge model(221). As the affinity of our anti-CD3 antibody 28F11 is reported to be 
similar to that of OKT3 (300 nM)(219, 234), our goal is to identify RA14 variants with at 
least low nM affinities for further testing.  
 
We chose RA14 as our model TCR not only because of convenience, but also 
because we believe a CD3/RA14 TRIG has a potential therapeutic future. RA14 is a 
human TCR that recognizes the pp65495-503 peptide (NLVPMVTAV) in the context of 
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HLA-A*0201, a relatively common HLA(248). Pp65-directed TCRs make up 70-90% of 
the CTL response to CMV-infected cells(249), suggesting that this antigen is relevant for 
viral targeting. Indeed, in many immunocompromised patients, the CMV TCR repertoire 
contains only a handful of conserved sequences, such as RA14, perhaps indicating that 
only a few CMV TCR clones are needed to control viremia(248). 
 
CMV infects 50-90% of adults worldwide, and while typically asymptomatic or 
latent in healthy individuals, CMV infection and reactivation is a major cause of 
morbidity and mortality of transplant recipients and congenitally-infected infants(125, 
250).  Despite being listed as a top priority for decades, there is still no licensed CMV 
vaccine(251), and a promising prophylactic antibody mixture from Genentech is no 
longer in active development(126). Current treatments for high-risk individuals are 
limited to anti-viral drugs(250), which can have poor safety profiles; and CMV 
hyperimmunoglobulin to prevent congenital infection, which has debatable efficacy(252). 
Thus, recombinant proteins like antibodies or TRIGs could be a useful approach for 
preventing disease(125). We propose that by using a bispecific molecule targeting a 
surface antigen, such as HLA-A*0201:pp65495-503, and CD3, we can help circulating 
CTLs target newly infected or reactivating cells immediately rather than targeting virions 
that are already circulating. One very crude study has been done using chemically-
conjugated antiCD3 and CMV hyperimmuneoglobulin, and was able to show that the 
bispecific conjugates enhanced cytotoxicity(253). We hope that through conscious and 
creative engineering, the TRIG molecule will offer a new approach to preventing CMV. 
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Appendix A 
 
SUPPLEMENTARY MATERIALS FOR CHAPTER 2 
 
 
 
Figure 19. Specific activity of humanized antibody variants.  
Humanized variants were designed in silico for each antibody heavy and light chain via five different 
methods: (a) ‘veneering’ (ven); (b) ‘grafting of abbreviated complementarity determining regions (CDRs)’ 
(abb); (c) ‘specificity determining residue-transfer’ (sdr); and (d) grafting of intact CDRs onto the hu4D5 
framework  or (e) a composite framework (fra). All pairwise combinations for a single antibody were 
transiently transfected into CHO cells.  The crude supernatant was then screened for PTx binding activity 
and total antibody production level by ELISA, with the ratio of these values indicating the specific activity 
of a given heavy/ light chain combination. A, Screening of hu1B7 and B, hu11E6 variants. Combinations 
marked with • had high specific activity due to poor expression and were not considered for scale-up. 
Combinations marked with * were ultimately selected for large-scale production. 
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Figure 20. Antibody thermal stability.  
Thermal denaturation melting curves for the A, 1B7 and B, 11E6 antibodies, comparing the murine, 
chimeric and humanized versions.   
 
 
 
Figure 21. Competition ELISA to assess solution binding affinities of purified antibodies.  
A, Comparison of m1B7, ch1B7 and hu1B7 antibodies. B, Comparison of m11E6, ch11E6 and hu11E6 
antibodies. Calculated Kd values are reported in Table 1. 
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Figure 22. Binding kinetics of antibody-PTx interaction.. 
  Black lines indicate experimental data; gray lines depict model fits.  Association and dissociation rates 
and calculated Kd are reported in Table 1.  
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Figure 23. Pilot murine protection data with recent human clinical isolate D420 and 
murine 1B7. 
 A, B-F, Dosing study with murine 1B7 to determine antibody concentrations within the dose-response 
regime. At the study terminus on day 10, mice were monitored for weight gain (B) and bacterial lung 
colonization rates (C). The CD45+ lymphocyte population was monitored on days 3, 7 and 10. The 
reported WBC on day 7 are n=2; all others n=4.  Statistical significance measured by Tukey’s Test, with * 
indicating p< 0.05. 
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Figure 24. Concentrations of anti-PTx antibodies in baboons.  
 Baboons were infected on Day 0, and antibodies were administered to the treatment group on Day 3 
(indicated by an arrow). Plot shows the serum levels of administered hu1B7+hu11E6 over time in treated 
animals and the induction of endogenous anti-PTx antibodies in control animals. An equimolar 
combination of hu1B7 and hu11E6 was used as a reference. Note, serum was not available for animal C3. 
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Figure 25. Detection of the hu1B7/hu11E6 combination in the nasopharyngeal wash of 
baboons. 
  Nasopharyngeal wash fluid for each baboon was tested for the presence of PTx-binding antibodies by PTx 
ELISA relative to a pure hu1B7/hu11E6 standard on day 2 or 3 ( icons) and on day 5, 6, or 7 after 
infection ( icons). Icons for control animals have no fill; icons for treated animals have gray fill. 
Geometric means for each population are shown as black bars.  
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A. 
 
B.  
 
 
Figure 26. Histopathological analysis of lung tissue. 
  A, Heavily colonized, moribund animal C2 exhibited gross adhesions and areas of necrosis, probably 
associated with abscess formation in the lobes. Between 30% (right lobe) and 70% (left lobe) of terminal 
airways remained patent and were filled with inflammatory cells, primarily alveolar macrophages. The 
right lung of animal C2 is shown; B. pertussis was recovered from the trachea and right lung of this animal.  
B, Mildly colonized animals exhibited evidence of very mild interstitial pneumonia with no gross lesions, 
>90% of all terminal airways were partially to totally patent. The right lobe of animal M2 is shown. 
 
 
 
Table 5. Humanized antibodies are more similar to the human repertoire than the original 
murine antibodies.  
 Murine antibody Z score Humanized antibody  Z-score 
1B7 light chain -1.055 -0.033 
1B7 heavy chain -1.065 -0.093 
11E6 light chain -1.104 -0.215 
11E6 heavy chain -0.507 +0.086 
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Table 6. Baboon model challenge details  
 Baboon Details Day 2/3 levels Day 16/17 levels 
 Day 0 
Age  
(months) 
Sex Day 0  
Weight 
(kg) 
WBC 
(×1000/µl) 
Colonization 
Level  
Cough 
Count 
(/hr) 
WBC 
(×1000/µl) 
Colonization 
Level 
C1 6.5 M 3.0 18 8.0×107 60.0 nd* nd* 
C2 5.9 M 2.1 34 3.0×107 24.0 42.9 4.5×107 
C3 8.7 M 3.1 19 2.5×107 12.5 35.0 8.0×104 
C4 7.1 F 2.6 28 1.8×107 2.5 24.0 5.0×103 
M1 6.0 M 2.9 28 1.5×103 10.0 11.4 0 
M2 6.0 M 2.4 23 1.7×104 13.0 7.0 0 
H1 6.9 F 2.3 30 3.8×107 102.5 18.9 0 
H2 8.3 M 2.3 14 1.3×108 64.0 9.8 0 
 
*nd, not determined as animal was moribund/ removed from study on day 11. 
 
  
132 
 
References 
1. World Health Organization, Causes of death, worldwideGlob. Heal. Obs. data Repos. 
(2012) (available at http://apps.who.int/gho/data/node.main.CODWORLD?lang=en). 
2. D. M. Ecker, S. D. Jones, H. L. Levine, The therapeutic monoclonal antibody market, 
MAbs 7, 9–14 (2015). 
3. S. R. Aggarwal, What’s fueling the biotech engine — 2012 to 2013, Nat. Biotechnol. 
32, 32–39 (2014). 
4. M. Hay, D. W. Thomas, J. L. Craighead, C. Economides, J. Rosenthal, Clinical 
development success rates for investigational drugs., Nat Biotechnol 32, 40–51 (2014). 
5. J. M. Reichert, Therapeutic monoclonal antibodies approved or in review in the 
European Union or the United StatesAntib. Soc. (2017) (available at 
http://www.antibodysociety.org/news/approved-antibodies/). 
6. The IMpact-RSV Study Group, Palivizumab, a Humanized Respiratory Syncytial 
Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus 
Infection in High-risk Infants., Pediatrics 102, 531–7 (1998). 
7. T. Migone, G. M. Subramanian, J. Zhong, L. M. Healey,  a. Corey, M. Devalaraja, L. 
Lo, S. Ullrich, J. Zimmerman,  a. Chen, M. Lewis, G. Meister, K. Gillum, D. Sanford, J. 
Mott, S. D. Bolmer, Raxibacumab for the treatment of inhalational anthrax, N. Engl. J. 
Med. 361, 135–144 (2009). 
8. B. J. Yamamoto, A. M. Shadiack, S. Carpenter, D. Sanford, L. N. Henning, N. 
Gonzales, E. O’Connor, L. S. Casey, N. V. Serbina, Obiltoxaximab prevents 
disseminated Bacillus anthracis infection and improves survival during pre- and 
postexposure prophylaxis in animal models of inhalational anthrax, Antimicrob. Agents 
Chemother. 60, 5796–5805 (2016). 
9. P. Mitchell, M. Med, C. Wriedt, S. Graves, D. Phil, M. P. Staples, D. Ph, B. Murphy, 
B. Sc, Treatment with Monoclonal Antibodies against Clostridium difficile Toxins, N. 
Engl. J. Med. 362, 197–205 (2010). 
10. H. Wu, D. S. Pfarr, S. Johnson, Y. A. Brewah, R. M. Woods, N. K. Patel, W. I. 
White, J. F. Young, P. A. Kiener, Development of Motavizumab, an Ultra-potent 
Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and 
Lower Respiratory Tract, J. Mol. Biol. 368, 652–665 (2007). 
11. S. Mazumdar, Raxibacumab, MAbs 1, 531–538 (2009). 
12. J. a Maynard, C. B. M. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. 
Iverson, G. Georgiou, Protection against anthrax toxin by recombinant antibody 
fragments correlates with antigen affinity., Nat. Biotechnol. 20, 597–601 (2002). 
13. L. D. Hernandez, F. Racine, L. Xiao, E. DiNunzio, N. Hairston, P. R. Sheth, N. J. 
Murgolo, A. G. Therien, Broad coverage of genetically diverse strains of clostridium 
difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope 
133 
 
modeling, Antimicrob. Agents Chemother. 59, 1052–1060 (2015). 
14. S. M. Lehar, T. Pillow, M. Xu, L. Staben, K. K. Kajihara, R. Vandlen, L. DePalatis, 
H. Raab, W. L. Hazenbos, J. Hiroshi Morisaki, J. Kim, S. Park, M. Darwish, B.-C. Lee, 
H. Hernandez, K. M. Loyet, P. Lupardus, R. Fong, D. Yan, C. Chalouni, E. Luis, Y. 
Khalfin, E. Plise, J. Cheong, J. P. Lyssikatos, M. Strandh, K. Koefoed, P. S. Andersen, J. 
A. Flygare, M. Wah Tan, E. J. Brown, S. Mariathasan, Novel antibody–antibiotic 
conjugate eliminates intracellular S. aureus, Nature 527, 323–8 (2015). 
15. D. A. Hill, C. Hoffmann, M. C. Abt, Y. Du, D. Kobuley, T. J. Kirn, F. D. Bushman, 
D. Artis, Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in 
intestinal microbiota with associated alterations in immune cell homeostasis., Mucosal 
Immunol. 3, 148–58 (2010). 
16. R. A. Britton, V. B. Young, Role of the intestinal microbiota in resistance to 
colonization by Clostridium difficile, Gastroenterology 146, 1547–1553 (2014). 
17. Z. Yang, J. Ramsey, T. Hamza, Y. Zhang, S. Li, H. G. Yfantis, D. Lee, L. D. 
Hernandez, W. Seghezzi, J. M. Furneisen, N. M. Davis, A. G. Therien, H. Feng, 
Mechanisms of protection against Clostridium difficile infection by the monoclonal 
antitoxin antibodies actoxumab and bezlotoxumab, Infect. Immun. 83, 822–831 (2015). 
18. A. Hey, History and Practice: Antibodies in Infectious Diseases, Microbiol. Spectr. 3, 
1–15 (2015). 
19. D. D. Richman, T. Wrin, S. J. Little, C. J. Petropoulos, Rapid evolution of the 
neutralizing antibody response to HIV type 1 infection., Proc. Natl. Acad. Sci. U. S. A. 
100, 4144–9 (2003). 
20. E. Medina, D. H. Pieper, Tackling Threats and Future Problems of Multidrug-
Resistant Bacteria, Curr. Top. Microbiol. Immunol. 398, 3–33 (2016). 
21. A.- Staphylococcus, H. I. Schwartz, T. Bellamy, M. Hernandez-illas, S. Jafri, Safety, 
Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-
Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy 
Adults, Antimi 61, 1–9 (2017). 
22. I. Desombere, S. Fafi-Kremer, F. Van Houtte, P. Pessaux, A. Farhoudi, L. Heydmann, 
L. Verhoye, S. Cole, J. A. Mckeating, G. Leroux-Roels, T. F. Baumert, A. H. Patel, P. 
Meuleman, Monoclonal anti-envelope antibody AP33 protects humanized mice against a 
patient-derived hepatitis C virus challenge, Hepatology 63, 1120–1134 (2016). 
23. M. Pelegrin, M. Naranjo-Gomez, M. Piechaczyk, Antiviral Monoclonal Antibodies: 
Can They Be More Than Simple Neutralizing Agents?, Trends Microbiol. 23, 653–665 
(2015). 
24. S. Bournazos, F. Klein, J. Pietzsch, M. S. Seaman, M. C. Nussenzweig, J. V. Ravetch, 
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo 
Activity, Cell 158, 1243–1253 (2014). 
25. N. A.L., D. E., Development trends for human monoclonal antibody therapeutics, 
134 
 
Nat. Rev. Drug Discov. 9, 767–774 (2010). 
26. L. E. McCoy, D. R. Burton, Identification and specificity of broadly neutralizing 
antibodies against HIV, Immunol. Rev. 275, 11–20 (2017). 
27. A. W. Nguyen, E. K. Wagner, J. R. Laber, L. L. Goodfield, W. E. Smallridge, E. T. 
Harvill, J. F. Papin, R. F. Wolf, E. A. Padlan, A. Bristol, M. Kaleko, J. A. Maynard, A 
cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon 
models of whooping cough, Sci. Transl. Med. 7, 1–9 (2015). 
28. L. Hua, J. J. Hilliard, Y. Shi, C. Tkaczyk, L. I. Cheng, X. Yu, V. Datta, S. Ren, H. 
Feng, R. Zinsou, A. Keller, T. O’Day, Q. Du, L. Cheng, M. Damschroder, G. Robbie, J. 
Suzich, C. K. Stover, B. R. Sellman, Assessment of an anti-alpha-toxin monoclonal 
antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia, 
Antimicrob. Agents Chemother. 58, 1108–1117 (2014). 
29. G. J. Babcock, T. J. Broering, H. J. Hernandez, R. B. Mandell, K. Donahue, N. 
Boatright, A. M. Stack, I. Lowy, R. Graziano, D. Molrine, D. M. Ambrosino, W. D. 
Thomas, Human monoclonal antibodies directed against toxins A and B prevent 
Clostridium difficile-induced mortality in hamsters, Infect. Immun. 74, 6339–6347 
(2006). 
30. C. T. Baldari, F. Tonello, S. R. Paccani, C. Montecucco, Anthrax toxins : a paradigm 
of bacterial immune suppression, 27 (2006), doi:10.1016/j.it.2006.07.002. 
31. P. Orth, L. Xiao, L. D. Hernandez, P. Reichert, P. R. Sheth, M. Beaumont, X. Yang, 
N. Murgolo, G. Ermakov, E. Dinunzio, F. Racine, J. Karczewski, S. Secore, R. N. 
Ingram, T. Mayhood, C. Strickland, A. G. Therien, Mechanism of action and epitopes of 
Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray 
crystallography, J. Biol. Chem. 289, 18008–18021 (2014). 
32. V. Oganesyan, L. Peng, M. M. Damschroder, L. Cheng, A. Sadowska, C. Tkaczyk, B. 
R. Sellman, H. Wu, W. F. Dall’Acqua, Mechanisms of Neutralization of a Human Anti-
α-toxin Antibody, J. Biol. Chem. 289, 29874–29880 (2014). 
33. N. Abboud, S.-K. Chow, C. Saylor, A. Janda, J. V Ravetch, M. D. Scharff, A. 
Casadevall, A requirement for FcγR in antibody-mediated bacterial toxin neutralization., 
J. Exp. Med. 207, 2395–2405 (2010). 
34. N. Mohamed, M. Clagett, J. Li, S. Jones, S. Pincus, G. D’Alia, L. Nardone, M. Babin, 
G. Spitalny, L. Casey, A high-affinity monoclonal antibody to anthrax protective antigen 
passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge, 
Infect. Immun. 73, 795–802 (2005). 
35. A. Nowakowski, C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. 
Montgomery, R. Sheridan, R. Blake, L. A. Smith, J. D. Marks, Potent neutralization of 
botulinum neurotoxin by recombinant oligoclonal antibody, 99, 11346–11350 (2002). 
36. P. Warrener, R. Varkey, J. C. Bonnell, A. DiGiandomenico, M. Camara, K. Cook, L. 
Peng, J. Zha, P. Chowdury, B. Sellman, C. K. Stover, A novel anti-PcrV antibody 
135 
 
providing enhanced protection against pseudomonas aeruginosa in multiple animal 
infection models, Antimicrob. Agents Chemother. 58, 4384–4391 (2014). 
37. T. Secher, L. Fauconnier, A. Szade, O. Rutschi, S. C. Fas, B. Ryffel, M. P. Rudolf, 
Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal 
antibody panobacumab (KBPA101) confers protection in a murine model of acute lung 
infection, J. Antimicrob. Chemother. 66, 1100–1109 (2011). 
38. Y. A. Que, H. Lazar, M. Wolff, B. François, P. F. Laterre, E. Mercier, J. Garbino, J. 
L. Pagani, J. P. Revelly, E. Mus, A. Perez, M. Tamm, J. J. Rouby, Q. Lu, J. Chastre, P. 
Eggimann, Assessment of panobacumab as adjunctive immunotherapy for the treatment 
of nosocomial Pseudomonas aeruginosa pneumonia, Eur. J. Clin. Microbiol. Infect. Dis. 
33, 1861–1867 (2014). 
39. J. J. Lim, R. Deng, M. A. Derby, R. Larouche, P. Horn, M. Anderson, M. Maia, S. 
Carrier, I. Pelletier, T. Burgess, P. Kulkarni, E. Newton, J. A. Tavel, Two Phase 1, 
Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To 
Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus 
Monoclonal Antibody, MHAA4549A, in Healthy Volunteers, Antimicrob. Agents 
Chemother. 60, 5437–5444 (2016). 
40. K. Ahmad, H. S. Malik, K. Bloom, K. J. Milks,  a F. Straight, C. W. Carroll, B. 
Moree, C. J. Fuller, B. Gronemeyer, W. Lu, E. Eugster, J. E. Tomkiel, H. L. Chang,  a 
Kagami, Y. Watanabe, M. C. Silva, K. M. Godek, L. E. Jansen, V. Kanelis, L. E. Kay, J. 
R. England, H. P. Yennawar, S. Tan, J. D. Garlick, D. Canzio, G. J. Narlikar, R. E. 
Kingston, G. H. Leno, S. Orthaus, S. Ohndorf, S. Diekmann, P. Hemmerich, H. Yang, N. 
Nozaki, T. Okazaki, K. Yoda, D. W. Cleveland, M. E. Lalonde, T. G. Kutateladze,  a 
Kelly, C. Wu, H. Kurumizaka, N. Cancer, Structure of RSV Fusion Glycoprotein, 
Science (80-. ). 340, 1113–1117 (2013). 
41. J. S. McLellan, Y. Yang, B. S. Graham, P. D. Kwong, Structure of respiratory 
syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of 
neutralizing epitopes., J. Virol. 85, 7788–96 (2011). 
42. L. van Mechelen, W. Luytjes, C. A. M. de Haan, O. Wicht, RSV neutralization by 
palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by 
Fc gamma receptors, Antiviral Res. 132, 1–5 (2016). 
43. C. J. Bruno, J. M. Jacobson, Ibalizumab: An anti-CD4 monoclonal antibody for the 
treatment of HIV-1 infection, J. Antimicrob. Chemother. 65, 1839–1841 (2010). 
44. J. M. Jacobson, J. P. Lalezari, M. A. Thompson, C. J. Fichtenbaum, M. S. Saag, B. S. 
Zingman, P. D’Ambrosio, N. Stambler, Y. Rotshteyn, A. J. Marozsan, P. J. Maddon, S. 
A. Morris, W. C. Olson, Phase 2a study of the CCR5 monoclonal antibody PRO 140 
administered intravenously to HIV-infected adults, Antimicrob. Agents Chemother. 54, 
4137–4142 (2010). 
45. M. Rao, D. Valentini, E. Dodoo, A. Zumla, M. Maeurer, Anti-PD-1/PD-L1 therapy 
for infectious diseases: learning from the cancer paradigm, Int. J. Infect. Dis. 56, 221–228 
136 
 
(2017). 
46. A. Zumla, M. Rao, E. Dodoo, M. Maeurer, Potential of immunomodulatory agents as 
adjunct host-directed therapies for multidrug-resistant tuberculosis., BMC Med. 14, 89 
(2016). 
47. Y. Delmas, B. Vendrely, B. Clouzeau, H. Bachir, H. N. Bui, A. Lacraz, S. H??lou, C. 
Bordes, A. Reffet, B. Llanas, S. Skopinski, P. Rolland, D. Gruson, C. Combe, Outbreak 
of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: Outcome with 
eculizumab, Nephrol. Dial. Transplant. 29, 565–572 (2014). 
48. N. S. Laursen, I. A. Wilson, Broadly neutralizing antibodies against influenza viruses, 
Antiviral Res. 98, 476–483 (2013). 
49. G. Nakamura, N. Chai, S. Park, N. Chiang, Z. Lin, H. Chiu, R. Fong, D. Yan, J. Kim, 
J. Zhang, W. P. Lee, A. Estevez, M. Coons, M. Xu, P. Lupardus, M. Balazs, L. R. Swem, 
An in vivo human-plasmablast enrichment technique allows rapid identification of 
therapeutic influenza A antibodies, Cell Host Microbe 14, 93–103 (2013). 
50. N. L. Kallewaard, D. Corti, P. J. Collins, U. Neu, J. M. McAuliffe, E. Benjamin, L. 
Wachter-Rosati, F. J. Palmer-Hill, A. Q. Yuan, P. A. Walker, M. K. Vorlaender, S. 
Bianchi, B. Guarino, A. De Marco, F. Vanzetta, G. Agatic, M. Foglierini, D. Pinna, B. 
Fernandez-Rodriguez, A. Fruehwirth, C. Silacci, R. W. Ogrodowicz, S. R. Martin, F. 
Sallusto, J. A. A. Suzich, A. Lanzavecchia, Q. Zhu, S. J. Gamblin, J. J. Skehel, Structure 
and Function Analysis of an Antibody Recognizing All Influenza A Subtypes, Cell 166, 
596–608 (2016). 
51. K. Tharakaraman, V. Subramanian, K. Viswanathan, S. Sloan, H.-L. Yen, D. L. 
Barnard, Y. H. C. Leung, K. J. Szretter, T. J. Koch, J. C. Delaney, G. J. Babcock, G. N. 
Wogan, R. Sasisekharan, Z. Shriver, A broadly neutralizing human monoclonal antibody 
is effective against H7N9., Proc. Natl. Acad. Sci. U. S. A. 112, 10890–5 (2015). 
52. S. Zolla-Pazner, T. Cardozo, Structure-function relationships of HIV-1 envelope 
sequence-variable regions refocus vaccine design., Nat. Rev. Immunol. 10, 527–35 
(2010). 
53. R. a Buonpane, H. R. O. Churchill, B. Moza, E. J. Sundberg, M. L. Peterson, P. M. 
Schlievert, D. M. Kranz, Neutralization of staphylococcal enterotoxin B by soluble, high-
affinity receptor antagonists., Nat. Med. 13, 725–9 (2007). 
54. H. Wu, D. S. Pfarr, Y. Tang, L. L. An, N. K. Patel, J. D. Watkins, W. D. Huse, P. A. 
Kiener, J. F. Young, Ultra-potent antibodies against respiratory syncytial virus: Effects of 
binding kinetics and binding valence on viral neutralization, J. Mol. Biol. 350, 126–144 
(2005). 
55. A. Mejias, C. Garcia-Maurino, R. Rodriguez-Fernandez, M. E. Peeples, O. Ramilo, 
Development and clinical applications of novel antibodies for prevention and treatment 
of respiratory syncytial virus infection, Vaccine 35, 496–502 (2016). 
56. X.-Z. Wang, V. W. Coljee, J. A. Maynard, Back to the future: recombinant polyclonal 
137 
 
antibody therapeutics., Curr. Opin. Chem. Eng. 2, 1–11 (2013). 
57. E. Von Behring, S. Kitasato, Ueber das zustandekommen der diphtherie-immunität 
und der tetanus-immunität bei thieren, Dtsch. Medizinische Wochenschrift 49, 1113–1114 
(1890). 
58. S. H. E. Kaufmann, crossm Remembering Emil von Behring : from Tetanus 
Treatment to Antibody Cooperation with Phagocytes, 8, 1–6 (2017). 
59. A. Casadevall, E. Dadachova, L. Pirofski, Passive antibody therapy for infectious 
diseases, Nat. Rev. Microbiol. 2, 695–703 (2004). 
60. M. a. Keller, E. R. Stiehm, Passive Immunity in Prevention and Treatment of 
Infectious Diseases, Clin. Microbiol. Rev. 13, 602–614 (2000). 
61. E. R. Stiehm, M. A. Keller, G. N. Vyas, Preparation and use of therapeutic antibodies 
primarily of human origin, Biologicals 36, 363–374 (2008). 
62. S. Johnson, C. Oliver, G. A. Prince, V. G. Hemming, S. David, S. Wang, M. 
Dormitzer, J. O. Grady, S. Koenig, K. James, R. Woods, G. Bansal, D. Couchenour, E. 
Tsao, W. C. Hall, J. F. Young, S. The, I. Diseases, N. Nov, S. Johnson, C. Oliver, G. A. 
Prince, V. G. Hemming, D. S. Pfarr, S. Wang, M. Dormitzer, J. O. Grady, S. Koenig, J. 
K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, J. F. Young, 
Development of a Humanized Monoclonal Antibody ( MEDI-493 ) with Potent in vitro 
and in vivo Activity against Respiratory Syncytial Virus, J. Infect. Dis. 176, 1215–1224 
(1997). 
63. H. C. Meissner, S. S. Long, A. A. of P. C. on I. D. and C. on F. and Newborn, 
Revised indications for the use of palivizumab and respiratory syncytial virus immune 
globulin intravenous for the prevention of respiratory syncytial virus infections., 
Pediatrics 112, 1447–1452 (2003). 
64. M. Bouvin-Pley, M. Morgand, L. Meyer, C. Goujard, A. Moreau, H. Mouquet, M. 
Nussenzweig, C. Pace, D. Ho, P. J. Bjorkman, D. Baty, P. Chames, M. Pancera, P. D. 
Kwong, P. Poignard, F. Barin, M. Braibant, Drift of the HIV-1 envelope glycoprotein 
gp120 toward increased neutralization resistance over the course of the epidemic: a 
comprehensive study using the most potent and broadly neutralizing monoclonal 
antibodies., J. Virol. 88, 13910–7 (2014). 
65. R. Kong, M. K. Louder, K. Wagh, R. T. Bailer, A. DeCamp, K. Greene, H. Gao, J. D. 
Taft, A. Gazumyan, C. Liu, M. C. Nussenzweig, B. Korber, D. C. Montefiori, J. R. 
Mascola, Improving neutralization potency and breadth by combining broadly reactive 
HIV-1 antibodies targeting major neutralization epitopes, J. Virol. 89, 2659–71 (2015). 
66. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. 
Buckler-White, M. Seaman, M. Piatak, J. D. Lifson, D. Dimitrov, M. C. Nussenzweig, 
M. A. Martin, Antibody-mediated immunotherapy of macaques chronically infected with 
SHIV suppresses viraemia, Nature 503, 277–80 (2013). 
67. K. Dutta, A. K. Varshney, M. C. Franklin, M. Goger, X. Wang, B. C. Fries, 
138 
 
Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B 
by combinations of monoclonal antibodies, J. Biol. Chem. 290, 6715–6730 (2015). 
68. J. D. Murga, M. Franti, D. C. Pevear, P. J. Maddon, W. C. Olson, Potent antiviral 
synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human 
immunodeficiency virus type 1, Antimicrob. Agents Chemother. 50, 3289–3296 (2006). 
69. S. K. Rasmussen, H. Naested, C. Muller, A. B. Tolstrup, T. P. Frandsen, 
Recombinant antibody mixtures: Production strategies and cost considerations, Arch. 
Biochem. Biophys. 526, 139–145 (2012). 
70. D. Corti, J. D. Kearns, Promises and pitfalls for recombinant oligoclonal antibodies-
based therapeutics in cancer and infectious disease, Curr. Opin. Immunol. 40, 51–61 
(2016). 
71. L. S. Nielsen, A. Baer, C. Müller, K. Gregersen, N. T. Mønster, S. K. Rasmussen, D. 
Weilguny, A. B. Tolstrup, Single-batch production of recombinant human polyclonal 
antibodies, Mol. Biotechnol. 45, 257–266 (2010). 
72. FDA Center for Drug Evaluation and Research, Guidance for industry: 
codevelopment of two or more new investigational drugs for use in combination (2013). 
73. V. Irani, A. J. Guy, D. Andrew, J. G. Beeson, P. A. Ramsland, J. S. Richards, 
Molecular properties of human IgG subclasses and their implications for designing 
therapeutic monoclonal antibodies against infectious diseases, Mol. Immunol. 67, 171–
182 (2015). 
74. E. M. Morrison, L. A. Yoo, L. A. Wims, S. L. Chan, E. M. Yoo, L. A. Wims, L. A. 
Chan, S. L. Morrison, Human IgG2 Can Form Covalent Dimers, J. Immunol. 170, 3134–
3138 (2003). 
75. M. van der Neut Kolfschoten, Anti-Inflammatory Activity of Human IgG4 
Antibodies by Dynamic Fab Arm Exchange, Science (80-. ). 317, 1554–1558 (2007). 
76. R. J. Brezski, G. Georgiou, Immunoglobulin isotype knowledge and application to Fc 
engineering, Curr. Opin. Immunol. 40, 62–69 (2016). 
77. B. M. Gunn, G. Alter, Modulating Antibody Functionality in Infectious Disease and 
Vaccination, Trends Mol. Med. 22, 969–982 (2016). 
78. D. O. Beenhouwer, E. M. Yoo, C. W. Lai, M. A. Rocha, S. L. Morrison, Human 
immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against 
Cryptococcus neoformans infection, Infect. Immun. 75, 1424–1435 (2007). 
79. D. J. DiLillo, G. S. Tan, P. Palese, J. V Ravetch, Broadly neutralizing hemagglutinin 
stalk-specific antibodies require FcγR interactions for protection against influenza virus 
in vivo., Nat. Med. 20, 143–51 (2014). 
80. T. T. Wang, J. Sewatanon, M. J. Memoli, J. Wrammert, S. Bournazos, S. K. 
Bhaumik, B. A. Pinsky, K. Chokephaibulkit, N. Onlamoon, K. Pattanapanyasat, J. K. 
Taubenberger, R. Ahmed, J. V. Ravetch, IgG antibodies to dengue enhanced for 
139 
 
FcγRIIIA binding determine disease severity, Science (80-. ). 355, 395–398 (2017). 
81. M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, G. Georgiou, Revisiting the 
Role of Glycosylation in the Structure of Human IgG Fc, ACS Chem Biol 7, 1596–1602 
(2012). 
82. R. Jefferis, Glycosylation as a strategy to improve antibody-based therapeutics., Nat. 
Rev. Drug Discov. 8, 226–34 (2009). 
83. T. Li, D. J. DiLillo, S. Bournazos, J. P. Giddens, J. V Ravetch, L. Wang, Modulating 
IgG effector function by Fc glycan engineering, Proc. Natl. Acad. Sci. 114, 3485–3490 
(2017). 
84. E. S. Ward, S. C. Devanaboyina, R. J. Ober, Targeting FcRn for the modulation of 
antibody dynamics, Mol. Immunol. 67, 131–141 (2015). 
85. W. F. D. Acqua, R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, Y. A. 
Brewah, H. Wu, P. A. Kiener, S. Langermann, W. F. Dall’ Acqua, R. M. Woods, E. S. 
Ward, S. R. Palaszynski, N. K. Patel, Y. A. Brewah, H. Wu, P. A. Kiener, S. 
Langermann, W. F. D. Acqua, R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, 
Y. A. Brewah, H. Wu, P. A. Kiener, S. Langermann, Increasing the Affinity of a Human 
IgG1 for the Neonatal Fc Receptor: Biological Consequences, J. Immunol. 169, 5171–
5180 (2002). 
86. W. F. Dall’Acqua, P. A. Kiener, H. Wu, Properties of Human IgG1s engineered for 
enhanced binding to the neonatal Fc Receptor (FcRn), J. Biol. Chem. 281, 23514–23524 
(2006). 
87. M. P. Griffin, A. A. Khan, M. T. Esser, K. Jensen, T. Takas, M. K. Kankam, T. 
Villafana, F. Dubovsky, Safety, tolerability, and pharmacokinetics of the respiratory 
syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, 
MEDI8897, in healthy adults, Antimicrob. Agents Chemother. 61, 1–9 (2017). 
88. S. Foss, R. Watkinson, I. Sandlie, L. C. James, J. T. Andersen, TRIM21: A cytosolic 
Fc receptor with broad antibody isotype specificity, Immunol. Rev. 268, 328–339 (2015). 
89. M. Bottermann, H. E. Lode, R. E. Watkinson, S. Foss, I. Sandlie, J. T. Andersen, L. 
C. James, Antibody-antigen kinetics constrain intracellular humoral immunity, Sci. Rep. 
6, 37457 (2016). 
90. K. Tsuchikama, Z. An, Antibody-drug conjugates: recent advances in conjugation and 
linker chemistries, Protein Cell , 1–14 (2016). 
91. C. Spiess, Q. Zhai, P. J. Carter, Alternative molecular formats and therapeutic 
applications for bispecific antibodies, Mol. Immunol. 67, 95–106 (2015). 
92. E. K. Wagner, X. Wang, A. Bui, J. A. Maynard, D. L. Burns, Ed. Synergistic 
Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo, Clin. 
Vaccine Immunol. 23, 851–862 (2016). 
93. A. DiGiandomenico, A. E. Keller, C. Gao, G. J. Rainey, P. Warrener, M. M. Camara, 
140 
 
J. Bonnell, R. Fleming, B. Bezabeh, N. Dimasi, B. R. Sellman, J. Hilliard, C. M. 
Guenther, V. Datta, W. Zhao, C. Gao, X.-Q. Yu, J. A. Suzich, C. K. Stover, A 
multifunctional bispecific antibody protects against Pseudomonas aeruginosa, Sci. Transl. 
Med. 6, 1–12 (2014). 
94. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. 
Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers, 
M. Schmidt, G. Riethmüller, C. Reinhardt, P. A. Baeuerle, P. Kufer, Tumor regression in 
cancer patients by very low doses of a T cell – engaging antibody, Science (80-. ). 321, 
974–977 (2008). 
95. D. D. Sloan, C. Y. K. Lam, A. Irrinki, L. Liu, A. Tsai, C. S. Pace, J. Kaur, J. P. 
Murry, M. Balakrishnan, P. A. Moore, S. Johnson, J. L. Nordstrom, T. Cihlar, S. Koenig, 
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting 
Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells, PLoS 
Pathog. 11, 1–29 (2015). 
96. H. Yang, S. Buisson, G. Bossi, Z. Wallace, G. Hancock, C. So, R. Ashfield, A. 
Vuidepot, T. Mahon, P. Molloy, J. Oates, S. J. Paston, M. Aleksic, N. J. Hassan, B. K. 
Jakobsen, L. Dorrell, Elimination of Latently HIV-infected Cells from Antiretroviral 
Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors, Mol. 
Ther. 24, 1913–1925 (2016). 
97. S. Sivapalasingam, D. Perez-caballero, M. Houghton, F. Yang, J. D. Davis, B. Gao, 
G. Geba, Phase 1 study evaluating safety , tolerability , pharmacokinetics and 
immunogenicity of REGN2222 in healthy adults : an investigational human monoclonal 
RSV-F antibody for RSV prevention, IDWeek poster Sess. (2015). 
98. U. F. Power, C. Stortelers, K. Allosery, J. A. Melero, Generation and Characterization 
of ALX-0171 , a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory 
Syncytial Virus Infection, Antimicrob. Agents Chemother. 60, 6–13 (2016). 
99. K. Dole, F. P. Segal, A. Feire, B. Magnusson, J. C. Rondon, J. Vemula, J. Yu, Y. 
Pang, P. Pertel, A First-in-Human Study To Assess the Safety and Pharmacokinetics of 
Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers, 
Antimicrob. Agents Chemother. 60, 2881–2887 (2016). 
100. S. H. Kim, Y. W. Shin, K. W. Hong, K. H. Chang, K. H. Ryoo, S. H. Paik, J. M. 
Kim, B. Brotman, W. Pfahler, A. M. Prince, Neutralization of hepatitis B virus (HBV) by 
human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees, 
Antiviral Res. 79, 188–191 (2008). 
101. M. M. Soares, S. W. King, P. E. Thorpe, Targeting inside-out phosphatidylserine as 
a therapeutic strategy for viral diseases., Nat. Med. 14, 1357–62 (2008). 
102. S. U. Nayak, J. M. Griffiss, R. McKenzie, E. J. Fuchs, R. A. Jurao, A. T. An, A. 
Ahene, M. Tomic, C. W. Hendrix, J. M. Zenilman, Safety and pharmacokinetics of 
XOMA 3AB, A novel mixture of three monoclonal antibodies against botulinum toxin A, 
Antimicrob. Agents Chemother. 58, 5047–5053 (2014). 
141 
 
103. T. Huynh, M. Stecher, J. Mckinnon, N. Jung, M. E. Rupp, C. H. System, Safety and 
Tolerability of 514G3, a True Human Anti-Protein A Monoclonal Antibody for the 
Treatment of S. aureus Bacteremia, IDWeek poster Sess. (2016), doi:10.1007/978-3-319-
24741-0_8. 
104. A. Pharmaceuticals, AR-301: Fully Human mAb Against Staphylococcus aureus 
(2017) (available at http://www.aridispharma.com/ar301.htm). 
105. H. Rouha, A. Badarau, Z. C. Visram, M. B. Battles, B. Prinz, Z. Magyarics, G. 
Nagy, I. Mirkina, L. Stulik, M. Zerbs, M. Jägerhofer, B. Maierhofer, A. Teubenbacher, I. 
Dolezilkova, K. Gross, S. Banerjee, G. Zauner, S. Malafa, J. Zmajkovic, S. Maier, R. 
Mabry, E. Krauland, K. D. Wittrup, T. U. Gerngross, E. Nagy, Five birds, one stone: 
Neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus 
with a single human monoclonal antibody, MAbs 7, 243–254 (2015). 
106. G. B. Pier, D. Boyer, M. Preston, F. T. Coleman, N. Llosa, S. Mueschenborn-
Koglin, C. Theilacker, H. Goldenberg, J. Uchin, G. P. Priebe, M. Grout, M. Posner, L. 
Cavacini, Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect 
against infection by both mucoid and nonmucoid strains., J. Immunol. 173, 5671–5678 
(2004). 
107. J. M. Jacobson, D. R. Kuritzkes, E. Godofsky, E. DeJesus, J. A. Larson, S. P. 
Weinheimer, S. T. Lewis, Safety, pharmacokinetics, and antiretroviral activity of multiple 
doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human 
immunodeficiency virus type 1-infected adults, Antimicrob. Agents Chemother. 53, 450–
457 (2009). 
108. C. Wang, W. Wong, H. Tsai, Y. Chen, M. Liao, S. Lynn, A Phase 2 Open-Label 
Trial of Antibody UB-421 Monotherapy as a Substitute for HAART, Conf. Retrovir. 
Opportunistic Infect. Poster ses (2017). 
109. K. J. Bar, M. C. Sneller, L. J. Harrison, J. S. Justement, E. T. Overton, M. E. 
Petrone, D. B. Salantes, C. A. Seamon, B. Scheinfeld, R. W. Kwan, G. H. Learn, M. A. 
Proschan, E. F. Kreider, J. Blazkova, M. Bardsley, E. W. Refsland, M. Messer, K. E. 
Clarridge, N. B. Tustin, P. J. Madden, K. Oden, S. J. O’Dell, B. Jarocki, A. R. Shiakolas, 
R. L. Tressler, N. A. Doria-Rose, R. T. Bailer, J. E. Ledgerwood, E. V. Capparelli, R. M. 
Lynch, B. S. Graham, S. Moir, R. A. Koup, J. R. Mascola, J. A. Hoxie, A. S. Fauci, P. 
Tebas, T.-W. Chun, Effect of HIV Antibody VRC01 on Viral Rebound after Treatment 
Interruption, N. Engl. J. Med. 375, 2037–2050 (2016). 
110. S.-Y. Ko, A. Pegu, R. S. Rudicell, Z. Yang, M. G. Joyce, X. Chen, K. Wang, S. Bao, 
T. D. Kraemer, T. Rath, M. Zeng, S. D. Schmidt, J.-P. Todd, S. R. Penzak, K. O. 
Saunders, M. C. Nason, A. T. Haase, S. S. Rao, R. S. Blumberg, J. R. Mascola, G. J. 
Nabel, Enhanced neonatal Fc receptor function improves protection against primate 
SHIV infection., Nature 514, 642–5 (2014). 
111. J. F. Scheid, J. A. Horwitz, Y. Bar-On, E. F. Kreider, C.-L. Lu, J. C. C. Lorenzi, A. 
Feldmann, M. Braunschweig, L. Nogueira, T. Oliveira, I. Shimeliovich, R. Patel, L. 
142 
 
Burke, Y. Z. Cohen, S. Hadrigan, A. Settler, M. Witmer-Pack, A. P. West, Jr., B. Juelg, 
T. Keler, T. Hawthorne, B. Zingman, R. M. Gulick, N. Pfeifer, G. H. Learn, M. S. 
Seaman, P. J. Bjorkman, F. Klein, S. J. Schlesinger, B. D. Walker, B. H. Hahn, M. C. 
Nussenzweig, M. Caskey, HIV-1 antibody 3BNC117 suppresses viral rebound in humans 
during treatment interruption, Nature 535, 556–560 (2016). 
112. M. Caskey, T. Schoofs, H. Gruell, A. Settler, T. Karagounis, E. F. Kreider, B. 
Murrell, N. Pfeifer, L. Nogueira, T. Y. Oliveira, G. H. Learn, Y. Z. Cohen, C. Lehmann, 
D. Gillor, I. Shimeliovich, C. Unson-O’Brien, D. Weiland, A. Robles, T. Kümmerle, C. 
Wyen, R. Levin, M. Witmer-Pack, K. Eren, C. Ignacio, S. Kiss, A. P. West, H. Mouquet, 
B. S. Zingman, R. M. Gulick, T. Keler, P. J. Bjorkman, M. S. Seaman, B. H. Hahn, G. 
Fätkenheuer, S. J. Schlesinger, M. C. Nussenzweig, F. Klein, Antibody 10-1074 
suppresses viremia in HIV-1-infected individuals, Nat. Med. 23, 185–191 (2017). 
113. J. Julien, S. Wang, A. Ramos, S. Fling, C. Wong, S. Phogat, T. Wrin, M. D. Simek, 
Broad neutralization coverage of HIV by multiple highly potent antibodies, Nature 477, 
466–470 (2012). 
114. R. Diskin, J. F. Scheid, P. M. Marcovecchio, A. P. West, F. Klein, H. Gao, P. N. P. 
Gnanapragasam, A. Abadir, M. S. Seaman, M. C. Nussenzweig, P. J. Bjorkman, 
Increasing the potency and breadth of an HIV antibody by using structure-based rational 
design., Science 334, 1289–93 (2011). 
115. C. J. Costanzo, thesis,  (2015). 
116. D. C. Ekiert, R. H. E. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. 
Ophorst, F. Cox, H. J. W. M. Korse, B. Brandenburg, R. Vogels, J. P. J. Brakenhoff, R. 
Kompier, M. H. Koldijk, L. A. H. M. Cornelissen, L. L. M. Poon, M. Peiris, W. 
Koudstaal, I. A. Wilson, J. Goudsmit, A Highly Conserved Neutralizing Epitope on 
Group 2 Influenza A Viruses, Science (80-. ). 333, 843–850 (2011). 
117. D. C. Ekiert, G. Bhabha, M. Elsliger, R. H. E. Friesen, M. Jongeneelen, M. Throsby, 
J. Goudsmit, I. A. Wilson, Antibody recognition of a highly conserved influenza virus 
epitope, Science (80-. ). 324, 246–251 (2009). 
118. A. M. Wollacott, M. F. Boni, K. J. Szretter, S. E. Sloan, M. Yousofshahi, K. 
Viswanathan, S. Bedard, C. A. Hay, P. F. Smith, Z. Shriver, J. M. Trevejo, Safety and 
Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody 
VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal 
Influenza A Outbreaks, EBioMedicine 5, 147–155 (2016). 
119. E. Sparrow, M. Friede, M. Sheikh, S. Torvaldsen, A. T. Newall, Passive 
immunization for influenza through antibody therapies, a review of the pipeline, 
challenges and potential applications, Vaccine 34, 5442–5448 (2016). 
120. E. L. Ramos, J. L. Mitcham, T. D. Koller, A. Bonavia, D. W. Usner, G. Balaratnam, 
P. Fredlund, K. M. Swiderek, Efficacy and safety of treatment with an anti-M2e 
monoclonal antibody in experimental human influenza, J. Infect. Dis. 211, 1038–1044 
(2015). 
143 
 
121. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, A 
Randomized, Controlled Trial of ZMapp for Ebola Virus Infection., N. Engl. J. Med. 375, 
1448–1456 (2016). 
122. M. Bitzan, R. Poole, M. Mehran, E. Sicard, C. Brockus, C. Thuning-Roberson, M. 
Rivière, Safety and pharmacokinetics of chimeric anti-shiga toxin 1 and anti-shiga toxin 
2 monoclonal antibodies in healthy volunteers, Antimicrob. Agents Chemother. 53, 3081–
3087 (2009). 
123. T. K. Hart, M. N. Blackburn, M. Brigham-Burke, K. Dede, N. Al-Mahdi, P. Zia-
Amirhosseini, R. M. Cook, Preclinical efficacy and safety of pascolizumab (SB 240683): 
A humanized anti-interleukin-4 antibody with therapeutic potential in asthma, Clin. Exp. 
Immunol. 130, 93–100 (2002). 
124. D. Gardiner, J. Lalezari, E. Lawitz, M. DiMicco, R. Ghalib, K. R. Reddy, K. M. 
Chang, M. Sulkowski, S. O. Marro, J. Anderson, B. He, V. Kansra, F. McPhee, M. Wind-
Rotolo, D. Grasela, M. Selby, A. J. Korman, I. Lowy, A Randomized, Double-Blind, 
Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody 
to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection, 
PLoS One 8 (2013), doi:10.1371/journal.pone.0063818. 
125. E. Acquaye-seedah, Z. P. Frye, J. A. Maynard, Immunotherapeutic Approaches To 
Prevent Cytomegalovirus-Mediated Disease, Microbiol. Spectr. 2, 1–14 (2013). 
126. J. H. Ishida, A. Patel, A. K. Mehta, P. Gatault, J. M. McBride, T. Burgess, M. A. 
Derby, D. R. Snydman, B. Emu, B. Feierbach, A. E. Fouts, M. Maia, R. Deng, C. M. 
Rosenberger, L. A. Gennaro, N. S. Striano, X. C. Liao, J. A. Tavel, Phase 2 Randomized, 
Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal 
Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant 
Recipients, Antimicrob. Agents Chemother. 61, 1–11 (2016). 
127. T. J. Gardner, K. R. Stein, J. A. Duty, T. M. Schwarz, V. M. Noriega, T. Kraus, T. 
M. Moran, D. Tortorella, Functional screening for anti-CMV biologics identifies a 
broadly neutralizing epitope of an essential envelope protein, Nat. Commun. 7, 13627 
(2016). 
128. Y.-W. Shin, K.-H. Ryoo, K.-W. Hong, K.-H. Chang, J.-S. Choi, M. So, P.-K. Kim, 
J.-Y. Park, K.-T. Bong, S.-H. Kim, Human monoclonal antibody against Hepatitis B 
virus surface antigen (HBsAg)., Antiviral Res. 75, 113–20 (2007). 
129. S. Liu, Y. Zhang, M. Moayeri, J. Liu, D. Crown, R. J. Fattah, A. N. Wein, Z.-X. Yu, 
T. Finkel, S. H. Leppla, Key tissue targets responsible for anthrax-toxin-induced 
lethality., Nature 501, 63–68 (2013). 
130. B. Wang, C. H. Lee, E. L. Johnson, C. A. Kluwe, J. C. Cunningham, H. Tanno, R. 
M. Crooks, G. Georgiou, A. D. Ellington, Discovery of high affinity anti-ricin antibodies 
by B cell receptor sequencing and by yeast display of combinatorial VH:VL libraries 
from immunized animals, MAbs 8, 1035–1044 (2016). 
131. 1 Peter D. Kwong1 Tongqing Zhou,1 Ivelin Georgiev,1* Xueling Wu,1* Zhi-Yong 
144 
 
Yang,1* Kaifan Dai,1 Andrés Finzi,2 Young Do Kwon,1 Johannes F. Scheid,3 Wei Shi,1 
Ling Xu,1 Yongping Yang,1 Jiang Zhu,1 Michel C. Nussenzweig,3 Joseph Sodroski,2,4 
Lawrence Shapiro,1,5 Gary J. Nab, Structural Basis for Broad and Potent Neutralization 
ofHIV-1 byAntibody VRC01, Science (80-. ). 120 (2010). 
132. X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther-
Bovendo, H. Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. 
Bohorova, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, J. Pettitt, G. G. Olinger, K. 
Whaley, B. Xu, J. E. Strong, L. Zeitlin, G. P. Kobinger, Reversion of advanced Ebola 
virus disease in nonhuman primates with ZMapp, Nature 514, 47–53 (2014). 
133. J. de Kruif, A. B. H. Bakker, W. E. Marissen, R. A. Kramer, M. Throsby, C. E. 
Rupprecht, J. Goudsmit, A Human Monoclonal Antibody Cocktail as a Novel 
Component of Rabies Postexposure Prophylaxis, Annu. Rev. Med. 58, 359–368 (2007). 
134. S. S. Hasan, A. Miller, G. Sapparapu, E. Fernandez, T. Klose, F. Long, A. Fokine, J. 
C. Porta, W. Jiang, M. S. Diamond, J. E. Crowe Jr., R. J. Kuhn, M. G. Rossmann, A 
human antibody against Zika virus crosslinks the E protein to prevent infection, Nat. 
Commun. 8, 14722 (2017). 
135. K. E. Pascal, C. M. Coleman, A. O. Mujica, V. Kamat, A. Badithe, J. Fairhurst, C. 
Hunt, J. Strein, A. Berrebi, J. M. Sisk, K. L. Matthews, R. Babb, G. Chen, K.-M. V. Lai, 
T. T. Huang, W. Olson, G. D. Yancopoulos, N. Stahl, M. B. Frieman, C. A. Kyratsous, 
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel 
humanized mouse model of MERS-CoV infection, Proc. Natl. Acad. Sci. 112, 8738–
8743 (2015). 
136. C. E. Mire, J. B. Geisbert, V. Borisevich, K. A. Fenton, K. N. Agans, A. I. Flyak, D. 
J. Deer, H. Steinkellner, O. Bohorov, N. Bohorova, C. Goodman, A. Hiatt, D. H. Kim, M. 
H. Pauly, J. Velasco, K. J. Whaley, J. E. Crowe, L. Zeitlin, T. W. Geisbert, Therapeutic 
treatment of Marburg and Ravn virus infection in nonhuman primates with a human 
monoclonal antibody, Sci. Transl. Med. 9, 1–9 (2017). 
137. J. D. Cherry, J. Heitman, Ed. Pertussis: Challenges Today and for the Future, PLoS 
Pathog. 9, e1003418 (2013). 
138. R. E. Black, S. Cousens, H. L. Johnson, J. E. Lawn, I. Rudan, D. G. Bassani, P. Jha, 
H. Campbell, C. F. Walker, R. Cibulskis, T. Eisele, L. Liu, C. Mathers, Global, regional, 
and national causes of child mortality in 2008: a systematic analysis, Lancet 375, 1969–
1987 (2010). 
139. C. D. Paddock, G. N. Sanden, J. D. Cherry, A. A. Gal, C. Langston, K. M. Tatti, K.-
H. Wu, C. S. Goldsmith, P. W. Greer, J. L. Montague, M. T. Eliason, R. C. Holman, J. 
Guarner, W.-J. Shieh, S. R. Zaki, Pathology and Pathogenesis of Fatal Bordetella 
pertussis Infection in Infants, Clin. Infect. Dis. 47, 328–338 (2008). 
140. D. Nieves, J. S. Bradley, J. Gargas, W. H. Mason, D. Lehman, S. M. Lehman, E. L. 
Murray, K. Harriman, J. D. Cherry, Exchange Blood Transfusion In The Management Of 
Severe Pertussis In Young Infants, Pediatr. Infect. Dis. J. 32, 698–699 (2013). 
145 
 
141. J. M. Warfel, L. I. Zimmerman, T. J. Merkel, Acellular pertussis vaccines protect 
against disease but fail to prevent infection and transmission in a nonhuman primate 
model, Proc. Natl. Acad. Sci. 111, 787–792 (2014). 
142. J. B. Robbins, R. Schneerson, J. M. Keith, M. A. Miller, J. Kubler-Kielb, B. 
Trollfors, Pertussis Vaccine: A critique, Pediatr. Infect. Dis. J. 28, 237–241 (2009). 
143. A. A. Weiss, E. L. Hewlett, G. A. Myers, S. Falkow, Pertussis Toxin and 
Extracytoplasmic Adenylate Cyclase as Virulence Factors of Bordetella pertussis, J. 
Infect. Dis. 150, 219–222 (1984). 
144. C. Andreasen, N. H. Carbonetti, Pertussis Toxin Inhibits Early Chemokine 
Production To Delay Neutrophil Recruitment in Response to Bordetella pertussis 
Respiratory Tract Infection in Mice, Infect. Immun. 76, 5139–5148 (2008). 
145. G. S. Kirimanjeswara, Pertussis toxin inhibits neutrophil recruitment to delay 
antibody-mediated clearance of Bordetella pertussis, J. Clin. Invest. 115, 3594–3601 
(2005). 
146. G. Fedele, M. Bianco, A.-S. Debrie, C. Locht, C. M. Ausiello, Attenuated Bordetella 
pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced 
Migration and Drives a Th1/Th17 Response, J. Immunol. 186, 5388–5396 (2011). 
147. H.-H. MU, M. A. COOLEY, W. A. SEWELL, Studies on the lymphocytosis 
induced by pertussis toxin, Immunol. Cell Biol. 72, 267–270 (1994). 
148. B. Thierry-Carstensen, T. Dalby, M. A. Stevner, J. B. Robbins, R. Schneerson, B. 
Trollfors, Experience with monocomponent acellular pertussis combination vaccines for 
infants, children, adolescents and adults—A review of safety, immunogenicity, efficacy 
and effectiveness studies and 15 years of field experience, Vaccine 31, 5178–5191 
(2013). 
149. J. Storsaeter, H. O. Hallander, L. Gustafsson, P. Olin, Low levels of antipertussis 
antibodies plus lack of history of pertussis correlate with susceptibility after household 
exposure to Bordetella pertussis, Vaccine 21, 3542–3549 (2003). 
150. M. Granstrom, K. Hanngren, A. M. Olinder-Nielson, P. Holmblad, A. Mark, 
Specific immunoglobulin for treatment of whooping cough, Lancet 338, 1230–1233 
(1991). 
151. J. B. Bruss, R. Malley, S. Halperin, S. Dobson, M. Dhalla, J. McIver, G. R. Siber, 
Treatment of severe pertussis: a study of the safety and pharmacology of intravenous 
pertussis immunoglobulin, Pediatr. Infect. Dis. J. 18, 505–511 (1999). 
152. S. A. Halperin, W. Vaudry, F. D. Boucher, K. Mackintosh, T. B. Waggener, B. 
Smith, Is pertussis immune globulin efficacious for the treatment of hospitalized infants 
with pertussis?, Pediatr. Infect. Dis. J. 26, 79–90 (2007). 
153. H. Sato, Y. Sato, Protective activities in mice of monoclonal antibodies against 
pertussis toxin, Infect. Immun. 58, 3369–3374 (1990). 
146 
 
154. Y. Sato, A. Ito, I. Ohishi, Effect of monoclonal antibody to pertussis toxin on toxin 
activity, Infect. Immun. 55, 909–915 (1987). 
155. J. M. Warfel, J. Beren, V. K. Kelly, G. Lee, T. J. Merkel, Nonhuman Primate Model 
of Pertussis, Infect. Immun. 80, 1530–1536 (2012). 
156. X. Wang, M. Gray, E. Hewlett, J. A. Maynard, The Bordetella adenylate cyclase 
repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies, J. 
Biol. Chem. 290, 3576–3591 (2015). 
157. J. N. Sutherland, J. a Maynard, Characterization of a Key Neutralizing Epitope on 
Pertussis Toxin Recognized by Monoclonal Antibody 1B7, Biochemistry 48, 11982–
11993 (2009). 
158. M. Nishida, N. Uematsu, H. Kobayashi, Y. Matsunaga, S. Ishida, M. Takata, O. 
Niwa, E. A. Padlan, R. Newman, BM-ca is a newly defined type I/II anti-CD20 
monoclonal antibody with unique biological properties, Int. J. Oncol. 38, 335–344 
(2011). 
159. P. Martineau, in Antibody Engineering, (2010), vol. 1, pp. 657–665. 
160. C. J. Boinett, S. R. Harris, G. C. Langridge, E. A. Trainor, T. J. Merkel, J. Parkhill, 
Complete Genome Sequence of Bordetella pertussis D420, Genome Announc. 3, e00657-
15 (2015). 
161. M. A. Miller, T. A. Khan, K. J. Kaczorowski, B. K. Wilson, A. K. Dinin, A. U. 
Borwankar, M. A. Rodrigues, T. M. Truskett, K. P. Johnston, J. A. Maynard, Antibody 
nanoparticle dispersions formed with mixtures of crowding molecules retain activity and 
In Vivo bioavailability, J. Pharm. Sci. 101, 3763–3778 (2012). 
162. K. R. Abhinandan, A. C. R. Martin, Analyzing the “Degree of Humanness” of 
Antibody Sequences, J. Mol. Biol. 369, 852–862 (2007). 
163. K. H. G. Mills, M. Ryan, E. Ryan, B. P. Mahon, A Murine Model in Which 
Protection Correlates with PertussisVaccine Efficacy in Children Reveals 
Complementary Rolesfor Humoral and Cell-Mediated Immunity inProtection against 
Bordetella pertussis, Infect. Immun. 66, 594–602 (1998). 
164. N. H. Carbonetti, G. V Artamonova, R. M. Mays, Z. E. V Worthington, Pertussis 
Toxin Plays an Early Role in Respiratory Tract Colonization by Bordetella pertussis, 
Infect. Immun. 71, 6358–6366 (2003). 
165. S. Mattoo, J. D. Cherry, Molecular Pathogenesis, Epidemiology, and Clinical 
Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella 
Subspecies, Clin. Microbiol. Rev. 18, 326–382 (2005). 
166. A. C. Moguinness, W. L. Bradford, J. G. Armstrong, The Production and Use of 
Hyperimmune Human Whooping Cough Serum, J. Pediatr. 16, 21–29 (1940). 
167. H. Macdonald, E. Macdonald, Experimental Pertussis, J. Infect. Dis. 53, 328–330 
(1933). 
147 
 
168. J. M. Warfel, J. Beren, T. J. Merkel, Airborne transmission of bordetella pertussis, J. 
Infect. Dis. 206, 902–906 (2012). 
169. E. M. Goebel, X. Zhang, E. T. Harvill, Bordetella pertussis infection or vaccination 
substantially protects mice against B. bronchiseptica infection, PLoS One 4 (2009), 
doi:10.1371/journal.pone.0006778. 
170. S. Alonso, K. Pethe, N. Mielcarek, D. Raze, C. Locht, Role of ADP-
Ribosyltransferase Activity of Pertussis Toxin in Toxin- Adhesin Redundancy with 
Filamentous Hemagglutinin during Bordetella pertussis Infection, Infect. Immun. 69, 
6038–6043 (2001). 
171. W. E. Smallridge, O. Y. Rolin, N. T. Jacobs, E. T. Harvill, Different effects of 
whole-cell and acellular vaccines on Bordetella transmission, J. Infect. Dis. 209, 1981–
1988 (2014). 
172. C. M. Healy, N. Ng, R. S. Taylor, M. A. Rench, L. S. Swaim, Tetanus and 
diphtheria toxoids and acellular pertussis vaccine uptake during pregnancy in a 
metropolitan tertiary care center, Vaccine 33, 4983–4987 (2015). 
173. M. Housey, F. Zhang, C. Miller, S. Lyon-Callo, J. McFadden, E. Garcia, R. Potter, 
Vaccination with Tetanus, Diphtheria, and Acellular Pertussis Vaccine of Pregnant 
Women Enrolled in Medicaid — Michigan, 2011–2013, MMWR Morb. Mortal. Wkly. 
Rep. 63, 839–842 (2014). 
174. B. Abu Raya, I. Srugo, A. Kessel, M. Peterman, D. Bader, R. Gonen, E. Bamberger, 
The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) 
immunization during pregnancy on newborn pertussis antibody levels - A prospective 
study, Vaccine 32, 5787–5793 (2014). 
175. J. M. Warfel, J. F. Papin, R. F. Wolf, L. I. Zimmerman, T. J. Merkel, Maternal and 
neonatal vaccination protects newborn baboons from pertussis infection, J. Infect. Dis. 
210, 604–610 (2014). 
176. G. J. Robbie, R. Criste, W. F. Dall’Acqua, K. Jensen, N. K. Patel, G. A. Losonsky, 
M. P. Griffin, A novel investigational Fc-modified humanized monoclonal antibody, 
motavizumab-YTE, has an extended half-life in healthy adults, Antimicrob. Agents 
Chemother. 57, 6147–6153 (2013). 
177. Australian Government Department of Health, Notifiable diseases surveillance, 
1917 to 1991 (2003) (available at 
https://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-
oz_dis19_91.htm-copy3). 
178. P. J. Spokes, H. E. Quinn, J. M. McAnulty, Review of the 2008–2009 pertussis 
epidemic in NSW: notifications and hospitalisations, N. S. W. Public Health Bull. 21, 
167–173 (2010). 
179. S. L. Sheridan, K. Frith, T. L. Snelling, K. Grimwood, P. B. McIntyre, S. B. 
Lambert, Waning vaccine immunity in teenagers primed with whole cell and acellular 
148 
 
pertussis vaccine: recent epidemiology, Expert Rev. Vaccines 13, 1081–1106 (2014). 
180. F. R. Mooi, N. a T. Van Der Maas, H. E. De Melker, Pertussis resurgence: waning 
immunity and pathogen adaptation - two sides of the same coin, Epidemiol. Infect. 142, 
685–694 (2014). 
181. K. Winter, J. Zipprich, K. Harriman, E. L. Murray, J. Gornbein, S. J. Hammer, N. 
Yeganeh, K. Adachi, J. D. Cherry, Risk factors associated with infant deaths from 
pertussis: a case-control study, Clin. Infect. Dis. 61, 1099–1106 (2015). 
182. A. Digiandomenico, A. E. Keller, C. Gao, G. J. Rainey, P. Warrener, M. M. Camara, 
J. Bonnell, R. Fleming, B. Bezabeh, N. Dimasi, B. R. Sellman, J. Hilliard, C. M. 
Guenther, V. Datta, W. Zhao, C. Gao, X. Yu, J. A. Suzich, C. K. Stover, A 
multifunctional bispecific antibody protects against Pseudomonas aeruginosa, Sci. Transl. 
Med. 6, 1–12 (2014). 
183. S. Bournazos, A. Gazumyan, M. S. Seaman, M. C. Nussenzweig, J. V Ravetch, 
Bispecific anti-HIV-1 antibodies with enhanced breadth and potency, Cell 165, 1609–
1620 (2016). 
184. J. B. B. Ridgway, L. G. Presta, P. Carter, “Knobs-into-holes” engineering of 
antibody CH3 domains for heavy chain heterodimerization., Protein Eng. 9, 617–621 
(1996). 
185. K. Smith, L. Garman, J. Wrammert, N.-Y. Zheng, J. D. Capra, R. Ahmed, P. C. 
Wilson, Rapid generation of fully human monoclonal antibodies specific to a vaccinating 
antigen, Nat. Protoc. 4, 372–384 (2009). 
186. A. F. Labrijn, J. I. Meesters, B. E. C. G. de Goeij, E. T. J. van den Bremer, J. 
Neijssen, M. D. van Kampen, K. Strumane, S. Verploegen, A. Kundu, M. J. Gramer, P. 
H. C. van Berkel, J. G. J. van de Winkel, J. Schuurman, P. W. H. I. Parren, Efficient 
generation of stable bispecific IgG1 by controlled Fab-arm exchange., Proc. Natl. Acad. 
Sci. U. S. A. 110, 5145–50 (2013). 
187. A. Sivasubramanian, A. Sircar, S. Chaudhury, J. Gray, Toward high-resolution 
homology modeling of antibody Fv regions and application of antibody-antigen docking, 
Proteins 74, 497–514 (2009). 
188. S. Lyskov, F. Chou, S. Conchuir, B. Der, K. Drew, D. Kuroda, J. Xu, B. Weitzner, 
P. Renfrew, P. Sripakdeevong, B. Borgo, J. Havranek, B. Kuhlman, T. Kortemme, R. 
Bonneau, J. Gray, R. Das, Serverification of molecular modeling applications: the 
Rosetta Online Server That Includes Everyone (ROSIE), PLoS One 8, 1–11 (2013). 
189. D. Duhovny, R. Nussinov, H. Wolfson, in Algorithms in Bioinformatics, (2002), pp. 
185–200. 
190. D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, H. J. Wolfson, PatchDock and 
SymmDock: servers for rigid and symmetric docking, Nucleic Acids Res. 33, 363–367 
(2005). 
191. P. E. Stein, A. Boodhoo, G. D. Armstrong, L. D. Heerze, S. A. Cockle, M. H. Klein, 
149 
 
R. J. Read, Structure of a pertussis toxin-sugar complex as a model for receptor binding., 
Nat. Struct. Biol. 1, 591–596 (1994). 
192. B. Friguet, A. F. Chaffotte, L. D. Ohaniance, M. E. Goldberg, Measurements of the 
true affinity constant in solution of antigen-antibody complexes by enzyme-linked 
immunosorbent assay, J. Immunol. Methods 77, 305–319 (1985). 
193. F. J. Stevens, Modification of an ELISA-based procedure for affinity determination: 
correction necessary for use with bivalent antibody, Mol. Immunol. 24, 1055–1060 
(1987). 
194. P. Gillenius, E. Jaatmaa, P. Askelof, M. Granstrom, M. Tiru, The standardization of 
an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary 
cells, J. Biol. Stand. 13, 61–66 (1985). 
195. H. Sato, Y. Sato, I. Ohishi, Comparison of pertussis toxin (PT)-neutralizing 
activities and mouse-protective activities of anti-PT mouse monoclonal antibodies, Infect. 
Immun. 59, 3832–3835 (1991). 
196. S. H. Millen, M. Watanabe, E. Komatsu, F. Yamaguchi, Y. Nagasawa, E. Suzuki, H. 
Monaco, A. A. Weiss, Single amino acid polymorphisms of pertussis toxin subunit S2 
(PtxB) affect protein function, PLoS One 10, 1–19 (2015). 
197. E. O. Saphire, P. W. H. I. Parren, R. Pantophlet, M. B. Zwick, G. M. Morris, P. M. 
Rudd, R. A. Dwek, R. L. Stanfield, D. R. Burton, I. A. Wilson, Crystal structure of a 
neutralizing human IgG against HIV-1 : a template for vaccine design, Science (80-. ). 
293, 1155–1159 (2001). 
198. C. A. Kowalsky, M. S. Faber, A. Nath, H. E. Dann, V. W. Kelly, L. Liu, P. Shanker, 
E. K. Wagner, J. A. Maynard, C. Chan, T. a. Whitehead, Rapid fine conformational 
epitope mapping using comprehensive mutagenesis and deep sequencing, J. Biol. Chem. 
290, 26457–26470 (2015). 
199. X. Zhang, L. Zhang, H. Tong, B. Peng, M. J. Rames, S. Zhang, G. Ren, 3D 
Structural Fluctuation of IgG1 Antibody Revealed by Individual Particle Electron 
Tomography, Sci. Rep. 5, 1–13 (2015). 
200. R. L. Stanfield, A. Zemla, I. a. Wilson, B. Rupp, Antibody elbow angles are 
influenced by their light chain class, J. Mol. Biol. 357, 1566–1574 (2006). 
201. A. J. Williams, G. Giese, J. Persson, Improved assembly of bispecific antibodies 
from knob and hole half-antibodies, Biotechnol. Prog. 31, 1315–1322 (2015). 
202. J. M. Elliott, M. Ultsch, J. Lee, R. Tong, K. Takeda, C. Spiess, C. Eigenbrot, J. M. 
Scheer, Antiparallel conformation of knob and hole aglycosylated half-antibody 
homodimers is mediated by a CH2-CH3 hydrophobic interaction, J. Mol. Biol. 426, 
1947–1957 (2014). 
203. R. M. Ionescu, J. Vlasak, C. Price, M. Kirchmeier, Contribution of variable domains 
to the stability of humanized IgG1 monoclonal antibodies, J. Pharm. Sci. 97, 1414–1426 
(2007). 
150 
 
204. J. M. Reichert, Therapeutic monoclonal antibodies approved or in review in the 
European Union or United StatesmAb Soc. (2015) (available at 
http://www.antibodysociety.org/news/approved-antibodies/). 
205. J. M. Reichert, Antibodies to watch in 2016, MAbs 8, 197–204 (2016). 
206. C. Morrison, Antibacterial antibodies gain traction, Nat. Rev. Drug Discov. 14, 737–
738 (2015). 
207. C. Tsai, S. Morris, Approval of Raxibacumab for the Treatment of Inhalation 
Anthrax Under the US Food and Drug Administration “Animal Rule,” Front. Microbiol. 
6, 1–5 (2015). 
208. US Food and Drug Administration, FDA approves new treatment for inhalation 
anthraxFDA news release (2016) (available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm). 
209. Y. Voronin, L. M. Mofenson, C. K. Cunningham, M. G. Fowler, P. Kaleebu, E. J. 
McFarland, J. T. Safrit, B. S. Graham, W. Snow, HIV Monoclonal Antibodies: A New 
Opportunity to Further Reduce Mother-to-Child HIV Transmission, PLoS Med. 11, 1–5 
(2014). 
210. B. Hazes, R. J. Read, Accumulating evidence suggests that several AB-toxins 
subvert the endoplasmic reticulum-associated protein degradation pathway to enter target 
cells, Biochemistry 36, 11051–11054 (1997). 
211. D. J. Vance, J. M. Tremblay, N. J. Mantis, C. B. Shoemaker, Stepwise engineering 
of heterodimeric single domain camelid VHH antibodies that passively protect mice from 
ricin toxin, J. Biol. Chem. 288, 36538–36547 (2013). 
212. C. Herrera, T. I. Klokk, R. Cole, K. Sandvig, N. J. Mantis, A bispecific antibody 
promotes aggregation of ricin toxin on cell surfaces and alters dynamics of toxin 
internalization and trafficking, PLoS One 11, 1–18 (2016). 
213. J. J. Rhoden, G. L. Dyas, V. J. Wroblewski, A modeling and experimental 
investigation of the effects of antigen Density, binding affinity, and antigen expression 
ratio on bispecific antibody binding to cell surface targets, J. Biol. Chem. 291, 11337–
11347 (2016). 
214. M. M. Ngundi, B. D. Meade, S. F. Little, C. P. Quinn, C. R. Corbett, R. A. Brady, 
D. L. Burns, Analysis of defined combinations of monoclonal antibodies in anthrax toxin 
neutralization assays and their synergistic action, Clin. Vaccine Immunol. 19, 731–739 
(2012). 
215. S. W. Martin, L. Pawloski, M. Williams, K. Weening, C. Debolt, X. Qin, L. 
Reynolds, C. Kenyon, G. Giambrone, K. Kudish, L. Miller, D. Selvage, A. Lee, T. H. 
Skoff, H. Kamiya, P. K. Cassiday, M. L. Tondella, T. a. Clark, Pertactin-negative 
bordetella pertussis strains: evidence for a possible selective advantage, Clin. Infect. Dis. 
60, 223–227 (2015). 
216. M. Williams, K. Sen, M. Weigand, T. Skoff, V. Cunningham, T. Halse, M. 
151 
 
Tondella, CDC Pertussis Working Group, Bordetella pertussis strain lacking pertactin 
and pertussis toxin, Emerg. Infect. Dis. 22, 319–322 (2016). 
217. C. Spiess, M. Merchant, A. Huang, Z. Zheng, N.-Y. Yang, J. Peng, D. Ellerman, W. 
Shatz, D. Reilly, D. G. Yansura, J. M. Scheer, Bispecific antibodies with natural 
architecture produced by co-culture of bacteria expressing two distinct half-antibodies., 
Nat. Biotechnol. 31, 753–758 (2013). 
218. S. M. Lewis, X. Wu, A. Pustilnik, A. Sereno, F. Huang, H. L. Rick, G. Guntas, A. 
Leaver-Fay, E. M. Smith, C. Ho, C. Hansen-Estruch, A. K. Chamberlain, S. M. Truhlar, 
E. M. Conner, S. Atwell, B. Kuhlman, S. J. Demarest, Generation of bispecific IgG 
antibodies by structure-based design of an orthogonal Fab interface., Nat. Biotechnol. 32, 
191–198 (2014). 
219. T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann, U. Syring, F. Hanakam, P. 
Kufer, G. Riethmuller, R. Bargou, P. A. Baeuerle, Extremely potent, rapid and 
costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by 
a single-chain bispecific antibody, Int. J. Cancer 100, 690–697 (2002). 
220. H. Kantarjian, A. Stein, N. Gökbuget, A. K. Fielding, A. C. Schuh, J.-M. Ribera, A. 
Wei, H. Dombret, R. Foà, R. Bassan, Ö. Arslan, M. A. Sanz, J. Bergeron, F. Demirkan, 
E. Lech-Maranda, A. Rambaldi, X. Thomas, H.-A. Horst, M. Brüggemann, W. Klapper, 
B. L. Wood, A. Fleishman, D. Nagorsen, C. Holland, Z. Zimmerman, M. S. Topp, 
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, N. 
Engl. J. Med. 376, 836–847 (2017). 
221. J. Pendzialek, K. Roose, A. Smet, B. Schepens, P. Kufer, T. Raum, P. A. Baeuerle, 
M. Muenz, X. Saelens, W. Fiers, Bispecific T cell engaging antibody constructs targeting 
a universally conserved part of the viral M2 ectodomain cure and prevent influenza A 
virus infection, Antiviral Res. 141, 155–164 (2017). 
222. C. Petrovas, S. Ferrando-Martinez, M. Y. Gerner, J. P. Casazza, A. Pegu, C. 
Deleage, A. Cooper, J. Hataye, S. Andrews, D. Ambrozak, P. M. Del Río Estrada, E. 
Boritz, R. Paris, E. Moysi, K. L. Boswell, E. Ruiz-Mateos, I. Vagios, M. Leal, Y. 
Ablanedo-Terrazas, A. Rivero, L. A. Gonzalez-Hernandez, A. B. McDermott, S. Moir, G. 
Reyes-Terán, F. Docobo, G. Pantaleo, D. C. Douek, M. R. Betts, J. D. Estes, R. N. 
Germain, J. R. Mascola, R. A. Koup, Follicular CD8 T cells accumulate in HIV infection 
and can kill infected cells in vitro via bispecific antibodies, Sci. Transl. Med. 9, eaag2285 
(2017). 
223. M. Mack, G. Riethmüller, P. Kufer, A small bispecific antibody construct expressed 
as a functional single-chain molecule with high tumor cell cytotoxicity., Proc. Natl. 
Acad. Sci. U. S. A. 92, 7021–5 (1995). 
224. C. Wu, H. Ying, C. Grinnell, S. Bryant, R. Miller, A. Clabbers, S. Bose, D. 
McCarthy, R.-R. Zhu, L. Santora, R. Davis-Taber, Y. Kunes, E. Fung, A. Schwartz, P. 
Sakorafas, J. Gu, E. Tarcsa, A. Murtaza, T. Ghayur, Simultaneous targeting of multiple 
disease mediators by a dual-variable-domain immunoglobulin., Nat. Biotechnol. 25, 
152 
 
1290–1297 (2007). 
225. M. Dillon, Y. Yin, L. Mccarty, D. Ellerman, D. Slaga, T. T. Junttila, G. Han, W. 
Sandoval, M. A. Ovacik, K. Lin, Z. Hu, A. Shen, J. E. Corn, C. Spiess, P. J. Carter, 
Efficient production of bispecific IgG of different isotypes and species of origin in single 
mammalian cells, MAbs (2016). 
226. J. Oates, B. K. Jakobsen, ImmTACs, Oncoimmunology 2, e22891 (2013). 
227. N. Liddy, G. Bossi, K. J. Adams, A. Lissina, T. M. Mahon, N. J. Hassan, J. 
Gavarret, F. C. Bianchi, N. J. Pumphrey, K. Ladell, E. Gostick, A. K. Sewell, N. M. 
Lissin, N. E. Harwood, P. E. Molloy, Y. Li, B. J. Cameron, M. Sami, E. E. Baston, P. T. 
Todorov, S. J. Paston, R. E. Dennis, J. V Harper, S. M. Dunn, R. Ashfield, A. Johnson, 
Y. McGrath, G. Plesa, C. H. June, M. Kalos, D. a Price, A. Vuidepot, D. D. Williams, D. 
H. Sutton, B. K. Jakobsen, Monoclonal TCR-redirected tumor cell killing., Nat. Med. 18, 
980–7 (2012). 
228. Y. Li, R. Moysey, P. E. Molloy, A.-L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. 
Liddy, J. Jacob, B. K. Jakobsen, J. M. Boulter, Directed evolution of human T-cell 
receptors with picomolar affinities by phage display., Nat. Biotechnol. 23, 349–54 
(2005). 
229. J. Oates, N. J. Hassan, B. K. Jakobsen, ImmTACs for targeted cancer therapy: Why, 
what, how, and which, Mol. Immunol. 67, 67–74 (2015). 
230. G. Friberg, D. Reese, Blinatumomab (Blincyto®); lessons learned from the 
bispecific t-cell engager (BiTE®) in acute lymphocytic leukemia (ALL), Ann. Oncol. 
(2017), doi:10.1093/annonc/mdx150. 
231. S. Atwell, J. B. Ridgway, J. A. Wells, P. Carter, Stable heterodimers from 
remodeling the domain interface of a homodimer using a phage display library., J. Mol. 
Biol. 270, 26–35 (1997). 
232. J. Chng, T. Wang, R. Nian, A. Lau, K. M. Hoi, S. C. Ho, P. Gagnon, X. Bi, Y. 
Yang, Cleavage efficient 2A peptides for high level monoclonal antibody expression in 
CHO cells, MAbs 7, 403–412 (2015). 
233. J. M. Boulter, M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, B. K. 
Jakobsen, Stable, soluble T-cell receptor molecules for crystallization and therapeutics, 
Protein Eng. Des. Sel. 16, 707–711 (2003). 
234.  Anti-CD3 antibodies and methods of use thereof (2010). 
235. S. Gras, X. Saulquin, J.-B. Reiser, E. Debeaupuis, K. Echasserieau, A. 
Kissenpfennig, F. Legoux, A. Chouquet, M. Le Gorrec, P. Machillot, B. Neveu, N. 
Thielens, B. Malissen, M. Bonneville, D. Housset, Structural bases for the affinity-driven 
selection of a public TCR against a dominant human cytomegalovirus epitope., J. 
Immunol. 183, 430–7 (2009). 
236. E. Walseng, S. Wälchli, L.-E. Fallang, W. Yang, A. Vefferstad, A. Areffard, J. 
Olweus, Soluble T-Cell Receptors Produced in Human Cells for Targeted Delivery, PLoS 
153 
 
One 10, e0119559 (2015). 
237. P. de Felipe, M. D. Ryan, Targeting of proteins derived from self-processing 
polyproteins containing multiple signal sequences, Traffic 5, 616–626 (2004). 
238. J. M. Boulter, M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, B. K. 
Jakobsen, Stable, soluble T-cell receptor molecules for crystallization and therapeutics, 
Protein Eng. Des. Sel. 16, 707–711 (2003). 
239. P. D. Holler, P. O. Holman, E. V Shusta, S. O’Herrin, K. D. Wittrup, D. M. Kranz, 
In vitro evolution of a T cell receptor with high affinity for peptide/MHC., Proc. Natl. 
Acad. Sci. U. S. A. 97, 5387–92 (2000). 
240. D. M. Gakamsky, E. Lewitzki, E. Grell, X. Saulquin, B. Malissen, F. Montero-
Julian, M. Bonneville, I. Pecht, Kinetic evidence for a ligand-binding-induced 
conformational transition in the T cell receptor., Proc. Natl. Acad. Sci. U. S. A. 104, 
16639–44 (2007). 
241. L. K. Chlewicki, P. D. Holler, B. C. Monti, M. R. Clutter, D. M. Kranz, High-
affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 
or CDR3, J. Mol. Biol. 346, 223–239 (2005). 
242. R. Kunaparaju, M. Liao, N.-A. Sunstrom, Epi-CHO, an episomal expression system 
for recombinant protein production in CHO cells., Biotechnol. Bioeng. 91, 670–7 (2005). 
243. E. Lunde, G. Å. Løset, B. Bogen, I. Sandlie, Stabilizing mutations increase secretion 
of functional soluble TCR-Ig fusion proteins., BMC Biotechnol. 10, 61 (2010). 
244. J. Carter, J. Zhang, T. L. Dang, H. Hasegawa, J. D. Cheng, I. Gianan, J. W. O’Neill, 
M. Wolfson, S. Siu, S. Qu, D. Meininger, H. Kim, J. Delaney, C. Mehlin, Fusion partners 
can increase the expression of recombinant interleukins via transient transfection in 
2936E cells, Protein Sci. 19, 357–362 (2010). 
245. M. Kieke, E. Shusta, E. Boder, L. Teyton, K. Wittrup, D. Kranz, Selection of 
functional T cell receptor mutants from a yeast surface- display library, Proc Natl Acad 
Sci U S A 96, 5651–6. (1999). 
246. D. H. Aggen, A. S. Chervin, F. K. Insaidoo, K. H. Piepenbrink, B. M. Baker, D. M. 
Kranz, Identification and engineering of human variable regions that allow expression of 
stable single-chain T cell receptors, Protein Eng. Des. Sel. 24, 361–372 (2011). 
247. A. S. Chervin, D. H. Aggen, J. M. Raseman, D. M. Kranz, Engineering higher 
affinity T cell receptors using a T cell display system, J. Immunol. Methods 339, 175–184 
(2008). 
248. L. Trautmann, M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. 
Cerundolo, M. Bonneville, Selection of T Cell Clones Expressing High-Affinity Public 
TCRs within Human Cytomegalovirus-Specific CD8 T Cell Responses, J. Immunol. 175, 
6123–6132 (2005). 
249. M. R. Wills, A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, J. G. 
154 
 
Sissons, The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is 
dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of 
pp65-specific CTL., J. Virol. 70, 7569–79 (1996). 
250. K. K. Biron, Antiviral drugs for cytomegalovirus diseases, Antiviral Res. 71, 154–
163 (2006). 
251. P. R. Krause, S. R. Blalek, S. B. Boppana, P. D. Griffiths, C. A. Laughlin, P. 
Ljungman, E. S. Mocarski, R. F. Pass, J. S. Read, M. R. Schleiss, S. A. Plotkin, Priorities 
for CMV vaccine development, Vaccine 32, 4–10 (2013). 
252. M. G. Revello, T. Lazzarotto, B. Guerra, A. Spinillo, E. Ferrazzi, A. Kustermann, S. 
Guaschino, P. Vergani, T. Todros, T. Frusca, A. Arossa, M. Furione, V. Rognoni, N. 
Rizzo, L. Gabrielli, C. Klersy, G. Gerna, CHIP Study Group, A randomized trial of 
hyperimmune globulin to prevent congenital cytomegalovirus., N. Engl. J. Med. 370, 
1316–26 (2014). 
253. L. G. Lum, M. Ramesh, A. Thakur, S. Mitra, A. Deol, J. P. Uberti, P. E. Pellett, 
Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-
CMV Bispecific Antibody, Biol. Blood Marrow Transplant. 18, 1012–1022 (2012). 
 
  
155 
 
 Vita 
 
Ellen Kathleen Wagner was born in Bakersfield, CA. but lived most of her 
formative years in Larkspur, CO. After graduating from Douglas County High School in 
2007, Ellen pursued her bachelor’s degree in chemical and biological engineering at the 
University of Colorado at Boulder. Her undergraduate highlights include spending a 
semester abroad at the University of Canterbury in Christchurch, New Zealand; writing 
an undergraduate thesis; and graduating Magna Cum Laude in 2007. Ellen worked as a 
process engineer for CH2M Hill for one year before starting graduate school at The 
University of Texas at Austin in the fall of 2012. During this time she was also able to 
spend 6 months as a visiting researcher at the University of Oslo in Oslo, Norway.  
 
 
 
Ellen.Wagner@utexas.edu 
This dissertation was typed by Ellen Kathleen Wagner.  
 
 
 
 
